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1 INTRODUCTION 
1.1 Quantitative Assessment of Quality of Epilepsy Treatment 
Management of patients with chronic disorders, such as epilepsy, requires frequent 
consultation and adjustment of treatment. Treatment outcome may be described using 
various methods, and the variety in these methods can complicate the comparison of 
treatment outcome in different studies. In the case of epilepsy treatment seizure 
characteristics and possible adverse effects of antiepileptic drugs, which have to be 
used continuously over a long period of time, are important parameters. The simple 
use of seizure frequency, though often employed, has met with criticism (appendix I). 
With respect to adverse effects of treatment a perusal of the literature shows that the 
reporting of adverse drug events leaves much to be desired (appendix Π). 
Clinimetrics allows the outcome of treatment to be expressed as quantitative 
indexes, thus enabling a quantitative assessment of the quality of treatment. We were 
interested whether clinimetric indexes can be used to support routine care of people 
with epilepsy. 
In order to test the feasibility of this method (chapter 2) a comparison was made 
between treatment outcome of secondary and tertiary epilepsy referral centres 
(chapter 3) (Wijsman et al., 1993) (Lammers et al., 1994). The clinimetric method was 
also compared with the subjective assessment of a clinician as to whether or not his 
treatment objectives had been reached (chapter 4) (Lammers MW et al., in press). 
In epilepsy treatment, as in many chronic pharmacotherapies, the balance between 
efficacy and toxicity is of great importance. The clinimetric method turned out to be 
particularly useful to tackle an ongoing debate whether treatment with a single 
antiepileptic drug has advantages over treatment with drug combinations (chapter 5) 
(Lammers MW et al., 1994). These studies tried to correlate outcome with dosage of 
medication and not serum levels. In a separate study the predictive value of serum 
levels was investigated (chapter 6). 
The studies employed a clinimetric index, the Composite Index of Impairment (СП), 
as a standardised measuring instrument for the assessment of quality of epilepsy 
treatment. The subjects included in the studies were patients from secondary and 
tertiary referral centres. 
In order to assess whether these cohorts received a pharmacotherapeutic regimen 
very different from the general population of people with epilepsy a 
pharmacoepidemiologic study was performed using data from a drug dispensing data 
base in order to assess and compare prescription methods for antiepileptic drugs in a 
large Dutch population (chapter 7). 
And finally possible prognostic factors for the severity of epilepsy were assessed in 
the study population (chapter 8). 
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1.2 Why Clinimetrics in Epileptology 
Epilepsy is a paroxysmal disorder with a variable expression of symptoms. After the 
diagnosis of epilepsy has been established, most patients will be treated with 
antiepileptic medication to prevent seizure recurrence. In newly diagnosed patients the 
treatment objective will be complete seizure freedom. Studies performed by Annegers, 
et al. (Annegers et al., 1979) and Goodridge and Shorvon (Goodridge-Shorvon, 1983) 
have indicated that approximately 70% of patients with epilepsy will become seizure 
free, which means that about 30% of patients with epilepsy will continue to have 
seizures. In patients for whom seizure freedom is not achievable with the medication 
currently available, an optimal balance between efficacy and side effects of 
antiepileptic drugs is the treatment objective. 
In the course of treatment of epilepsy regular visits to outpatient clinics are 
necessary. The outcome of treatment is usually based upon a qualitative comparison 
with the previous status of the patient. In Clinimetrics, quantitative indexes are used to 
express clinical situations, which make them a useful tool in the assessment of 
treatment effects in a chronic disorder such as epilepsy. 
In the case of multicentre trials, clinimetric indexes will improve the uniformity of 
assessment and the comparability of results. This is of the utmost importance in 
clinical drug trials, because for statistical reasons usually multicentre trials will be 
necessary. 
1.3 Clinical Symptoms and Signs of Epilepsy 
Epilepsy is a disorder defined as repeated, sudden, mostly brief, discharges of brain 
cells, accompanied by a disturbance of function. The disturbance of function is 
expressed in physical phenomena, which depend on the localisation of the discharging 
brain cells. The diagnosis 'epilepsy' is made when epileptic seizures recur without 
being evoked by special stimuli. 
Classifications of seizure types, and of epilepsies and epileptic syndromes have been 
developed by the International League Against Epilepsy (Commission on Classification 
and Terminology of the International League Against Epilepsy, 1981 and 1989). The 
epilepsies are classified as generalised epilepsies or epilepsies with local onset. A 
further distinction is whether the epilepsy is symptomatic or idiopathic. 
Outcome of therapy generally refers to the presence or absence of seizures. Seizures 
can be subdivided into partial seizures, primarily generalised seizures, unclassified 
seizures, and non epileptic seizures. Partial seizures are defined as seizures with a local 
or relatively local onset, either with or without secondary generalisation (Table 1.1). 
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Table 1.1 Classification of partial seizures. 
IA Simple partial seizure 
1. 
2. 
3. 
4. 
With motor signs and symptoms 
a. focal motor without march 
b. focal motor with march (Jacksonian) 
c. versive 
d. postural 
e. phonatory (vocalisation or arrest of speech) 
With special sensory or somatosensory signs and symptoms 
a. somatosensory 
b. visual 
с auditory 
d. olfactory 
e. gustatory 
f. vertiginous 
With autonomic symptoms 
With psychic symptoms 
a. dysphasia 
b. dysmnesic 
c. cognitive 
d. affective 
e. illusions 
f. structured hallucinations 
IB Complex partial seizure 
1. Simple partial onset followed by impairment of consciousness 
a. with simple partial features (ÏA1. - I A4.) followed by impaired consciousness 
b. with automatisms 
2. With impairment of consciousness at onset 
a. with impairment of consciousness only 
b. with automatisms 
1С Partial seizures evolving to secondarily generalised seizures 
1. Simple partial seizures (IA) evolving to generalised seizures 
2. Complex partial seizures (IB) evolving to generalised seizures 
3. Simple partial seizures evolving to complex partial seizures evolving to generalised seizures 
In simple partial seizures consciousness is not impaired, although very complex 
phenomena may occur. In complex partial seizures consciousness is always impaired. 
The seizure may contain brief periods of impaired consciousness only, or various 
complex actions. A simple partial seizure may evolve into a complex partial seizure or 
into a secondarily generalised seizure. Also, complex partial seizures may secondarily 
generalise. 
Primarily generalised seizures are defined as seizures in which both hemispheres are 
involved right from the initial stage (table 1.2). 
12 
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Table 1.2. Classification of generalised seizures. 
ΠΑ Absence seizures 
1. Typical absences 
a. impairment of consciousness only 
b. with mild clonic components 
c. with atonic components 
d. with tonic components 
e. with automatisms 
f. with autonomic components 
2. Atypical absences 
a. with features of IIA1 more pronounced 
b. Onset and/or cessation that is not abrupt 
IIB Myoclonic seizures 
Myoclonic jerks (single or multiple) 
IIC Clonic seizures 
ПР Tonic seizures 
HE Tonic-clonic seizures 
IIF Atonic seizures 
1.4 Clinimetric Indexes 
In clinical medicine a variety of types of measurement are employed. One way of 
measurement is called mensuration, in which observed phenomena are converted into 
raw data. An example of mensuration is to express weight in kilograms, or the severity 
of pain in none, mild, moderate, severe. With quantification the data of each individual 
patient are then put into groups, which summarize the collective information of each 
group. 
Feinstein has introduced the term clinimetric indexes for rating scales that express 
clinical phenomena (Feinstein 1987) (Feinstein 1993). A clinimetric index is 
constructed from one or more medical variables. A variable expresses raw data in 
classes of information. Medical variables may contain demographic features such as 
age or gender, or epidemiologic features such as dietary intake or lifestyle. Medical 
variables may also express information from paraclinical tests like laboratory tests and 
instrumental investigations (ECG, EEG, X-ray, etc.) 
The data used for clinimetric indexes are obtained from patient histories, physical 
examinations, and clinical reasoning. Clinimetric indexes may also include paraclinical 
data, such as laboratory findings; but in order to be labelled as a clinimetric index, at 
least some clinical data must be included. 
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An example of a clinimetric index is the Glasgow Coma Scale. In this index various 
features of consciousness are considered: motor response, verbal response, and eye 
opening response. For each of these features a rating scale was developed, ranging 
from 1 to 4 for eye opening response, from 1 to 6 for motor response, and from 1 to 5 
for verbal response. These scores are then put together to define the level of 
consciousness ranging from 3 for deep coma to 15 for complete consciousness. 
According to Feinstein a clinimetric index has to meet at least four scientific and 
statistical criteria: reproducibility, accuracy, sensibility, and responsiveness. 
Reproducibility means that the same result has to be obtained when the rating is 
repeated by the same or by any other investigator. The measurement has to be 
accurate, meaning that the result has to correspond with a "golden standard" as 
reference value. For the clinimetric indexes a golden standard is not always available. 
A clinimetric index can then be compared with another index that relates to the same 
phenomenon. A third requirement for a clinimetric index is called sensibility or face 
validity. A clinimetric index has to make good common sense in demonstrating what 
we want to measure. Lastly a clinimetric index has to show responsiveness, meaning 
that it describes the change we want to demonstrate. 
Clinimetric indexes can be used for various clinical purposes, i.e. to describe 
conditions, note changes, make predictions, and choose interventions. 
1.5 Clinimetrics and Epilepsy 
Clinimetric indexes for epilepsy can be used to render achievements in treatment. Its 
use is therefore to register changes in the clinical state of a patient with epilepsy in the 
course of treatment. 
Since epilepsy is a paroxysmal disorder, outcome of treatment cannot always be 
measured immediately, unlike the effects of treatment on for example pain or dyspnea. 
One therefore has to look at both the intra-episodic as well as the inter-episodic 
periods of the disorder. For the intra-episodic attributes of an epileptic seizure one can 
look at the duration of a seizure, its type, possible causing factors, and the signs which 
immediately follow the seizure. Inter-episodic variables are for example the duration of 
intervals between seizures, the social impact of epilepsy, and side effects of 
antiepileptic medication. 
1.6 Review of Clinimetric Indexes for Epilepsy 
Over the years attempts have been made to quantify the outcome of treatment in 
epilepsy. In clinical evaluation of treatment outcome and severity of epilepsy, seizure 
frequency was most generally used as the parameter of measurement. The assessment 
of seizure frequency alone would be sufficient in case one wants to know the chance 
to register a seizure in a given period. If more than one seizure type occurs in one 
patient, and if the occurrence of one excludes the presence of the other while the 
seizure-type-specific seizure frequency differs, then simple counting of events per 
14 
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period will not be meaningful. Also, for the assessment of the impact of seizures on 
the quality of life of the patient, or for the evaluation of various interventions on a 
group of people with epilepsy, simply referring to seizure frequency may not be 
enough. 
Recently, seizure severity is also taken into account, and different scales have been 
developed to include seizure severity in the assessment. Examples of these scales 
include: the Liverpool Seizure Severity Scale (Baker et al., 1991), the Chalfont Seizure 
Severity Scale (Duncan Sander, 1991), the Occupational Hazard Scale (Janz 1989), and 
the Veterans Affairs Seizure Frequency and Severity Rating Scale (Cramer et al., 
1983). The questionnaires used to assess the outcome of these indexes are shown in 
appendix ΙΠ. 
1.6.1 The Liverpool Seizure Severity Scale was developed by Baker et al. (1991) to 
assess seizure severity, perceived seizure severity, and psychosocial consequences of 
intractable epilepsy. This scale is made up of 19 items and divided into two sections, 
one with regard to the perception of control of the seizure, and the other with ictal and 
post-ictal consequences of the seizure. Seizure frequency is not taken into 
consideration in this scale, and the scale is used to describe the severity of individual 
seizure types and not the overall severity of epilepsy. The Liverpool scale does not 
assign standardised scores to the items, but is a description of the perception of 
severity of the seizures. 
1.6.2 The Chalfont Seizure Severity Scale, developed by Duncan and Sander (1991), 
has features of both patient and observer based information for the assessment of 
seizure severity. It is a scale with 10 items which are concerned with seizure severity 
and not seizure frequency. Some items in this scale allow to make a distinction 
between different seizure types, and others describe the interference with function of 
the patient during the seizure. Some modifying factors are assigned, depending on the 
time each modifier occurs in the total number of seizures. 
1.6.3 In the Occupation Hazard Scale developed by Janz (1989) less emphasis is put 
on seizure type, but more on the possible social impairment caused by the seizures. 
This scale was used to evaluate the suitability of patients for selected occupations. It 
only offers a limited number of possible examples, but it can be applied as a guide for 
grading occupational suitability, or to mark changes in seizure severity over time. 
1.6.4 The Veterans Affairs Seizure Frequency and Severity Rating Scale (Cramer et al., 
1983) was developed as an evaluation and selection criterion for a comparative study 
of the four most frequently prescribed antiepileptic drugs in the USA at that time, i.e. 
carbamazepine, phenytoin, phénobarbital, and primidone. The rating scale considers 
seizure frequency, seizure type, and toxicity of medication for the assessment of the 
15 
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overall impairments of the disorder. Seizure frequency ratings are modified according 
to the seizure type(s). For the VA seizure scale only the most frequently occurring 
seizure types have been rated, i.e. simple and complex partial seizures, and primarily 
and secondarily generalised tonic clonic seizures, as the other seizure types classified 
by the ILAE (Table 1.2) are seldom seen. A complex partial seizure rates 
approximately three times as high as a simple partial seizure, and a non-linear 
relationship exists between generalised tonic-clonic seizure and a complex partial 
seizure. The following modifying factors are applied to assess seizure severity: 
1. Presence of an aura, in the case of a generalised tonic-clonic or complex partial 
seizure. The patient is aware of the fact that a seizure is about to occur, in which 
case he can take precautions to prevent self-harm. When an aura is present, the 
seizure score is reduced by 20 percent. 
2. Precipitating factors provoking a seizure, which are avoidable, such as lack of 
sleep, use of alcohol, reduce the seizure score by 50 percent. 
3. Restriction of seizures to the period of sleep or of awakening, reduces the seizure 
score by 40 percent. 
4. Restriction of interference with function to less than 15 minutes reduces the 
seizure score by 50 percent. 
5. Clustering of seizures reduces the seizure score by 50 percent. 
6. Drug serum levels below the target range reduce the seizure score by 70 percent 
and serum levels in the low therapeutic range reduces the seizure score by 20 
percent. 
The score obtained after applying the necessary modifying factors is the seizure 
severity score. Toxicity of antiepileptic medication is then scored with the use of two 
rating scales: a neurotoxicity rating and a systemic toxicity rating. The scoring ranges 
are based on severity and importance of the side effects. After adding up the seizure 
severity score and the toxicity scores a composite score is formed which expresses the 
overall impairment caused by the disorder. A difference of approximately 10 points in 
the composite score indicates a clinically important difference. A composite score > 50 
denotes an unacceptable epilepsy control, and a change in treatment is indicated. 
Quantification of seizure severity and side effects is applied only in the VA Seizure 
Frequency and Severity Rating Scale. This format enables the assessment of all seizure 
related impairments which can be useful as a tool in the assessment of outcome of 
epilepsy treatment. For this reason we applied an adapted form of the VA Seizure 
Frequency and Severity Rating Scale for our study. 
16 
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2. METHODOLOGY 
2.1 Population 
Patient data were collected at the following four epilepsy outpatient clinics in The 
Netherlands in the course of three years: 
1. The epilepsy outpatient clinic of the University Hospital Nijmegen. 
2. The outpatient clinic of the Instituut voor Epilepsiebestrijding in Heemstede. 
3. The outpatient clinic of the Instituut voor Epilepsiebestrijding in Utrecht. 
4. The outpatient clinic of the Hans Berger Kliniek in Breda. 
The latter three are specialised epilepsy centres. 
Patients were examined more than once by the investigator in order to select a 
group of patients with a stable epilepsy control. 
2.1.1 The selection criteria for the study were as follows: 
2.7.7.7 Inclusion 
1. Patients visiting an adult outpatient epilepsy clinic 
(age: 15 years and above); 
2. Patient's history with at least two or more unprovoked seizures; 
3. Patients with an accurate history including adequate neurophysiological data for a 
firm diagnosis, suffering from well-defined types of seizures according to the 
Classification of the International League Against Epilepsy. 
2.1.1.2 Exclusion 
1. Patients with factors believed to complicate the evaluation process; these factors 
included progressive brain disorders, obvious non-compliance in drug usage or 
seizure registration, pseudo-seizures and severe mental retardation. 
2.2 The Procedure 
At their regular visits to the outpatient clinics the patients were first seen by their 
clinician. The clinician filled out a questionnaire (appendix Г ) for the investigator in 
which he stated several aspects of the patient's epilepsy, treatment, and treatment 
outcome. These aspects were: 
1. Type of epilepsy and seizure type(s) according to the classifications of the ILAE. 
2. Treatment objective. The clinician could choose between seizure freedom, 
treatment impairment/benefit balance, or other than the two aforementioned 
treatment objectives. 
3. Whether the treatment objective was considered achieved. 
4. Antiepileptic drugs and dosages prescribed. 
18 
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5. Global clinical state of the patient. This was expressed on a visual analog scale 
ranging from 1 to 7. A clinical state of 1 indicated that the patient was doing very 
well, and a clinical state of 7 indicated that the epilepsy was poorly controlled and 
hospital admittance or referral for epilepsy surgery was considered. 
After the visit to their clinician the patients were interviewed and examined by the 
investigator, in order to collect the data necessary for the assessment of the indexes. 
These data were: time since the last visit to the outpatient clinic, seizure frequency 
per seizure type, existence of modifying factors per seizure type, and presence and 
severity of side effects of medication. 
Additionally, for a study on prognostic factors in the treatment outcome of epilepsy, 
data were collected about the aetiology and course of the epilepsy, serum levels of 
antiepileptic drugs, the patient's medical history, additional medication, and results of 
EEG and/or CT-scan. 
A total number of 534 patients had entered at the closure of the study programme. 
2.3 Methodology for the assessment of impairments 
For our study into the question whether a clinimetric index can support routine care 
of patients with epilepsy, we adapted the Veterans Affairs (VA) Seizure Frequency and 
Severity Rating Scale described in chapter 1.6.4 (Cramer et al, 1983). This VA rating 
scale was developed for a comparative study on the efficacy of four antiepileptic 
drugs. In that study seizure scores were modulated if the serum level of the 
antiepileptic drugs were under the "therapeutic range" so that an AED was not 
considered inefficacious when not used to its full potential. 
In our study we evaluated the situation of chronic patients with epilepsy regardless 
of the number or the dosage of antiepileptic drugs used. Therefore, serum levels are 
not used as a modifying factor in this study. 
The other items of the VA Seizure Frequency and Severity Rating Scale are used 
unchanged. These items were chosen in the VA study in consultation with several 
neurologists in the USA. Some items of the VA Rating Scale have been changed since 
the start of this study. In our study we used the original rating scales, so that over time 
the data of the patients should be consistent. 
The clinimetric index used in this study, the Composite Index of Impairments (СИ), 
reflects all treatment related impairments, i.e. paroxysmal impairments (seizures) 
caused by the disorder under treatment and drug induced impairments or side effects. 
Other effect parameters concerning psychosocial and occupational impacts due to 
disabilities were not taken into consideration, because this study only focuses on direct 
patient's variables. 
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2.3.1. The Composite Index of Impairments consists of three subscales: the Seizure 
Activity Index (the modified Index of Seizures), the Neurotoxicity Rating, and the 
Systemic Toxicity Rating. This construction of three subscales enables the observation 
of the balance between efficacy and side effects of treatment. The outcomes of all 
three subscales are dimensionless units, so that the results can be summated to give a 
composite score. 
2.3.1.1 The Seizure Activity Index takes type and frequency of each seizure type into 
account by means of the Index of Seizures (IS). The relationship between the IS and 
seizure frequency for the different seizure types is shown in figure 2.1. The index 
score for each seizure type is shown in Tables 2.1a-2.1c. 
0 1 2 3 4 S 6 7 8 9 10 
frequency of seizures 
Figure 2.1. Relationship between the Index of Seizures and the number of seizures either per year (in case 
of tonic-clonic seizures (-)) or per month (in case of complex partial seizures (x) or simple partial seizures 
(*)) From Wijsman et al 1991, printed with permission 
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Table 2,1a. Scoring method for generalised tonic-clonic seizures in the Index of Seizures» 
Generalised Tonic-Clonic Seizure IS score 
Number of seizures/12 months 
Two seizures/first 3 months 
Two seizures/6 months 
= 20 (for each seizure) 
If last visit > 12 months ago 
= 50 
= 45 
One seizure/first 3 months 
One seizure/6 months 
= 40 
= 40 
Two seizures/6-12 months 
One seizure/6-12 months 
= 30 
= 20 
Two seizures/12-24 months 
One seizure/12/24 months 
= 20 
= 10 
Seizure free >24 months 
Table 2.1b. 
Complex 
Scoring method for 
Partial Seizure 
complex partial seizures 
= 0 
in the Index of Seizures. 
IS score 
Equal to or greater than 3 seizures/month 
Two seizures/month 
One seizure/month 
10 (for each seizure) 
= 25 
= 20 
Less than 1 seizure/month and greater than 
1 seizure/3 months 
Equal to or less than 1/3 months 
Seizure free >1 year 
= 15 
= 10 
= 0 
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Table 2.1c. Scoring method for simple partial seizures in the Index of Seizures. 
Simple Partial Seizure IS score 
Equal to or greater than 7 seizures/month 
Six seizures/month 
Five seizures/month 
Four seizures/month 
Three seizures/month 
Two seizures/month 
One seizure/month 
Less than 1 seizure/month and greater than 
1 seizure/3 months 
Equal to or less than l/3months 
Seizure free > 1 year 
= 33 (+3 for each additional seizure 
over 7) 
= 30 
= 28 
= 25 
= 23 
= 20 
= 15 
= 13 
= 10 
= 0 
2.3.1.2 The modulators The modulators are applied per seizure type and the individual 
scores for each seizure type are added up to produce the Seizure Activity Index. This 
method enables individualisation of the seizure score for each patient. 
These modifiers are: 
I. Presence of an aura, with time to take precautions to avoid self-harm, (score 
reduction 20%) 
II. Precipitating factors preceding the seizures, 
(score reduction 50%) 
III. Seizure occurring only during sleep or at awakening, (score reduction 40%) 
Г . Duration of impairment of functioning after the seizure less than 15 minutes. 
(score reduction 50%) 
V. Clustering of seizures, (score reduction 50%) 
2.3.1.3 The Neurotoxicity Rating Scale (NTX) scores the severity of the neurological 
side effects of medication. The scoring range of the NTX is shown in Table 2.2. 
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Table 2.2. Range of Neurotoxicity scores per symptom as used in the Composite Index of Impairments. 
Neurotoxicity 
Diplopia 
Nystagmus 
Dysarthria 
Ataxia 
Dysdiadochokinesis 
Tremor 
Sedation 
Affect and mood disturbances 
Cognitive impairments 
Dizziness 
Headache 
Scoring range 
15-30 
5-10 
5-30 
5-50 
15 
10-50 
5-50 
5-50 
5-50 
3-50 
3-50 
2.3.1.4 The Systemic Toxicity Rating Scale (STX) scores the severity of the systemic 
side effects of medication (Table 2.3). 
Table 23. Range of Systemic Toxicity scores per symptom as used in the Composite Index of 
Impairments. 
Systemic toxicity 
Gastrointestinal problems 
Haematopoietic problems 
Dermatologie problems 
Impotence 
Kidney disease 
Liver disease 
Weight gain 
Changes in hair/hair loss 
Scoring range 
3-50 
50 
20-50 
20-50 
50 
25-50 
3-20 
5-50 
A Composite Index of Impairments score of 0 indicates complete seizure control, and 
no side effects of medication. A CII score of 50 or more indicates an unacceptable 
control of epilepsy, and treatment adjustments are required. 
2.3.2 Validation of the Composite Index of Impairments 
The reproducibility and suitability of the СП was studied to validate the methodology 
used (Wijsman et al., 1991). 
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2.3.2. / Reproducibility 
Reproducibility was studied in 24 outpatients. These outpatients were first 
interviewed by their treating clinician and subsequently by the investigator, using the 
same scoring method. This was based on the use of a questionnaire. This study was 
performed to test the inter-rater reliability. The СП was divided into four ranges for 
the qualification of impairment and levels of epilepsy control. (Table 2.4) 
Table 2.4. Qualifications of impairment and level of epilepsy control corresponding to four ranges of 
the Composite Index of Impairments. 
Composite Index 
of 
Impairments 
0 
1-10 
11-49 
>50 
Impairments 
none 
mild 
moderate 
severe 
Epilepsy control 
optimal 
acceptable 
acceptable 
unacceptable 
The scores of the 24 patients were compared, using the investigator's scores as a 
standard, and к statistics was applied. The individual scores of both the clinician and 
the investigator correlated well (r=0.90). No systematic difference was seen between 
the scores obtained by both evaluators. The inter-rater agreement for four ranges of the 
СИ was moderate (к=0.52). The agreement on whether the epilepsy control was 
acceptable or unacceptable was good (к=0.63). This result corroborates the validity of 
the Composite Index of Impairments. 
232.2 Suitability 
The suitability of the СП was tested in a prospective study in which 47 outpatients 
participated. The treating clinician, who was unaware of the scoring system was asked 
to fill out the questionnaire consisting of all the elements for constructing the СП 
without knowledge of the scoring labels. The scores of the СП were assessed by the 
investigator. The scores were then compared with the length of time until the next 
consultation. The hypothesis was tested that there was an increased chance that the 
time until the next consultation for patients with а СП score <50 (acceptable epilepsy 
control) would be > 3 months and that this time would be < 3 months for patients with 
а СП score >50 (unacceptable epilepsy control). The relation between the length of 
time until the next consultation and the СП score was significant (Wilcoxon rank sum 
test p<0.01) and inverse (r=-0.66), and shows the suitability of the Composite Index of 
Impairments as an indicator of clinical severity of epilepsy. 
24 
CHAPTER!: Methodology 
2.4 Analysis of Drug Treatment and Dosage 
For the purpose of assessment of drug exposure of the patients in this study we 
applied the method developed by the WHO Drug Utilization Research Group, WHO 
Collaborating Centre for Drug Statistics Methodology, and the Nordic Council on 
Medicine. They developed a system known as the Anatomical Therapeutic Chemical 
(АТС) Classification and a unit of measurement for comparative drug utilization 
studies, the Defined Daily Dose (DDD) (WHO Collaborating Centre for Drugs 
Statistics Methodology and Nordic Council on Medicines, 1991). In the АТС 
classification each main group is divided into 5 levels: 1st level, anatomical main 
group; 2nd level, therapeutic main group; 3rd level, therapeutic subgroup; 4th level, 
chemical/therapeutic subgroup; 5th level, subgroup for chemical substance. The 
'antiepileptics' are placed in АТС group N03: Central Nervous System, antiepileptics. 
The DDD was developed based on the assumed average dose per day for the drug 
used in its main indication in adults. The DDD is expressed in the amount of active 
substance. For each drug a DDD is assigned by the WHO-Oslo. A written dose-
document is prepared by WHO-Oslo based on international textbooks, journals and 
documentation approved by drug control authorities. The dose-documentations are 
available on request from Oslo. 
The advantages of the DDD as a tool in drug utilization studies is that this unit is 
independent of differences in price and differences in preparation, and can thus be 
used for international and national comparison of drug utilization. 
Also the DDD methodology has been applied when relating the frequency of adverse 
events to drug use (Lunde, 1989). 
It was posited that drugs used for the same indication prescribed at a Defined Daily 
Dose should be equipotent. According to the severity of the disease different fractions 
of the Defined Daily Dose will be used for individual patients. This is the Prescribed 
Daily Dose (PDD). In order to be able to compare the exposure of each individual 
patient, regardless of which AED they used, we employed the Prescribed Daily 
Dose/Defined Daily Dose ratio. The PDD/DDD ratio in this study serves as a measure 
for the degree of exposure of each individual patient to the drug(s) prescribed. The 
PDD/DDD ratio measures the relative potency of the drugs prescribed in the same 
dimensionless units and thus allows a comprehensive assessment of the intensity of the 
antiepileptic treatment given. 
Pharmacoepidemiologists use the term Prescribed Daily Dose to express the average 
dose actually prescribed in a given patient population. The argument for this was that 
the DDD recommended by the WHO did not accurately reflect the drug exposure in 
some populations and that the PDD is more accurate than the WHO-DDD because it is 
based on the actual dose prescribed by physicians for a new prescription, as obtained 
from databases referring to the groups studied. We employed the same term 'PDD' in 
a different manner, as a tool referring to the dose of antiepileptic drug actually 
prescribed for the individual patient. 
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In those cases where more than one AED per patient was prescribed, the PDD/DDD 
ratios for individual drugs were added up. The rationale of adding up PDD/DDD ratios 
of different antiepileptic drug is based upon the definition of the DDD as the average 
maintenance dose for the main indication in adults of that particular drug. Unless there 
is potentiation or interference in the activity, half a DDD of AED-I plus half a DDD 
of AED-Π should be as effective as a full dose of either of them. Meinardi and Meijer 
have shown that in a special centre for epilepsy the average amount of antiepileptic 
drug, expressed in DDDs, used per patient in 1972, was almost the same as in 1985 
notwithstanding a substantial change in the choice of drugs prescribed (Meinardi, 
Meijer, 1990). Therefore, the procedure of summating different PDD/DDD ratio's was 
considered valid. 
2.5 Methodology for the antiepileptic serum level study 
Furthermore a study was performed to compare the dose-effect relationship with the 
serum level-effect relationship, employing the Composite Index of Impairments. 
Dosage of medication was expressed by the PDD/DDD ratio. We developed an 
analogous ratio for the serum levels of AEDs, the Actual Serum Level (ASL)/Average 
Therapeutic Level ratio. The Average Therapeutic Level (ATL) was assessed, by 
analysing data from papers published on this issue (Meijer, 1991; Fröscher, et al., 
1981; Schobben, 1979; Keyser, et al., 1990a; Larkin, et al., 1991; Pippenger, 1980; 
Eadie, 1984). The Actual Serum Level is the serum level found for each AED 
prescribed for the patient. As was done for the PDD/DDD ratio, the ASL/ATL ratios 
were summated when the patients were treated with polytherapy. For this study the 
data of the first 100 patients who were treated with monotherapy and the first 100 
patients who were treated with polytherapy were examined. Of these 200 patients 60 
patients visited their attending physician twice within the time span of the intake 
period and on both occasions blood samples were taken. The data from patients who 
had a change in dosage (n=35), were analysed separately to determine whether or not a 
correlation existed between either the PDD/DDD ratio or the ASL/ATL ratio and the 
clinimetric indexes. 
2.6 Methodology for ρ harmacoepide mio logical study 
For the study on use of antiepileptic drugs (AED) we obtained data from the 
PHARMO drug data base (Herings, 1993). 
This data base contains histories of dispensed drugs, obtained from 27 pharmacies 
covering all prescription drugs dispensed in 6 middle-sized Dutch cities, with a total 
number of approximately 300,000 inhabitants. Information on drug prescription by 
means of the PHARMO drug data base has been collected for some cities since 1986, 
and for all 6 cities since 1989. 
The PHARMO database is restricted to the community-dwelling part of the 
population in these six cities. 
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For our study we used data collected from 1989 onwards. The following data were 
collected: patient's age and gender, drug prescribed, number of units dispensed, units 
per day used, and estimated duration of use. Standard doses were obtained by dividing 
the Prescribed Daily Dose (PDD) by the Defined Daily Dose (DDD). 
From this data we defined patients as exposed to one (monotherapy) or more 
(polytherapy) antiepileptics (AED). 
To measure the use of a newly introduced drug the dispensing histories of the patients 
using vigabatrin in 1992 were assessed from 1989 until 1992. AEDs included in our 
study were: carbamazepine (CBZ), clonazepam (CZP), ethosuximide (ESM), 
phénobarbital (PB), phenytoin (PHT), mesuximide (MSM), methylphenobarbital 
(MPB), oxcarbazepine (OCB), primidone (PRM), valproate (VPA), and vigabatrin 
(GVG). 
The percentage of patients using one or more AEDs was estimated in the population 
of 1992 with the whole year serving as the point prevalence for all those who used one 
or more AEDs during a period longer than 180 days of which at least one day in 1992. 
Patients who used one or more AEDs during a period longer than 180 days were 
defined as patients having epilepsy. This time span was considered sufficient in order 
to eliminate those patients who used these drugs incidentally for indications other than 
epilepsy. 
2.7 Methodology for the assessment of prognostic factors f or the severity of epilepsy 
For the assessment of possible prognostic factors patients with a stable epilepsy 
control were included in this study. Patients were considered to have a stable epilepsy 
control when the CII scores did not vary more than 10 points in the period of 
assessment. A total of 60 patients entered this study. 
2.7.1 Prognostic factors 
At the start of the assessment period patient data were collected for a study of the 
presence of possible prognostic factors through an interview by the investigator (ML) 
and from patient records. The following data was collected: 
1. Gender 
2. Age at onset 
3. Seizure type(s) 
4. Epilepsy 
5. The cause of epilepsy 
6. History of febrile convulsions 
7. Family history of epilepsy or febrile convulsions 
8. History of intrauterine and perinatal complications 
9. History of delayed psychomotor development 
10. Presence of abnormality on CT scan or MRI scan 
11. Presence of abnormality in EEG last available. 
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12. History of status epilepticus 
13. History of two or more seizures per day 
14. History of seizure remission and drug free periods 
15. Time between cause of epilepsy and first seizure 
16. Treatment delay 
18. Effect of the initial treatment 
19. History of tolerance for AEDs 
20. History of change or reduction of antiepileptic medication due to side effects 
21. Longest seizure free period in the last two years 
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EPILEPSY TREATMENT IN THE NETHERLANDS. 
The contents of this chapter have been previously published: 
3.1 Epilepsy Treatment in The Netherlands. Comparison of two Medical Centres. 
Wijsman DJP1, Lammers MW1, Hekster YA2, Keyser A1, Renier WO1, Meinardi 
H1, Van Lier H3. 
Acta Neurologica Scandinavia 1993;87:438-442. 
3.2 Epilepsy treatment in The Netherlands. Comparison of matched groups of two 
medical centres. Lammers MW1, Hekster YA2, Keyser A1, Renier WO1, Meinardi 
H1, van Lier H3, Wijsman DJP1. 
Acta Neurologica Scandinavica 1994;89:415-420. 
Institute of Neurology, University Hospital Nijmegen; 
Department of Clinical Pharmacy, University Hospital Nijmegen; 
Department of Medical Statistics, University Hospital Nijmegen. 
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3. EPILEPSY TREATMENT IN THE NETHERLANDS 
3.1 Comparison of two Medical Centres 
3.1.1 Introduction 
In order to enhance the efficacy of medical management, it is indispensable to 
compare existing treatment policies with respect to their outcome, using strict 
assessment methodology. Firstly one needs to describe the existing treatment policy, in 
operational terms. Secondly each distinct treatment policy should be evaluated through 
outcome measurement. 
It is likely that different policies apply for care offered in secondary and tertiary 
referral care facilities. In order to test the feasibility of comparison of epilepsy 
treatment policies it was decided to compare these policies for 1) secondary and 2) 
tertiary referrals. A university outpatient clinic was selected to collect secondary 
referrals. For the tertiary referrals the outpatient population of a comprehensive 
epilepsy centre was available. 
For the comparison of secondary and tertiary referral care facilities several 
characteristics of the two groups, which could be of influence on the course of the 
epilepsy, have been taken into consideration: age, gender, type of seizure, duration of 
epilepsy, type of medication and dose prescribed using the prescribed daily 
dose/defined daily dose ratio (PDD/DDD ratio) (chapter 2.4). 
Also the following indices have been determined on clinimetrical basis: the Index 
of Seizures (IS), the Seizure Activity Index (SA) and the Composite Index of 
Impairments (Cramer, et al., 1983, Mattson, et al., 1985, Feinstein, 1987, Wijsman, et 
al., 1991). Other effect parameters concerning psychosocial and occupational impacts 
due to disabilities and handicaps were left out of consideration. 
3.1.2 Statistical analysis 
For the study of gender distribution at the centres the χ2 test was used. In the study 
of differences between the three centres and between two centres separately, e.g. 
Heemstede and Utrecht or Heemstede and Nijmegen the Kruskal-Wallis test was used. 
When significant differences were found between the centres the Wilcoxon rank sums 
tests were also used. As no significant difference was found between the group of 
Heemstede and Utrecht these were subsequently considered as one group. In addition, 
for the assessment of correlation of the individual variables the Spearman correlation 
coefficient was used. The differences were statistically significant when ρ <0.05. 
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3.1.3 Results 
3.1.3J. Population characteristics 
3.1.3.1.1. Number of patients 
The number of patients entering the study were 345, 225 for the Epilepsy Centre: 
Instituut voor Epilepsiebestrijding (Heemstede 118 and Utrecht 107) and 120 for the 
University Hospital Nijmegen. 
3.1.3.1.2 Gender 
The group of the Epilepsy Centre included 108 men (48%) and 117 women (52%). 
In the group of the University Hospital there were 61 men (51%) and 59 women 
(49%). There was no difference between the centres concerning gender distribution 
(p=0.81). 
3.1.3.1.3 Age 
No significant difference was observed concerning the age distribution between 
groups from the Epilepsy Centre and the University Hospital (p=0.16). Even though 
for the Epilepsy Centre a peak was seen for the age group of 30-49 years and for the 
University Hospital there was a peak for the age group of 20-29 years. 
3.1.3.1.4 Duration of epilepsy 
A significant difference was seen in the duration of the epilepsy between the 
Epilepsy Centre and the University Hospital (p=0.0001). The median duration of the 
epilepsy was 20 years for the Epilepsy Centre and 10 years for the University 
Hospital. 
3.1.3.1.5 Seizure types 
At the University Hospital a higher percentage of patients had primarily generalised 
tonic-clonic seizures (PGTCS) 45.8% vs 11.6% for the Epilepsy Centre (p=<0.001), 
whereas at the Epilepsy Centre a higher percentage of patients with secondarily 
generalised tonic-clonic (SGTCS) seizures was observed, although not significantly 
different, 16.4% vs 9.2% for the University Hospital (p=0.08). No difference was seen 
concerning the partial seizures between the Epilepsy Centre and the University 
Hospital. The patients of the Epilepsy Centre had a greater diversity of seizure types. 
Apart from the above mentioned types myoclonic, tonic, and atonic seizures were seen 
in this group, although mostly in combinations with other seizure types. 
Patients with more than one seizure type were more common at the Epilepsy Centre 
than at the University Hospital, 45.4% vs 15.1% respectively (p<0.001). 
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3.1.3.1.6 Treatment 
More patients were treated with monotherapy at the University Hospital 62.5% vs 
28.0% at the Epilepsy Centre (p<0.001). At both centres if monotherapy was used 
carbamazepine was the preferred drug. 
The average number of antiepileptic drugs (AED) used per patient was 2.0 for the 
Epilepsy Centre and 1.4 for the University Hospital. 
The PDD/DDD ratio showed a significant difference between the two centres. The 
median PDD/DDD ratio was 1.7 for the Epilepsy Centre and 0.8 for the University 
Hospital (p=0.0001). 
Carbamazepine was prescribed most frequently at both centres, although significantly 
more so at the Epilepsy Centre (p=0.001), valproate was the second most prescribed 
drug at the Epilepsy Centre and at the University Hospital phenytoin and valproate 
shared the second place (Table 3.1.1). 
Table 3.1.1. Most prescribed antiepileptic drugs (AED). 
AED 
Carbamazepine 
Valproate 
Phenytoin 
Phénobarbital 
Other AEDs 
University Hospital 
percentage (n) 
56.7 (68) 
26.7 (32) 
27.5 (33) 
18.3 (22) 
8.3 (10) 
Epilepsy Centre 
percentage (n) 
74,7 (168) 
44.0 (99) 
33.3 (75) 
12.9 (29) 
39.1 (88) 
At the Epilepsy Centre a greater diverseness was seen in the drugs prescribed. 
Drugs which at that time were still in the premarketing phase like vigabatrin or 
oxcarbazepine were prescribed at the Epilepsy Centre but not at the University 
Hospital (Table 3.1.2). 
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Table 3.1.2. Average dose and PDD/DDD ratio of AEDs prescribed. 
AED 
Acetazolamide 
Carbamazepine 
Clobazam 
Clonazepam 
Diazepam 
Ethosuximide 
Flunarizine 
Nitrazepam 
Oxazepam 
Oxcarbazepine 
Phénobarbital 
Phenytoin 
Primidone 
Valproate 
Vigabatrin 
University Hospital 
mg 
0.00 
837.67 
0.00 
4.00 
8.00 
100.00 
0.00 
0.00 
30.00 
0.00 
113.25 
271.00 
450.00 
1349.33 
0.00 
η 
68 
2 
2 
1 
1 
22 
33 
4 
32 
PDD/DDD 
0.84 
0.50 
0.80 
0.08 
0.60 
1.13 
0.90 
0.36 
0.90 
Epilepsy Centre 
mg 
375.00 
938.10 
17.96 
3.92 
7.33 
800.00 
5.00 
7.50 
0.00 
1650.00 
61.21 
335.47 
579.55 
1372.73 
1520.00 
η PDD/DDD 
2 
168 
27 
3 
3 
10 
2 
2 
3 
29 
75 
11 
99 
25 
0.50 
0.93 
0.90 
0.49 
0.73 
0.64 
0.50 
1.50 
1.65 
0.61 
1.20 
0.46 
0.92 
0.76 
The DDD for Acetazolamide and Flunarizine were defined for their principal uses, i.e. glaucoma and 
migraine respectively. 
3.1.3.2 Clinimetric assessment 
3.1.3.2.1 Index of Seizures (IS) 
A significant difference for the IS was observed between the University Hospital 
and the Epilepsy Centre (p=0.0007). Complete seizure remission (IS=0) was achieved 
for more patients at the University Hospital than for the patients at the Epilepsy 
Centre, 43.3% vs 19.2% respectively (p<0.001). In the group of patients with an IS 
score of > 100 no significant difference was found between the two centres. At the 
University Hospital 13.3% of the patients had a score for the IS of >100, at the 
Epilepsy Centre this was 16.4% (p=0.57). 
3.1.3.2.2 Seizure Activity Index (SA) 
The SA also showed a significant difference between the University Hospital and 
the Epilepsy Centre (p=0.0024). Although the mean SA was lower for the University 
Hospital, 10% of these patients had an SA >100 compared to 8.9% for the Epilepsy 
Centre (p=0.86). 
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3.1.3.2.3 Toxicity Ratings 
Neurotoxicity rating (NTX) was significantly lower at the University Hospital 
(p=0.0001) in comparison with the Epilepsy Centre. As for the Systemic toxicity rating 
(STX), this was likewise significantly lower for the University Hospital than for the 
Epilepsy Centre (p=0.021). At the Epilepsy Centre 15.0% of the patients had an STX 
>0 and at the University Hospital this was only 4.2%. 
3.1.3.2.4 Composite Index of Impairments (СИ) 
The СП was significantly higher at the Epilepsy Centre (p=0.0001). At the 
University Hospital 37.5% of the patients had complete seizure control and no side-
effect of the medication, which resulted in а СИ score of 0. This was the case for 
merely 8.9% at the Epilepsy Centre (p<0.001). For the group of patients with a СИ 
score of >100, like with the IS and SA, no significant difference was found between 
the two centres. At the Epilepsy Centre 10.7% had an СП score >100, and at the 
University Hospital this was 10.8% (p=1.00) (fig. 3.1.1) 
percentage of patients Composite Index of Impairments 
0 10 20 30 40 50 60 70 80 90 100 >100 
СП 
Ц University Hospital ΞΞΞ Epilepsy Centre 
Univ 
Epile 
37.5 
8.9 
1.7 
9.8 
16.7 
13.6 
5.8 
17.8 
4.1 
7.9 
3.3 
9.8 
1.7 
6.5 
1.7 
4.2 
0.8 
1.9 
0 
2.8 
0.8 
1.4 
10.8 
10.7 
Figure 3.1.1. Distribution of the Composite Index of Impairments for the University Hospital and the 
Epilepsy Centre. 
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At both centres no clear correlation was observed between the duration of the 
epilepsy and the outcome of any of the indexes (Spearman correlation coefficient was 
0.06 or lower). Also no significant correlation was seen between the PDD/DDD ratio 
and the toxicity ratings (Spearman correlation coefficient was 0.49 or lower). 
3.1.4 Discussion 
In the assessment of epilepsy treatment policies two medical centres have been 
compared. A University Hospital, which provides secondary referral care and a 
Comprehensive Epilepsy Centre, which provides tertiary referral care. 
Effect parameters concerning psychosocial and occupational impacts due to 
disabilities and handicaps were left out of consideration. Despite of their great 
importance for the assessment of the patient's wellbeing and quality of life (Baker, et 
al., 1991), it is believed that they are more informative about the interactions between 
the disease characteristics and the personality of the patient. Furthermore the sensitivity 
and specificity of quality of life models for the efficacy of certain antiepileptic drugs 
have not yet been demonstrated sufficiently and as yet are not designed to reflect 
pharmacotherapy policies (Spilker, 1992). 
Marked differences were found with respect to the duration of the epilepsy of the 
patients at both centres. At the Epilepsy Centre the duration of the epilepsy was two 
times longer. This would implicate that a longer duration of epilepsy leads to a more 
severe form of this disorder, so that specialised care is necessary. Also the greater 
variation in seizure types observed in the Epilepsy Centre and the combination of 
different seizure types can be the expression of intractability. 
At the University Hospital more patients had primarily generalised tonic-clonic 
seizures (PGTCS) than at the Epilepsy Centre. At the Epilepsy Centre more 
secondarily generalised tonic-clonic seizures (SGTCS) were seen. This might be due to 
different ways of interpretation and of diagnosing the seizures or to the fact that partial 
epilepsies have a less good prognosis for seizure control, so they would be encountered 
more often at a specialised centre. Beghi et al. (Beghi, et al , 1982) reported 57.8% 
PGTCS in a survey of hospitalised patients at neurology departments and 9.6% 
SGTCS, which coincides with the occurrences at the University Hospital. Keränen et 
al. (Keränen, et al., 1988), however, found a more balanced distribution of both seizure 
types: 23.0% for PGTCS and 25.5% for SGTCS in a population of 1220 epileptic 
patients. The better average seizure control at the University Hospital might be due to 
the higher occurrence of PGTCS, which have a good prognosis for seizure remission. 
Keränen found similar frequencies for complex partial seizures as were found in both 
centres in our survey, but a higher incidence of simple partial seizures: 7.5% for 
Keränen, 1.7% for the University Hospital and 1.3% for the Epilepsy Centre. 
In a recent paper by Remy et al. (Remy, et al., 1992) in which a comparison was 
made between a neurology department, an epilepsy centre, and a neurosurgical 
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department, a similar distribution of partial and generalised epilepsies at respectively 
the neurology department and the epilepsy centre as in our study was reported. 
At the Epilepsy Centre less patients were on monotherapy. This could be expected 
on grounds that at a specialised institution more patients have severe forms of epilepsy, 
leading to more medication. Remy et al. also found more patients in their population 
on monotherapy at the neurology department (42.1%) as compared with 6.4% at the 
epilepsy centre. In our study the percentage of patients on monotherapy was higher 
than Remy's for both centres, 62.5% for the University Hospital and 28.0% for the 
Epilepsy Centre. More polytherapy, together with a higher average dosage prescribed 
per drug would explain the higher PDD/DDD ratio for the Epilepsy Centre. 
Surprisingly the PDD/DDD ratio did not correlate with the toxicity ratings, thus a 
higher PDD/DDD did not lead to more toxicity. The serum levels of the drugs could 
not be taken into consideration, because not all serum levels were available. Therefore, 
no final conclusion could be reached as to the correspondence between the PDD/DDD 
ratio, serum level and toxicity rating. Another possible explanation for the lack of 
correlation between the PDD/DDD ratio and the toxicity rating might be the long 
duration of epilepsy and the subsequent development of tolerance for the adverse 
effects of the drugs. 
At a specialised Epilepsy Centre it would be expected that patients would have a 
more severe form of epilepsy than at a clinic for secondary referral care. This 
difference is shown in the outcome of the Index of Seizures. At the University 
Hospital a higher percentage of patients had an IS score of 0, which indicates complete 
seizure remission, and they also had in general a lower IS score, signifying better 
seizure control. 
At the University Hospital 88.3% of the patients had one or more factors which 
decrease the seizure severity; at the Epilepsy Centre this was 55.6%. 
The Composite Index of Impairments is in general higher for patients at the 
Epilepsy Centre, which indicates a lesser control of the epilepsy and/or more toxicity 
of medication. The point that at the Epilepsy Centre fewer patients are seizure free can 
be explained by the fact that when a patient at the Epilepsy Centre is completely 
seizure free for some time, this patient will be referred back to a secondary care 
facility or to his or her general practitioner. 
Surprisingly in the group of patients with very poor control of the epilepsy, i.e. a 
СП > 100 no marked difference was seen between the two centres. The presence of 
such a group at a secondary referral care facility is surprising because one would 
expect that these patients would have been referred to the next echelon. 
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3.1.5 Conclusions 
Distinct differences have been found comparing a secondary referral care facility 
and a tertiary referral care facility concerning treatment policies as well as outcome of 
treatment, while no significant differences were found between subgroups of the 
tertiary referral care facility. 
This study shows that the Composite Index of Impairments, a tool first used in drug 
efficacy studies, is sufficiently sensitive to identify differences in health care facilities 
for epilepsy. 
Further analysis is needed to obtain an answer as to why differences between the 
two groups exist. It is possible that the differences in treatment and outcome are based 
either on the difference in patient characteristics or treatment policies characteristics of 
the two groups. For example the group of the Epilepsy Centre had a greater variety of 
seizure types than the group of the University Hospital and the duration of the epilepsy 
was longer in the first group. In order to find a possible answer to these questions a 
study is initiated where patients of both centres are compared matched with respect to 
factors expected to influence outcome, e.g. duration of epilepsy and seizure type. 
Results of that study will be presented in section 3.2. 
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3.2 Epilepsy Treatment in The Netherlands. Comparison of Matched Groups of two 
Medical Centres. 
3.2.1 Introduction 
In order to test the feasibility of comparing epilepsy treatment policies and outcome, 
a secondary epilepsy care facility (University Hospital) and a tertiary epilepsy care 
facility (Epilepsy Centre) have been audited in a previous study by Wijsman et al. 
(Wijsman, et al., 1993). In that study marked differences have been found between the 
two centres in parameters indicating outcome of treatment. Between the two centres 
distinct differences were observed in the distribution of seizure types, duration of the 
epilepsy, and treatment policies. It was not clear however from the study why these 
differences exist. It is possible that the differences in the treatment and the outcome of 
treatment are based either on differences in the patient groups or differences of 
treatment approaches. 
In order to find a possible answer to these questions the patient groups of both 
centres were matched according to seizure type and duration of epilepsy. 
3.2.2 Statistical analysis 
For the study of gender distribution at the centres the χ2 test was used. In the study 
of the different variables the Kruskal-Wallis test was applied. When significant 
differences were found between the centres, the Wilcoxon rank sums test was also 
employed. The differences were found statistically significant when ρ <0.05. 
3.2.3 Matching according to seizure type and duration of epilepsy 
In the initial comparison study 345 patients were entered, a group of 225 from the 
Epilepsy Centre, and a group of 120 from the University Hospital. As was mentioned 
above, the patients of both centres were matched according to seizure type and 
duration of epilepsy. In total 64 patients entered this study, 32 patients per centre. 
3.2.4 Results 
3.2.4. J Population characteristics 
3.2.4.1.1 Seizure type 
After the matching procedures the seizure distribution was as described in table 
3.2.1. Primarily generalised tonic-clonic seizures and complex partial seizures were 
most frequently seen in this patient group. 
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Table 3.2.1. Distribution of seizure types. 
seizure type 
CPS 
SGTCS 
PGTCS 
SPS+SGTCS 
CPS+SGTCS 
percentage of patients (n=pairs) 
28.1 (9) 
15.6 (5) 
34.4 (11) 
3.1 (1) 
18.8 (6) 
CPS=complex partial seizure; SGTCS=secondarily generalised tonic-clonic seizure; PGTCS=primarily generalised tonic-clonic seizure; 
SPSesimple partial seizure. 
3.2.4.1.2 Duration of epilepsy 
The duration of epilepsy for the matched groups is shown in table 3.2.2. A peak 
was seen for the duration of the epilepsy of 6 to 10 years. 
Table 3.2.2. Duration of epilepsy. 
duration of epilepsy 
1- 5 years 
6-10 years 
11-15 years 
16-20 years 
percentage of patients (n=pairs) 
25.0 (8) 
43.8 (14) 
18.8 (6) 
12.5 (4) 
3.2.4.1.3 Gender 
For the group of the Epilepsy Centre 16 men and 16 women (50% each) entered the 
study and for the University Hospital this was 17 men (53.1%) and 15 women (46.9%) 
respectively. No significant difference was found in the gender distribution between the 
two groups (p=1.00). 
3.2.4.1.4 Age 
Concerning the age distribution a significant difference was only found in the age 
group of 15-19 years, with 6 patients (18.8%) at the Epilepsy Centre and 1 patient 
(3.1%) at the University Hospital. No great differences were observed in the other age 
groups. 
3.2.4.1.5 Treatment 
At both centres carbamazepine was the drug of first choice (at the Epilepsy Centre 
68.8%, at the University Hospital 50.0%) and valproate was the second most 
frequently prescribed drug for the Epilepsy Centre (50.0%). At the University Hospital 
valproate and phenytoin shared a second place, closely followed by phénobarbital. 
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There was no significant difference between both centres for the frequency of 
prescription of these four drugs, (table 3.2.3) 
Table 323, Most frequently prescribed antiepileptic drugs. 
AED 
Carbamazepin 
Valproate 
Phenytoin 
Phénobarbital 
Other AEDs 
Epilepsy Centre 
percentage (n) 
68.8 (22) 
50.0 (16) 
25.0 (8) 
9.4 (3) 
25.0 (8) 
University Hospital 
percentage (n) 
50.0 (16) 
31.3 (10) 
28.1 (9) 
21.9(7) 
9.4 (3) 
Concerning the individual drugs prescribed in this group it was noticed that the drugs 
ethosuximide and diazepam were only prescribed at the University Hospital. Clobazam 
and vigabatrin were only prescribed at the Epilepsy Centre, (table 3.2.4.) 
Table 3.2.4. Average dose and PDD/DDD ratio of AED prescribed. 
AED 
Carbamazepine 
Clobazam 
Diazepam 
Ethosuximide 
Phénobarbital 
Phenytoin 
Primidone 
Valproate 
Vigabatrin 
Epilepsy Centre 
mg 
813.64 
13.33 
-
-
73.33 
285.71 
500.00 
1250.00 
1500.00 
(η) 
(22) 
(3) 
-
-
(3) 
(8) 
(2) 
(16) 
(3) 
PDD/DDD 
0.81 
0.67 
-
-
0.73 
0.95 
0.40 
0.83 
0.75 
University Hospital 
mg (η) 
678.33 (16) 
-
10.00 (1) 
1000.00 (1) 
133.00 (7) 
354.00 (9) 
1250.00 (1) 
1037.50 (10) 
-
PDD/DDD 
0.68 
-
1.00 
0.80 
1.33 
1.18 
1.00 
0.69 
-
PDD/DDD=prescribed daily dose/defined daily dose. 
At the University Hospital more patients were treated with monotherapy (56.2%) 
compared to the Epilepsy Centre (40.6%), although this difference was not statistically 
significant. When the patients were treated with monotherapy, carbamazepine was most 
frequently prescribed at the Epilepsy Centre, (53.8% of the patients on monotherapy). 
At the University Hospital, carbamazepine and valproate monotherapy were prescribed 
for an equal number of patients (44.4%). At the Epilepsy Centre 56.2% of the patients 
were treated with polytherapy and at the University Hospital this value was 37.5%. 
This difference was not statistically significant. 
The average number of AED used per patient was 1.8 for the Epilepsy Centre and 
1.4 for the University Hospital. 
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The différence as to the PDD/DDD ratio between the two centres was not 
statistically significant, but only marginally so (p=0.056). 
3.2.4.2 Clinimetric assessment 
3.2.4.2.1 Index of Seizures (IS) 
For the distribution of the Index of Seizures a statistically significant difference was 
seen between both centres (p=0.037). Complete seizure remission was achieved for 
more patients at the University Hospital than at the Epilepsy Centre, 56.3% vs 18.8% 
respectively, which was statistically significant (p=0.003). In the group of patients with 
an IS score of >100 no statistical difference was seen; 21.9% for the University 
Hospital and 18.8% for the Epilepsy Centre. 
3.2.4.2.2 Seizure Activity Index (SA) 
For the Seizure Activity Index no significant difference was observed between the 
two centres (p=0.060). As was seen before for the IS more patients of the University 
Hospital than patients of the Epilepsy Centre had an SA score of 0, but twice as many 
patients at the University Hospital as at the Epilepsy Centre had an SA score of >100, 
18.8% vs 9.4% respectively, although this was not statistically significant. 
3.2.4.2.3 Toxicity Ratings 
The Neurotoxicity rating (NTX) was significantly lower for the patients at the 
University Hospital than at the Epilepsy Centre (p=0.003). At the University Hospital 
71.9% of the patients had an NTX of 0, while at the Epilepsy Centre this was 21.9%. 
The Systemic toxicity rating was likewise significantly lower for the patients at the 
University Hospital than at the Epilepsy Centre (p=0.016). At the Epilepsy Centre 
18.1% of the patients had an STX >0 and at the University Hospital this was only 
6.2%. 
3.2.4.2.4 Composite Index of Impairments (СП) 
For the distribution of the Composite Index of Impairments a statistically significant 
difference was found between the University Hospital and the Epilepsy Centre 
(p=0.014). At the University Hospital far more patients than at the Epilepsy Centre had 
а СП score of 0 (45.9% vs 9.4% (p=0.001)), indicating that more patients were seizure 
free and had no side-effects of medication at the University Hospital. On the other 
hand 18.8% of the patients at the University Hospital had а СП score of >100, this 
was only the case for 9.4% of the patients at the Epilepsy Centre, however again this 
was not statistically significant, (fig. 3.2.1) 
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Figure 3.2.1. Distribution of the Composite Index of Impairments for the University Hospital and the 
Epilepsy Centre. 
3.2.5 Discussion 
In a previous study two medical centres were compared to assess epilepsy treatment 
policies and treatment outcome, using clinimetrical indexes (Wijsman, et al., 1993). 
These centres were a University Hospital, which provides secondary epilepsy care and 
a Comprehensive Epilepsy Centre, which provides tertiary epilepsy care. Marked 
differences were found with respect to both treatment policies and outcome of 
treatment. Also differences in the distribution of seizure types and the duration of 
epilepsy were observed between the two centres. At the Epilepsy Centre a larger 
variety of seizure types was observed and also many patients had multiple types of 
seizures. This could point to the presence of a larger number of patients with 
intractable epilepsy. At the Epilepsy Centre the duration of epilepsy was twice that 
observed at the University Hospital. A longer duration of epilepsy could be the 
expression of more severe forms of epilepsy, or more psychosocial problems. 
In order to find answers as to why these differences in treatment and outcome of 
treatment exist, the patients of the two centres were matched according to factors 
expected to influence the outcome, i.e. seizure type and duration of epilepsy. 
The matching procedures resulted in a group of 32 matched pairs only. This 
influences the power of the statistics. 
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In this study concerning matched pairs no big difference was found in the treatment 
strategies of both centres. Both centres used almost the same drugs to treat the 
patients, and where the drugs used were the same, an equal number of patients was 
treated in each group. The dose prescribed for the drugs, expressed as the Prescribed 
Daily Dose/Defined Daily Dose ratio, did not differ significantly between the two 
centres. Also the number of drugs per patient was not significantly different for both 
centres. 
Marked differences were found for the outcome of treatment. At the University 
Hospital a higher percentage of patients had a score for the Index of Seizures of 0, 
indicating complete seizure remission. At the University Hospital also a lower average 
IS score was observed signifying better seizure control. However the number of 
patients with an IS score of >100 was the same in both centres. 
The Seizure Activity Index which expresses the seizure related handicap did not 
differ significantly (p=0.060) because at the Epilepsy Centre 65.6% of the patients had 
one or more factors which decreased the seizure severity, compensating the higher IS 
score. While at the University Hospital this was only the case for 59.4%. 
There was a significant difference in the STX and NTX. The Epilepsy Centre score 
was higher than the University Hospital score, despite the fact that the overall 
pharmacological treatment did not differ significantly between the two centres. The 
reason for this difference is not clearly understood. The toxicity scores were not 
specifically greater in particular age groups. However the weight of the patients could 
be of influence on the toxicity scores, and this data is not available. 
At the University Hospital a higher percentage of patients had a score for the 
Composite Index of Impairments of 0, which indicates complete seizure remission and 
no toxicity of medication. Also the average СИ score was lower for the University 
Hospital than for the Epilepsy Centre. The number of patients with a СП score >100 
did not differ significantly between both centres. This was also the case for the number 
of patients with a high IS score. 
3.2.6 Conclusions 
No distinct differences were found in the treatment policies between a secondary 
epilepsy care centre and a tertiary epilepsy care centre after patients were matched 
according to seizure type and duration of epilepsy. Yet there were distinct differences 
in treatment outcome as assessed by the Composite Index of Impairments. The 
combination "same treatment but different outcome" agrees with an expected 
prevalence of more difficult to treat patients in a tertiary referral care centre. The 
matching variables "seizure type" and "duration of epilepsy" were thought to reflect the 
severity of epilepsy. Selecting patients by matching for seizure type and duration of 
epilepsy as evidence of similar severity is apparently insufficient to obtain completely 
comparable groups. Our results could mean that other factors, aside from the seizure 
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type and duration of epilepsy are of importance to the outcome of treatment of 
epilepsy. 
The finding that pharmacotherapy is similar in the secondary and tertiary centre 
suggests that pharmacotherapy is pushed to its limits in both, and that referral to a 
tertiary facility is mainly for the non-pharmacotherapeutic care modalities available. 
This could not be assessed as the Composite Index of Impairments is essentially an 
index to measure outcome of pharmacotherapy and the psychosocial aspects are not 
taken into consideration. A quality of life scale would probably be a more appropriate 
index to compare secondary and tertiary referral care centres. Such scales are presently 
under development (Meinardi, et al., eds., 1993). 
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4. A CLINIMETRIC ANALYSIS OF TREATMENT OBJECTIVES AND 
CLINICAL STATUS. INDIVIDUALISED TREATMENT IN EPILEPTIC 
PATIENTS. 
4.1 Introduction 
In recent years attention has focused on clinimetric analysis of the treatment of 
patients with epilepsy (Cramer et al., 1983; Feinstein, 1987; Mattson et al., 1985; 
Smith et al., 1987; Wijsman et al., 1991; Wijsman et al., 1993). 
In many medical curricula emphasis is placed on the diagnosis of diseases and 
disorders based upon the symptoms and signs collected by history taking, physical 
examination, and laboratory tests. Much less emphasis is given to treatment. In 
particular this is evident when reading textbooks and inspecting texts for advice on 
how to deal with chronic disorders for which the goal of complete restitutio ad 
integrum is unachievable. Clinimetrics allows the outcome of treatment to be expressed 
as quantitative indexes. 
In this study the more or less implicit goals pursued by a clinician who treats 
patients with epilepsy are compared with the results of a clinimetric assessment of the 
treatment outcome. The relationship of these data with monopharmacy and 
polypharmacy is also assessed. Objective of the study was to assess the feasibility, the 
advantages and disadvantages of the use of quantitative outcome measurements in 
routine clinical epilepsy care. 
4.2 Statistical analysis 
For the study of the treatment objectives and their outcome, the χ2 test was applied. 
For the assessment of differences in age and gender distribution, as well as the 
differences in the clinical status ratings, the Wilcoxon matched-pairs signed rank test 
scores and the Kruskal-Wallis test were used. 
To assess the correlation of the individual variables, the Spearman correlation 
coefficient was used. The differences were statistically significant when p<0.05. 
4.3 Results 
4.3.1 Gender, age at onset, and duration of epilepsy 
Of the total of 248 patients who entered this study, 116 were men (47%) and 132 
were women (53%). No statistically significant difference was seen in the gender 
distribution. 
Table 4.1 shows the age at onset of epilepsy in relation to treatment. For 25% of the 
patients on monopharmacy, the age at onset was before the age of 10; for the patients 
on polypharmacy, this was the case in 37.2% of the cases. This difference was not 
statistically significant. 
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Table 4.1. Age at onset of epile 
Age at onset epilepsy 
(years) 
0 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
71-80 
81-90 
¡)sy 
Monopharmacy 
% N=84 
1.5 
11.2 
52.9 
11.2 
11.8 
5.9 
1.5 
1.5 
-
1.5 
Polypharmacy 
% N=164 
5.5 
31.7 
37.8 
15.2 
4.3 
3.7 
1.2 
-
0.6 
-
Total 
% N=248 
4.0 
27.4 
39.5 
16.5 
6.0 
4.0 
1.2 
0.4 
0.4 
0.4 
N=number of patients 
For 70% of the patients with epilepsy since infancy, the objective was treatment 
impairment/benefit balance. For patients with an age at onset between 1 and 20 years, 
the treatment objectives were equally distributed. For the patients with an age at onset 
older than 20, again a higher percentage (61%) had treatment impairment/benefit 
balance as objective. 
Table 4.2 displays the duration of the epilepsy in relation to treatment. For 40.5% of 
the patients on monopharmacy, the duration of epilepsy was 11 years or less, while for 
the patients on polypharmacy this occurred in only 16.5% of the cases (p=0.01). The 
mean duration of epilepsy was 23 years for the whole group, with a mean duration of 
17 years for the patients on monopharmacy and 26 years for the patients on 
polypharmacy. 
Table 4.2. Duration of epilepsy in relation to treatment 
Duration 
(years) 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
Monopharmacy 
% N=84 
40.5 
28.6 
13.1 
8.3 
7.1 
1.2 
1.2 
Polypharmacy 
% N=164 
16.5 
22.6 
20.7 
23.2 
12.2 
4.3 
0.6 
Total 
% N=248 
24.6 
24.6 
18.1 
18.1 
10.5 
4.9 
1.2 
N=number of patients 
The duration of epilepsy did not appear to influence the choice of treatment objective. 
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4.3.2 Seizure types 
In the whole group, 79% of the patients had partial seizures and 21% primary 
generalized seizures. Complex partial seizures with or without secondary 
generalization, and primary generalized tonic- clonic seizures were most often seen, 
23.0%, 23.4%, and 12.5%, respectively. More than half of the patients (53.6%) had 
one seizure type, the others had two or more seizure types. 
4.3.3 Treatment 
In this study, 84 patients (33.9%) were treated with monopharmacy, in which case 
carbamazepine was the most frequently prescribed drug (50.0%), followed by valproate 
(33.3%). 
In the total population of this study, an average of 1.98 AEDs were prescribed per 
patient. 
In polypharmacy a total of 59 different combinations of 17 AEDs were used. 
Carbamazepine in combination with valproate was the most frequently (21.3%) 
prescribed polypharmacy. 
Of the patients with partial seizures (N=196), 30% were treated with monopharmacy 
and 70% with polypharmacy (p=0.01). Of the patients with primarily generalized 
seizures (N=52), half were treated with monopharmacy and the other half with 
polypharmacy. 
In monopharmacy patients, the daily dosage of the AEDs did not correlate with the 
NTX or the STX scores. In polypharmacy patients, the daily dosage correlated only 
with the NTX score (corr. coefficient=0.33, p<0.01). For the patients treated with 
monopharmacy, the average toxicity scores were lower than for the patients treated 
with polypharmacy (sum of the toxicity scores: 8.5 and 17.1, respectively). Also the 
average СП score was lower for patients on monopharmacy than for patients on 
polypharmacy (23 and 44, respectively). 
4.3.4 Treatment Objectives 
In order to see whether the judgement of the clinician was influenced by the seizure 
type and treatment, we examined the agreement between the clinician's evaluation and 
the clinimetric scores for the patients with partial seizures on monopharmacy and 
polypharmacy, and patients with primarily generalized seizures on monopharmacy and 
polypharmacy (Figures 4.2a, 4.2b, 4.3a, 4.3b). 
4.3.4.1 Complete Seizure Remission 
For 112 patients (45.2%), the treatment objective was complete seizure remission. 
According to the treating clinician, this objective was achieved by 85.7% of these 
patients. However only 62.5% had an IS score of 0-10. For the remaining 42 patients, 
the IS score ranged from 15 to 75, with a median of 20. For 14.3% of the patients, the 
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treatment objective of seizure remission had not been achieved according to the 
treating clinician, and no patient of this group had an IS score between 0 and 10. 
When considered in more detail, the following picture emerges. Of the patients with 
complete seizure remission as their treatment objective, 71% (80 patients) had partial 
seizures, 44% of whom were treated with monopharmacy, as is shown in Figure 4.2a. 
In the case of partial seizures and monopharmacy, the clinician was of the opinion that 
complete seizure remission was achieved in 83% of the patients. However, according 
to the IS score this was only correct for 69% of the patients. When the clinician 
judged that the treatment objective was not achieved, it was in complete agreement 
with the IS scores. 
Of the patients with partial seizures who were treated with polypharmacy (56%), the 
clinician considered that 87% of these patients achieved complete seizure remission. 
The IS scores were in agreement for 79% of these patients and disagreed for 21% of 
the cases. Again the IS scores were in complete agreement when the clinician thought 
that the patients had not achieved complete seizure remission. 
Complete Seizure Remission 
(N-112) 
Monopharmacy 
44% N-35 
Achieved 
S3%N-29 
PS 
71% N-80 
Not achieved 
17% N-« 
IS<-10 
69% N-20 
IS>10 
31% N-S 
IS<-10 
0% 
IS>10 
100% 
Polypharmacy 
56%N-4S 
Achieved 
g7% N-39 
IS<-10 
79% N-31 
IS>10 
2 1 » N - § 
Not achieved 
13% N-6 
1 
IS<-10 
0% 
IS>10 
100% 
Figure 4.2a. Outcome of treatment objective "Complete Seizure Remission" for patients with partial 
seizures. 
PS= Partial Seizures; N= number of patients; 
(Not) Achieved= (Not) Achieved according to clinician. 
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Primary generalized seizures was the seizure type for 29% of the patients with 
complete seizure remission as treatment objective (Figure 4.2b). Of these patients 62% 
were treated with monopharmacy, and the clinician judged the treatment objective 
achieved in 95% of the cases. This evaluation was in agreement with the IS scores for 
79% of these patients. When the clinician judged the treatment objective not achieved, 
this was in complete agreement with the IS scores. 
Of the patients with primary generalized seizures, 38% were on polypharmacy. The 
clinician was of the opinion that 75% had achieved complete seizure remission, an 
evaluation that agreed with the IS scores for only 44% of the patients. Again when the 
clinician judged the treatment objective not to have been achieved for these patients, it 
was in complete agreement with the IS scores. 
Complete Seizure Remission 
(N-112) 
! P G S i 
j 29% N « 3 2 I 
I Monopharmacy 
i 62% N - 2 0 
Achieved ¡ 
95% N-19 | 
ι is<-io 
I 7 9 * N-1$ 
IS>10 
I 21» N»4 
j Not achieved 
1
 5 % N - 1 
IS<-10 j 1S>10 
100% 
г 
! Polvphaxmac 
38% N-12 
Achieved 
75% N-9 
1 
, IS<-10 
1 44% N-4 
* 
1 IS 
1 56* 
Ί 
>10 ' ! 
N - 5 | 1 
) ! 
j Not achieved 
¡ 25% N-3 
I 
1S<-10 
0% 
I 1S>10 
j 100% 
Figure 4.2b, Outcome of treatment objective "Complete Seizure Remission" for patients with primarily 
generalised seizures 
PGS= Primarily Generalised Seizures, N= Number of patients; 
(Not) Achieved= (Not) Achieved according to clinician 
No statistically significant difference was seen in the achievement of this treatment 
objective between the patients on monopharmacy or polypharmacy, nor between 
patients with partial seizures or primary generalized seizures. 
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4.3.4.2 Treatment Impairment/Benefit Balance 
A balance between impairment due to and benefit from treatment was the objective 
for 136 patients (54.8%). According to the clinician this goal was achieved for 72.1% 
of the patients. However 27.6% of these patients (38 patients) had а СП score of more 
than 50, a fact indicating that the epilepsy was not adequately controlled (Cramer et 
al., 1983; Wijsman et al., 1991). 
Although complete seizure remission was thought not to be achievable for these 
patients, 12.5% had an IS score of 0-10. One patient had а СП score of 0, meaning 
complete seizure remission and no side-effects of medication. 
Figures 4.3a and 4.3b show the agreement between the clinician's evaluation and 
the СП score for the treatment impairment/benefit balance goal. Of these patients, 85% 
had partial seizures (Figure 4.3a). For patients with partial seizures 20% were treated 
with monopharmacy, 83% of whom achieved this objective according to the clinician. 
The СП scores agreed for 79% of these patients and disagreed for 21%. When the 
clinician judged the treatment objective not achieved (17%), the СП scores disagreed 
in 50% of the cases. Of the patients (80%) with partial seizures who were treated with 
polypharmacy, the clinician considered 70% to have achieved a good treatment 
impairment/benefit balance. For 72% of these patients the СП scores were in 
agreement. According to the clinician 30% did not achieve this treatment objective. 
The СП score disagreed with this evaluation in 64% of the cases. 
Treatment Impairment/Benefit Balance 
(N-136) 
Monophannacy 
20% N-23 
PS 
85% N-116 
Achieved 
83% N-19 
Net achieved 
17%N-4 
СП<-50 
79%N-15 
CT>50 
21% N-4 50% N-2 
СП<-50 СП>50 
Polypharmacy 
8 0 % N - 9 3 
Achfeved 
70%N-65 
Not achieved 
30% N-2* 
CD<-50 СП>50 
50% N-2 72%N-47 21% N-l l 64% N-l l 36% N-10 
СП<-50 СП>50 
Figure 4.3a. Outcome of treatment objective "Treatment Impairment/Benefit Balance" for patients with 
partial seizures. 
PS= Partial Seizures; N= Number of patients; 
(Not) Achieved= (Not) Achieved according to clinician. 
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Of the patients with treatment impairment/benefit balance as the goal, 15% had 
primary generalized seizures, 30% of whom were on monopharmacy (Figure 4.3b). 
According to the clinician, 83% of these patients achieved the treatment objective, 
while according to the СП scores this was correct in 80% of the cases. There was no 
disagreement between the clinician's judgement and the СП scores when the treatment 
objective was considered not to have been achieved. In the case of primary generalized 
seizures and polypharmacy (70%), the clinician was of the opinion that treatment 
impairment/benefit balance was achieved for 64% of the patients. The СП scores 
agreed in 56% of the cases. When the clinician considered the treatment objective not 
to have been achieved, the СП score was in agreement in only 20% of the cases. 
Treatment Impairment/Benefit Balance 
(N=136) 
Monopharmacy 
3 0 % N - 6 
1 
Achieved 
83%N-S 
1 
СЛК-50 
80%N-4 
1 
СП>50 
20%N-1 
PGS 
15% N-20 
Not achieved 
17% N-l 
СП<-50 
0% 
OI>50 
100% 
1 
1 
Achieved 
6 4 % N - 9 
1 
СП<-50 
56%N-5 
Polypharmacy 
70% N-14 
1 
СП>50 
44%N-4 
Not achieved 
36%N-5 
1 
СП<-50 
20% N-l 
СП>50 
80%N-4 
Figure 4.3b. Outcome of treatment objective "Treatment Impairment/Benefit Balance" for patients with 
primarily generalised seizures. 
PGS= Primarily generalised Seizures; N= number of patients; 
(Not) Achieved= (Not) Achieved according to clinician. 
No statistical significant difference was seen in the achievement of this treatment 
objective between the patients on monopharmacy or polypharmacy, or between patients 
with partial seizures or primary generalized seizures. 
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4.3.5 Treatment Objectives and Clinical Status 
None of the patients had a clinical status rating of 6 or 7 (Table 4.3). 
Table 4.3. Treatment Objective and Clinical Status Rating 
Treatment Objective 
Seizure Remission + 
Seizure Remission -
Impairment/Benefit + 
Impairment/Benefit -
Total 
Clinical Status Rating 
1 2 3 4 5 6 7 
η η η η η η η 
14 75 6 1 - - -
1 12 3 . . . . 
- 53 33 12 - - -
- 3 26 7 2 - -
15 143 68 20 2 - -
n=number of patients 
+ = objective achieved according to clinician 
- = objective not (yet) achieved according to clinician 
When patients were seizure free but had a clinical status rating of more than 1, this 
was associated with high toxicity ratings. 
In those patients where the objective was treatment impairment/benefit balance, a bad 
clinical status was found to correlate with a high IS score, high toxicity ratings or 
both. 
The overall clinical status rating correlated with the outcome of the Composite 
Index of Impairments (corr. coefficient=0.45, p<0.01) (Table 4.4). 
Table 4.4. Clinical Status Rating and СП 
Clinical Status Rating 
1 
2 
3 
4 
5 
6 
7 
CII 
Mean (Range) 
16 ( 0- 55) (n= 15) 
26 ( 0-170)(n=143) 
53 ( 5-195) (n= 68) 
73 (21-227) (n= 20) 
67 (45- 88) (n= 2) 
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4.4 Discussion 
Clinimetric analysis of the treatment of patients with epilepsy has been applied by 
various authors over the past ten years (Cramer et al., 1983; Feinstein, 1987; Mattson 
et al., 1985; Smith et al., 1987; Wijsman et al., 1991; Wijsman et al., 1993). 
Our study compared the attainment of the implicit goals pursued by the clinician 
with the results obtained from a clinimetric assessment of the case, which has served 
as the 'golden' standard. 
4.4.1 Age at onset and duration of epilepsy 
The age at onset influenced the choice of the treatment objectives in so far that a 
higher percentage of the patients with epilepsy since infancy had impairment/benefit 
balance as the treatment objective. This is not surprising because epilepsy starting at 
infancy has a poor prognosis for complete seizure remission (Rodin, 1968; Reynolds, 
Elwes, Shorvon, 1983). 
The duration of epilepsy did not influence the choice of treatment objective. The 
response to treatment at any stage during the epilepsy might have influenced the 
choice of treatment objective more than the actual duration of epilepsy. 
4.4.2 Treatment 
In this study of epileptic patients from tertiary care centres 34% of the patients were 
on monopharmacy and 66% on polypharmacy. This percentage is the same as was 
found in a previous study by these authors. (Wijsman et al., 1993) 
4.4.3 Seizure type 
The seizure types influenced the choice of the treatment objective. For patients with 
partial seizures the impairment/benefit balance was most frequently the treatment 
objective, while for patients with primary generalized seizures this was complete 
seizure remission. This may either point to the fact that for patients with partial 
seizures, seizure freedom is more difficult to achieve or that physicians try harder to 
control generalized seizures because of the risks involved. 
As might be expected, complete seizure remission was more frequently the treatment 
objective in patients on monopharmacy than in patients on polypharmacy (65% versus 
35%). 
4.4.4 Outcome of treatment objectives 
4.4.4.1 Complete Seizure Remission 
Complete seizure remission was the treatment objective for 112 patients. According 
to the treating epileptologist, this goal was reached in 85.7% of the cases. However 
only 62.5% of the 112 patients had an IS score of 0-10, indicating complete seizure 
remission. 
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When considering the clinimetric scores as the 'golden' standard, it may be 
concluded that the clinicians had overestimated the results of their treatment in 23.2% 
of their patients. Without further study the reason for this discrepancy can only be 
guessed at. No discrepancy was observed in the evaluation of the clinician and the IS 
score when the clinician was of the opinion that complete seizure remission had not 
been achieved. 
4.4.4.2 Treatment Impairment/Benefit balance 
Treatment impairment/benefit balance was the desired goal for 136 patients. 
According to the treating clinician, this treatment objective was achieved in 79.4% of 
the patients. However 27.6% of these patients had а СП score of more than 50 which 
indicates an inadequate control of the epilepsy according to the Veterans Affairs (VA) 
group (Cramer et al., 1983). Apparently the treating clinician had overestimated the 
results of his treatment. Of the patients who, according to the treating clinicians, had 
not achieved their treatment objective, 55.2%, nevertheless, had а СП score of 50 or 
less, which would indicate that the epilepsy is adequately controlled. The treating 
clinician's opinion that the patients with а СП of 50 or less whom he felt did not 
obtain the treatment objective could reflect his expectation that these patients could 
reach a better treatment impairment/benefit balance. 
The СП score, the score for the impairments caused by the disorder, did correlate 
significantly with the clinical status ratings given by the treating clinician. 
That the clinician in some case did not declare failure of reaching the goal of 
striking an optimal balance between seizure control and drug toxicity when the СП 
score was over 50, may have several explanations. We declared the СП for the purpose 
of this study to be the "golden standard". It was a consensus of the physicians 
originally involved in the construction of the Composite Index that a score of 50 points 
from seizures and side effects usually is a maximum tolerable level for most patients. 
It is possible that the clinician is not guided by clearcut objectives in the management 
of his patients and thus the request to pronounce these objectives creates an artificial 
situation. Or perhaps even though the clinician does formulate objectives, these are 
gauged in accordance with an implicitly estimated treatment potential which could be 
achieved by the patient. Such a standard would be inherent in each individual, and 
thus, would differ from the criteria incorporated in the СП score of 50 chosen by the 
VA group as being the criterium for the decision to change from drug A to drug В in 
a drug trial. The pronouncement of the clinician about the clinical status of his patients 
did correlate well with the СП which argues in favour of the explanation that the 
physicians and some of their patients did accept the situation as the best achievable 
even though the patient remained at a level of more than 50 points of seizure and side 
effects. 
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4.4.5 Clinical Status 
Although the clinician's assessment of the clinical status does correlate with the СП, 
the changes as assessed by the clinician in the many years of follow up will not reveal 
the underlying component responsible for these changes. The Composite Index of 
Impairments, being constructed from objective data, could easily determine such 
factors. 
58 
Chapter 5 
Monotherapy or Polytherapy for Epilepsy Revisited. 
A Quantitative Assessment. 
Lammers MW1, Hekster YA2, Keyser A1, van Lier H3, Meinardi H1, Renier WO1. 
Submitted for publication. 
1
 Institute of Neurology, University Hospital Nijmegen; 
2
 Department of Clinical Pharmacy, University Hospital Nijmegen. 
3
 Department of Medical Statistics, University Hospital Nijmegen. 
59 
Clinimetrics in epileptology 
5. MONOTHERAPY OR POLYTHERAPY FOR EPILEPSY REVISITED. 
A QUANTITATIVE ASSESSMENT. 
5.1 Introduction 
5.1.1 Monotherapy versus polytherapy 
Remaining seizure free is sufficiently important for many patients with epilepsy, for 
them to accept the adverse effects of continual use of antiepileptic drugs (AEDs). The 
problem of toxicity of antiepileptic drugs has been reviewed repeatedly (Meinardi and 
Stoel 1974; Meinardi 1980; Schmidt 1982; Oxley, Janz, Meinardi, 1983). There is a 
long tradition of using several AEDs simultaneously for the treatment of epilepsy 
(polytherapy). Reynolds and Shorvon, however, signalled three major problems 
associated with this practice: 1. Chronic toxicity; 2. Exacerbation of seizures; 3. Drug 
interactions (Reynolds and Shorvon, 1981). The evidence however lacks quantitative 
support. 
As part of the studies on the feasibility and profitability of using quantitative data it 
was decided to examine whether the incidence and/or severity of adverse effects was 
affected by the use of one AED (monotherapy) or several AEDs (polytherapy) to 
control seizures. 
Since we were only interested in comparing adverse effects in monotherapy and 
polytherapy, efficacy of monotherapy and polytherapy was not assessed in this study. 
Efficacy would be related to the severity of the epilepsy. There is no a priori reason to 
expect that sensitivity to toxic effects of AEDs is related to the severity of the 
epilepsy. 
5.1.2 Quantification of adverse effects 
Studies on the adverse effects of antiepileptic drugs rarely use quantitative data in 
order to describe the adverse effects. Quantitative data have been largely restricted to 
laboratory findings or to the results of psychological tests which both are intrinsically 
quantified. When semi-quantification is employed, categories are usually poorly 
defined and terms such as mild, moderate, or severe are used with no explanation 
what is exactly meant. (Appendix II; Lammers, Meinardi, 1993) Especially in chronic 
disorders quantitative outcome measurements have the advantage of accurate 
comparison between different stages of treatment, and are highly needed for proper 
assessment of therapeutic approaches. 
Recognizing the need for detailed measurement methodology during the design of a 
multicentre study of antiepileptic drugs, the VA Cooperative Study Group has 
developed a.o. rating scales appropriate to measure adverse effects of the drugs under 
study (phénobarbital, primidone, phenytoin and carbamazepine). (Cramer, et al., 1983; 
Mattson, et al., 1985) We have adapted these scales for the assessment of epilepsy care 
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comparing secondary and tertiary referral centres (Chapter 2). In this paper we have 
applied this methodology to permit a quantitative comparison of adverse effects that 
accompany monotherapy and poly therapy. This allows the distinction between 
frequency and severity of symptoms and signs of drug toxicity. 
5.2 Statistical analysis 
Fisher's exact test (2-tail) was applied for the assessment of differences in gender and 
for the study of the overall prevalence of adverse effects, and for the prevalence per 
stratum of PDD/DDD ratios. Fisher's exact test was used because of the size of the 
strata. The Kruskal-Wallis test was used for the assessment of differences in the 
severity of adverse effects. Differences were considered statistically significant when 
p<0.05. Multiple regression analysis was used to investigate whether gender, age, 
duration of epilepsy, the use of either mono- or polytherapy, by themselves or together 
could explain the variance in outcome of the toxicity scores. However, no factor 
reached significance. 
5.3 Results 
5.3.1 Population 
Of the total of 289 patients entering the main study, 124 were men (43%) and 165 
were women (57%). No statistically significant difference was seen in the gender 
distribution between patients on monotherapy and patients on polytherapy with a 
PDD/DDD ratio <2.0. 
The mean age of the patients on monotherapy was 37 years (range 15-76 years), 
and of patients on polytherapy 43 years (range 15-75 years). This difference in mean 
ages between patients on monotherapy and polytherapy was statistically significant 
(p=0.000l). 
Also a statistically significant difference was found for the mean duration of 
epilepsy between patients on monotherapy (18 years, range 1-64 years) and patients on 
polytherapy (26 years, range 1-70 years) (p=0.0001). 
For the patients on polytherapy with a PDD/DDD ratio >2.0 the mean age was 44 
years (range 15-80 years) and the duration of epilepsy was 27.5 years (range 2-70 
years). No statistical difference was seen in age and duration of epilepsy between this 
group and the group of patients on polytherapy with a PDD/DDD ratio <2.0. 
5.3.2 Number of antiepileptic drugs prescribed in polytherapy 
Of those 131 patients on polytherapy with a PDD/DDD ratio <2.0, 118 patients 
were prescribed 2 AEDs and 13 patients 3 AEDs. Of the patients with a PDD/DDD 
ratio >2.0 44 patients were prescribed 2 AEDs, 72 patients 3 AEDs, and 18 patients 4 
AEDs (Table 5.1). 
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Tabic 5.1. Distribution of the number of AEDs over the various PDD/DDD ratio's. 
PDD/DDD ratio 
0.01-0.33 
0.34-0.66 
0.67-1.00 
1.01-1.33 
1.34-1.66 
1.67-2.00 
2.01-2.33 
2.34-2.66 
2.67-3.00 
3.01-3.33 
3.34-3.66 
3.67-4.00 
4.01-4.33 
4.34-4.66 
4.67-5.00 ' 
5.01-5.33 
5.34-5.66 
1 AED 
10 
62 
64 
18 
4 
3 
-
-
-
-
-
-
-
-
-
-
-
2 AED 
1 
16 
17 
42 
38 
23 
11 
9 
1 
-
-
-
-
-
-
-
3 AED 
1 
-
-
-
3 
10 
5 
14 
14 
13 
8 
7 
6 
1 
1 
2 
1 
4 AEDs 
-
-
-
-
-
-
5 
-
-
2 
3 
4 
1 
2 
-
1 
AED= antiepileptic drug 
5.3.3 Adverse effects, prevalence and severity 
Overall no significant differences in the prevalence of adverse effects were found 
between patients on monotherapy and polytherapy who had similar PDD/DDD ratios 
(Tables 5.2 and 5.3). 
Table 5.2. Prevalence and severity of neurological adverse effects per dosage for patients on 
monotherapy and polytherapy. 
PDD/DDD 
ratio 
0.01-0.33 
0.34-0.66 
0.67-1.00 
1.01-1.33 
1.34-1.66 
1.67-2.00 
η 
10 
62 
64 
18 
4 
3 
Monotherapy 
ncs 
median score 
% (25-75 pere) 
50 
60 
72 
78 
75 
67 
5 (5-5) 
10 (5-15) 
10 (8-20) 
10(5-20) 
15 (10-30) 
17 (5-30) 
η 
2 
16 
17 
45 
48 
Polytherapy 
ncs 
median score 
% (25-75 pere) 
50 
75 
82 
63 
81 
35 (35-35) 
9 (5-15) 
16 (5-28) 
15 (10-25) 
15 (13-25) 
ncs= neurotoxicity cumulative score 
η s number of patients per stratum 
% = percentage of patients per stratum with adverse effects 
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Table 5 3 . Prevalence and severity of systemic adverse effects per dosage for patients on monotherapy 
and polytherapy. 
PDD/DDD 
ratio 
0.01-0.33 
0.34-0.66 
0.67-1.00 
1.01-1.33 
1.34-1.66 
1.67-2.00 
η 
10 
62 
64 
18 
4 
3 
Monotherapy 
ses 
median score 
% (25-75 pere) 
10 
23 
22 
33 
25 
37 
3 (5-5) 
10(5-15) 
6 (8-20) 
5 (5-20) 
50 (10-30) 
10 (5-30) 
η 
2 
16 
17 
45 
48 
Polytherapy 
ses 
median score 
% (25-75 pere) 
-
31 
24 
23 
29 
10 (10-20) 
25 (16-17) 
10 (8-15) 
12 (5-25) 
scs= systemic toxicity cumulative score 
η = number of patients per stratum 
% = percentage of patients per stratum with adverse effects 
Looking separately at neurotoxicity and systemic toxicity did not change that finding. 
When specific adverse effects were considered the only significant differences in 
prevalence seen were sedation (37% in those on mono- and 52% in those on 
polytherapy, p<0.05) and cognitive impairment (27% in those on mono- and 34% in 
those on polytherapy, p<0.05) (table 5.4). 
Table 5.4. Distribution of adverse effects in monotherapy and polytherapy. 
Neurological effects 
Diplopia 
Nystagmus 
Dysarthria 
Ataxia 
Dysdiadochokinesis 
Tremor 
Sedation 
Affect and mood 
disturbances 
Cognitive impairments 
Dizziness 
Headache 
Monotherapy N=161 
% 
5.0 
6.2 
6.8 
11.8 
1.2 
18.0 
37.3 
6.2 
26.7 
7.5 
9.3 
median score 
(25-75 pere) 
15 (15-15) 
5 (5-10) 
5 (5-5) 
5 (5-15) 
15 (15-15) 
10 (10-10) 
5 (5-5) 
5 (5-5) 
5 (5-5) 
5 (3-7.5) 
5 (5-10) 
Polytherapy N=128 
median score 
% (25-75 pere) 
10.2 
9.4 
6.3 
14.8 
1.6 
22.7 
52.3 
10.9 
34.4 
10.9 
10.2 
15 (15-15) 
5 (5-5) 
5 (5-7.5) 
5 (5-15) 
10(5-15) 
10 (10-10) 
5 (5-10) 
5 (5-5) 
10(5-10) 
5 (3-5) 
5 (3-10) 
% = percentage of patients with adverse effects (some had multiple effects) 
N = number of patients per therapy group 
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continuance table 5.4 
Systemic effects 
Gastro-intestinal 
problems 
Hematopoietic 
problems 
Dermatological 
problems 
Impotence 
Kidney disease 
Liver disease 
Weight gain 
Change in hair/ 
hair loss 
Monotherapy N=161 
% 
5.0 
-
1.9 
0.6 
-
-
11.2 
12.4 
median score 
(25-75 pere) 
4 (3-7.5) 
15(15-15) 
50 (50-50) 
10(3-10) 
5 (5-5) 
Poly therapy N=128 
median score 
% (25-75 pere) 
9.4 
-
3.9 
1.6 
-
-
8.6 
15.6 
4 (3-10) 
15 (15-15) 
25 (25-25) 
10 (3-20) 
5 (5-7.5) 
% - percentage of patients with adverse effects (stime had multiple effects) 
N = number of patients per therapy group 
In both groups, sedation was the most common adverse effect. The prevalence of 
individual systemic adverse effects did not differ between the groups. 
Neither the cumulated scores, nor the median scores for intensity of each specific 
adverse-effect differed significantly between patients on mono- and on polytherapy. 
Also the distribution of the severity scores for the adverse effects separately did not 
differ between patients on monotherapy and polytherapy. 
5.3.4 Adverse effects, prevalence and severity for PDD/DDD ratio >2.0 
The prevalence of adverse effects in patients on polytherapy with a PDD/DDD ratio 
>2.0 was higher than in patients on polytherapy with a PDD/DDD ratio <2.0, 91% and 
78%, respectively. This difference was statistically significant, p<0.05. 
The prevalence of neurological adverse effects showed some increase with higher 
doses of AEDs, although this was not statistically significant. The severity of 
neurological adverse effects also increased with higher doses, but seemed to reach a 
peak at about 4.0 PDD/DDD ratio (table 5.5) 
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Table 5.5. Prevalence and severity of neurological (NTX) and systemic (STX) adverse effects for 
PDD/DDD ratio >2.0. 
PDD/DDD 
ratio 
2.01-2.33 
2.34-2.66 
2.67-3.00 
3.01-3.33 
3.34-3.66 
3.67-4.00 
4.01-4.33 
4.34-4.66 
4.67-5.00 
5.01-5.33 
5.34-5.66 
Polytherapy N= 
η 
28 
30 
23 
14 
10 
10 
10 
2 
3 
2 
2 
NTX 
% 
71 
83 
83 
93 
100 
90 
100 
100 
100 
100 
100 
134 
median ncs 
20.0 
15.0 
19.0 
20.0 
21.5 
35.0 
25.5 
25.0 
15.0 
10.0 
13.0 
Polytherapy N=134 
η 
28 
30 
23 
14 
10 
10 
10 
2 
3 
2 
2 
STX 
% 
32 
23 
35 
50 
40 
30 
10 
50 
-
100 
-
median ses 
10.0 
20.0 
15.0 
20.0 
12.5 
3.0 
3.0 
25.0 
-
25.0 
-
ncs= neurotoxicity cumulative score 
scs= systemic toxicity cumulative score 
α = number of patients per stratum 
% s percentage of patients per stratum with adverse effects 
5.4 Discussion 
Prevalence of polytherapy 
Reynolds and Shorvon remark that "There seems little doubt that polytherapy has 
characterized the treatment of epilepsy throughout the ages..". (Reynolds and Shorvon, 
1981). On examining textbooks over the years there is little evidence that the use of 
polytherapy has been based solely on rational choice. Guelen et al. collected data on 
plasma concentrations of AEDs from eleven institutions in the Netherlands, Norway, 
England, Germany and the USA (Guelen et al., 1975). They obtained information on 
11,720 patients over the period 1969 -1974. The average number of AEDs prescribed 
per patient in that period was 3.2 of which 85% consisted of AEDs and 15% of 
stimulants such as amphetamines or caffeine, and/or vitamins and/or neuroleptic drugs. 
Only 4.2% were taking a single drug. Thanks to the advocacy of Reynolds and 
Shorvon and other epileptologists, most physicians treating epilepsy nowadays will 
start with a single antiepileptic drug. In a previous study we examined 225 patients 
from the Special Centres for Epilepsy and found an average use of 2.0 AED per 
patient, but only 28 % were on monotherapy (Wijsman et al., 1993). Those on 
polytherapy used on average 2.4 AED per patient. From the University Hospital 
Nijmegen 120 patients were studied, they used on average 1.4 AED/patient and 62.5% 
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were on monotherapy. Those on polytherapy used on average 2.1 AED per patient. 
Polytherapy is therefore still an issue. 
The present study is on pooled data from the Epilepsy Centres and Nijmegen 
University. Of the 426 patients 38% used monotherapy. Those on polytherapy used on 
average 2.45 AED. 
Possible confounders 
The data from our patients have been standardised in two respects. Adverse effects 
of AEDs have been assessed quantitatively with respect to the prevalence of the 
adverse effects as well as their severity. The scores are presumed to be independent of 
the type of the drug responsible. The AED doses were standardised using the 
PDD/DDD ratio. Obviously the concept of adding fractions of the DDD as a measure 
of drug-exposure does not take into account linearity of dose/effect relationships or 
metabolic or dynamic interactions of the drugs in individuals. The concept has, 
however, been used extensively in pharmaco-epidemiological studies (Lunde, 1989) 
As our study is a prospective observational study it has the inherent weakness that the 
parameters could not be set according to the demands of the study. All patients visiting 
the outpatient clinic who met the entry criteria were studied. The patients on 
monotherapy and those on polytherapy did not differ with respect to gender, but they 
differed significantly with respect to mean age and mean duration of epilepsy. Patients 
on monotherapy were on average younger and had been suffering from epilepsy for a 
shorter period. Whether or not this difference influences the occurrence of adverse 
effects cannot be judged from this study. When the results were analysed with multiple 
regression analysis, age and duration did not explain the variance in frequency and 
severity of adverse effects. The patients on polytherapy with a PDD/DDD ratio <2.0 
and those with a PDD/DDD ratio >2.0 did not differ significantly either in gender, age 
or duration of epilepsy. 
In the main arm of the study (n=289) 71% of patients on monotherapy and 79% on 
polytherapy had adverse effects. This result from a prospective study contrasts with the 
results obtained by Wijsman et al. in a retrospective study who found 20.9% with 
adverse effects on monotherapy and 20.5% with adverse effects on polytherapy 
(Wijsman et al., 1991). Our results are more in agreement with the prospective study 
of Keyser et al. in which 57.3% of the patients reported adverse effects, and the 
Collaborative Group for Epidemiology of Epilepsy from Milan, Italy who found 
adverse effects in 41.6% of the patients, although the selection of patients for these 
two studies does not allow detailed comparison to be made (Keyser et al., 1990; 
Collaborative Group for Epidemiology of Epilepsy, 1988). 
No overall difference was seen in both the prevalence and the severity of 
neurological and systemic adverse effects, when patients on monotherapy and 
polytherapy with similar PDD/DDD ratios were compared. It is remarkable that on 
stratification neither the frequency nor the severity increased notably per stratum, 
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although the trend was in this direction. As this was an observational study, it may 
well be that our results reflect the practice not to increase dose beyond a tolerable 
level. The dose tolerated, may however, differ from person to person. Analysis of the 
data of patients on polytherapy shows an increase in frequency of adverse effects to 
100% when the PDD/DDD ratio rises to >3.0. The severity of adverse effects increases 
up to a PDD/DDD ratio of 4.0 followed by a fall at higher doses. We attribute this to 
the practice of giving such high doses only to patients who are relatively insensitive to 
adverse effects. Patients on polytherapy had a significantly longer duration of epilepsy, 
which might have led to the development of tolerance to some adverse effects, and 
thus to a lower prevalence and severity. This fact could not be confirmed in the 
context of this study, and will require further investigation. 
Lack of correlation 
The prevalence of adverse effects in the group on polytherapy (n=262) was higher 
for patients with a PDD/DDD ratio of more than 2.0. No correlation was found 
between the number of AEDs and prevalence of neurological adverse effects. This 
again would suggest that the occurrence and the severity of adverse effects are 
influenced by the total dose, and not by the number of AEDs prescribed. The study by 
Keyser et al. showed that patients treated with polytherapy had a higher prevalence of 
adverse effects than patients treated with monotherapy (Keyser et al., 1990). In that 
study, all patients were compared, irrespective of the dose of medication, in contrast to 
the patients in the main arm of the present study where only patients with similar 
PDD/DDD ratios were compared. 
Sedation and cognitive impairment were the two neurological adverse effects which 
did occur more frequently in patients on polytherapy. However, there was no 
difference in the intensity (median level of NTX-score) of these adverse effects 
between the two groups. There is no prima facie explanation for this finding, which 
obviously needs further study. 
This study underlines the feasibility of applying clinimetric methods to the analysis 
of adverse drug effects. It appears that frequency and intensity of adverse effects are 
not very sensitive to changes in dose. Also, no difference was found between 
monotherapy and polytherapy. As the distribution of the dose of AEDs was uneven 
between the group on mono- and polytherapy, our study only permits a tentative 
conclusion that the frequency and severity of adverse effects is independent of the use 
of either. It may be thought that a complicating factor is the longer duration of 
epilepsy in the cohort on polytherapy. However this was not confirmed by the 
statistical analysis. 
An experimental study is planned to verify or refute the conclusions from this 
observational study. 
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6. DOSES NOR SERUM LEVELS OF ANTIEPILEPTIC DRUGS ARE 
PREDICTIVE FOR EFFICACY AND ADVERSE EFFECTS. 
6J Introduction 
The purpose of this study is to demonstrate the use of two measures for therapeutic 
potency when assessing antiepileptic therapy, in particular with multiple drugs 
(polypharmacy). Furthermore the correlation between pharmacotherapy and quantitative 
outcome measures using an adaptation of scales developed for drug trials by the 
Veteran Affairs cooperative study group (Cramer et al., 1983) was investigated. In 
particular we were interested whether drug doses or serum levels would be best 
indicators for outcome. 
In the nineteen hundred sixties and seventies measurement of serum levels of 
antiepileptic drugs was increasingly used for monitoring of antiepileptic 
pharmacotherapy. Notwithstanding the publication of several monographs on this topic, 
it still is controversial whether a clear-cut relationship exists between serum level and 
efficacy or serum level and adverse effects (Meijer et al. eds., 1973; Schneider et al. 
eds., 1975; Gardner-Thorpe et al. eds., 1977; Johanessen et al. eds., 1980) In particular 
in polytherapy where metabolic interactions between the drugs may occur, it is 
important to follow serum levels and to know how they are to be interpreted. 
For the measurement of exposure to antiepileptic drugs the Prescribed Daily 
Dose/Defined Daily Dose ratio (PDD/DDD ratio) was employed as was described in 
previous chapters. In analogy with the PDD/DDD ratio we propose the use of the 
Actual Serum Level/Average Therapeutic Level ratio (ASL/ATL ratio) as a tool for the 
study of AED efficacy. 
In order to determine the nominator, the average value was obtained employing the 
therapeutic ranges as published in handbooks and other publications (Table 6.1) 
(Schobben, 1979; Pippenger, 1980; Fröscher et al., 1981; Keyser et al., 1990; Larkin 
et al., 1991; Meijer et al., 1991). 
Table 6.1. Average Therapeutic Level (ATL) per Antiepileptic Drug» 
Antiepileptic Drug 
CBZ 
CLB 
CZP 
ESM 
OCB 
PB 
PHT 
VPA 
Average Therapeutic level (pg/ml) 
7 
0.35 
0.04 
70 
22 
30 
15 
70 
CBZ= carbamazepine; CLB= clobazam; CZP= clonazepam; ESM= ethosuximide; 
OCB= oxcarbazepine; PB= phénobarbital; PHT= phenytoin; VPA= valproate. 
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To assess whether this ASL/ATL ratio can be used as a parameter to predict drug 
effects, the data of a population of epileptic patients on mono- and polytherapy was 
studied. 
We have stratified the СИ and subindices (IS, SA, NTX, STX) according to these 
ASL/ATL ratios. This was done separately for ASL/ATL ratios of all patients on 
monotherapy and of all patients on polytherapy. For all patients, both on mono- and on 
polytherapy we assessed whether the PDD/DDD ratio or the ASL/ATL ratio was a 
better predictor of the СП. Also, prediction on each of the subindices was separately 
assessed. Furthermore we looked at the range and average of the ASL/ATL ratio's 
stratified according to the PDD/DDD ratio's. 
6.2 Statistical Analysis 
In the analysis of possible differences in population characteristics of the group on 
monopharmacy and polypharmacy the χ2 test was applied. 
For the analysis of the correlations in this study, the Spearman Correlation 
Coefficient was applied. A correlation was considered acceptable when the correlation 
coefficient was at least 0.70. 
6.3 Results 
6.3.1 Population characteristics 
Of the 200 patients who entered this study 103 were men and 97 were women. The 
mean age for the patients who entered the study was 39 years. The age at seizure onset 
did not differ significantly between patients on monopharmacy and patients on 
polypharmacy, although more patients on polypharmacy had seizures since infancy 
(Table 6.2). 
Table 6.2. Age at Onset. 
Age at Onset 
0 
1-10 
11-20 
21-30 
31-40 
41-50 
51-60 
61-70 
Monopharmacy 
N=100 
2 
26 
43 
15 
7 
4 
2 
1 
Polypharmacy 
N=100 
9 
27 
39 
13 
5 
4 
3 
-
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One hundred and fifty-one patients in this study had partial seizures, and forty-nine 
patients suffered from generalised seizures. In the group treated with monopharmacy 
more patients had generalised seizures than in the group treated with polypharmacy, 29 
and 20 respectively. 
6.3.2 Treatment 
6.3.2.1 Drug distribution 
For patients on monopharmacy carbamazepine was prescribed most frequently, i.e. 
for 48 patients, followed by valproate (35 patients). The other AED's used in 
monopharmacy were phenytoin (9 patients), oxcarbazepine (5 patients), and 
phénobarbital (3 patients). 
In polypharmacy carbamazepine was also the most frequently prescribed AED, i.e. 
for 86 patients, followed by valproate (55 patients). Table 6.3 shows the number of 
patients per AED in monopharmacy and polypharmacy. 
Table 6.3. Number of patients per antiepileptic drug. 
AED 
CBZ 
CLB 
CZP 
ESM 
OCB 
PB 
PHT 
VPA 
Monopharmacy 
N=100 
48 
-
-
-
5 
3 
9 
35 
Polypharmacy 
N=100 
86 
13 
5 
12 
2 
21 
47 
55 
CBZ= carbamazepine; CLB= clobazam; CZP= clonazepam; ESM= ethosuximide; 
OCB= oxcarbazepine; PB= phénobarbital; PHT= phenytoin; VPA= valproate. 
Of the group on polypharmacy 60 patients were prescribed 2 AED's, 38 patients 3 
AED's, and 2 patients used 4 AED's. For all 200 patients the mean number of AED's 
per patient was 1.7. For patients on polypharmacy the mean number of AED per 
patient was 2.5 (range 1 to 4). 
6.3.2.2 PDD/DDD ratio 
In the group of patients on monopharmacy the median PDD/DDD ratio was 0.7 
(range 0.1-2.0) and the mean PDD/DDD ratio was 0.8. In the group on polypharmacy 
the median summated PDD/DDD ratio was 2.1 (range 0.7-5.2) and the mean 
PDD/DDD ratio was 2.2. When patients were treated with polypharmacy the median 
PDD/DDD ratio per AED for patients using 2 AED's was 0.90, for patients using 3 
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AED's this was 1.02, and for patients using 4 AED's the median PDD/DDD ratio per 
AED was 0.98. 
In polypharmacy the median PDD/DDD ratio for the individual AED was higher 
than in monopharmacy, with the exception of phénobarbital. (Table 6.4) 
Table 6.4. Median PDD/DDD ratio for each individual antiepileptic drug. 
AED 
CBZ 
CLB 
CZP 
ESM 
OCB 
PB 
PHT 
VPA 
Monopharmacy 
Median PDD/DDD ratio (range) 
0.73 (0.10-2.00) 
-
-
-
0.63 (0.45-0.90) 
0.83 (0.50-1.00) 
1.08(0.58-1.33) 
0.77(0.20-1.33) 
η 
48 
-
-
-
5 
3 
9 
35 
Polypharmacy 
Median PDD/DDD ratio (range) 
0.94 (0.20-2.00) 
0.73 (0.50-2.00) 
0.13 (0.13) 
0.57 (0.20-1.20) 
1.28 (0.60-1.95) 
0.72 (0.10-2.10) 
1.13 (0.50-2.00) 
1.01 (0.40-2.33) 
η 
86 
13 
5 
12 
2 
21 
47 
55 
CBZ= carbamazepine; CLB= clobazam; CZP= clonazepam; ESM= cthosuximide; 
OCB= oxcarbazepine; PB= phénobarbital; PHT= phenytoin; VPA= valproate. 
6.3.2.3 ASL/ATL ratio 
The median ASL/ATL ratio for the patients on monopharmacy was 0.90 (range 
0.17-1.76) as was the mean ASL/ATL ratio, and for the patients on polypharmacy the 
median summated ASL/ATL ratio was 2.1 (range 0.83-4.50) with a mean ASL/ATL 
ratio of 2.1. In polypharmacy the median ASL/ATL ratio per drug was 0.90 for 
patients using 2 AED's, 0.84 for patients using 3 AED's, and 0.71 for patients using 4 
AED's. 
The ASL/ATL ratio for the individual AED was lower in patients on polypharmacy 
than in patients on monopharmacy, with the exception of phenytoin. (Table 6.5). 
The median PDD/DDD ratio per drug increases when the number of drugs per 
patient goes up, however, the ASL/ATL ratio per drug decreases with the increasing 
number of drugs per patient. 
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Table 6.5. Median ASL/ATL ratio for each individual antiepileptic drug. 
AED 
CBZ 
CLB 
CZP 
ESM 
OCB 
PB 
PHT 
VPA 
Monopharmacy 
Median ASL/ATL ratio (range) 
0.92(0.24-1.44) 
-
-
-
0.54 (0.30-0.85) 
0.59(0.17-0.99) 
0.79(0.19-1.49) 
0.97(0.50-1.76) 
η 
48 
-
-
-
5 
3 
9 
35 
Polypharmacy 
Median ASL/ATL ratio (range) 
0.89 (0.29-1.67) 
1.08 (0.23-2.71) 
1.44(0.43-2.50) 
0.63 (0.21-1.37) 
0.17(0.13-0.20) 
0.56 (0.04-1.21) 
0.88(0.31-1.67) 
0.89(0.23-1.71) 
η 
86 
13 
5 
12 
2 
21 
47 
55 
CBZ» Carbamazepins, CLB= clobazam; CZP= clonazepam; ESM= ethosuximide; 
OCB- oxcarbazepine; PB= phénobarbital; PHT= phenytoin; VPA= valproate. 
6.3.2.4 PDD/DDD ratio, ASL/ATL ratio and Clinimetric Indexes 
No statistically significant difference was seen between the correlations of the 
PDD/DDD ratio with the clinimetric indexes and the correlations of the ASL/ATL 
ratio with the clinimetric indexes when looking at the whole population (n=200) 
(p>0.05). For PDD/DDD ratio as well as the ASL/ATL ratio the correlation with the 
clinimetric indexes was marginal, although slightly better for the PDD/DDD ratio 
(table 6.6). 
Table 6.6. Correlation coefficients of the (summated) PDD/DDD and the ASL/ATL ratios with the 
clinimetric indices. 
Clinimetric 
Indices 
IS 
SA 
NTX 
STX 
СИ 
PDD/DDD ratio 
corr. coeff 
0.241 
0.214 
0.339 
0.010 
0.311 
ρ value 
0.0006 
0.0023 
0.0001 
0.8851 
0.0001 
ASL/ATL ratio 
corr. coeff 
0.228 
0.199 
0.336 
-0.010 
0.282 
ρ value 
0.0012 
0.0046 
0.0001 
0.8836 
0.0001 
In polypharmacy the correlations of both ratios with the clinimetric indexes were 
slightly better than in monopharmacy, but this difference did not reach statistical 
significance (p>0.05) (tables 6.7 and 6.8). 
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Table 6.7. Correlation coefficients of the PDD/DDD and summated PDD/DDD ratio with the 
clinimetric indices in monopharmacy and polypharmacy. 
Clinimetric Indices 
IS 
SA 
NTX 
STX 
СИ 
Monopharmacy 
coir, coeff 
0.263 
0.263 
-0.072 
-0.033 
0.127 
ρ value 
0.0082 
0.0082 
0.4789 
0.7450 
0.2000 
Polypharmacy 
corr. coeff 
0.153 
0.156 
0.268 
-0.181 
0.183 
ρ value 
0.1281 
0.1212 
0.0069 
0.0716 
0.0612 
Table 6.8. Correlation coefficients of the ASL/ATL and summated ASL/ATL ratio with the clinimetric 
indices in monopharmacy and polypharmacy. 
Clinimetric Indices 
IS 
SA 
NTX 
STX 
CII 
Monopharmacy 
corr. coeff 
0.151 
0.181 
0.057 
-0.146 
0.074 
ρ value 
0.1336 
0.0712 
0.5740 
0.1461 
0.4500 
Polypharmacy 
corr. coeff 
0.222 
0.201 
0.148 
-0.158 
0.167 
ρ value 
0.0266 
0.0454 
0.1420 
0.1157 
0.0900 
When studying the correlation between the two ratios and the clinimetric indexes of 
the 35 patients, who had had a change of doses and who were assessed individually, 
no correlation was found. 
632.5 PDD/DDD ratio and ASL/ATL ratio 
A good correlation was found between the PDD/DDD ratio and the ASL/ATL ratio 
for the whole group (corr. coeff. 0.77, p=0.0001). The correlation between these two 
ratios was better for the patient group on polypharmacy than for the patient group on 
monopharmacy (corr. coeff. 0.50 (p=0.0001) and 0.31 (p=0.002), respectively). 
6.4 Discussion 
The median PDD/DDD ratio was less for patients on monopharmacy (0.8) than for 
patients on polypharmacy (2.2). The median PDD/DDD ratio for the whole group of 
patients was 1.5. The average number of AEDs prescribed per patient was 1.7. This 
reflects a tendency to prefer monotherapy over polytherapy. However, as recently as 
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the 20th International Epilepsy Congress which was held July 1993 in Oslo a sattelite 
symposium was devoted to rational polypharmacy in treatment of epilepsy. 
When patients are treated with polypharmacy, the physicians apparently prescribe 
about the same median PDD/DDD ratio per AED as in monopharmacy, thus obtaining 
a higher summated PDD/DDD ratio. Clonazepam and ethosuximide were an exception 
to this rule, as the median PDD/DDD ratios for these drugs were well under the 
Defined Daily Dose. It is possible that the daily doses the WHO Collaborating Centre 
for Drug Statistics advises for these antiepileptic drugs are set too high. 
Tables 6.4 and 6.5 show that although the median PDD/DDD ratio of clonazepam is 
low according to WHO standards, the mean ASL/ATL ratio is high (1.44). 
The median PDD/DDD ratio for the individual drugs was higher in polypharmacy 
than in monopharmacy. Clinicians might prescribe higher doses in polytherapy in 
anticipation of or in reaction to interactions between AED's. This is corroborated by 
the finding that most individual serum levels, expressed in ASL/ATL ratios, were 
lower in polypharmacy than in monopharmacy. 
The correlation of the PDD/DDD ratio with the outcome measures for seizure 
frequency and toxicity was poor. In polypharmacy better correlations were seen both 
between the PDD/DDD ratio with the clinimetric indexes, and of the ASL/ATL ratio 
with the clinimetric indexes, than in monopharmacy. 
No statistically significant difference was seen between the correlation of the two 
ratio's with the clinimetric indexes, although the correlation for the PDD/DDD ratio 
was slightly better than for the ASL/ATL ratio. The effect of individual patient 
variables which have an impact on drug kinetics, such as age , gender, liver and 
kidney function, and protein binding of the AED have not been taken into 
consideration in this study, which may have clouded the results (Hekster et al., 1993). 
Also the effect of metabolites on the outcome of the indexes were not analysed in this 
study. Even, when two sets of data were available, assessing the correlation within 
patients between respectively the PDD/DDD ratio, the ASL/ATL ratio and the 
clinimetric indexes, did not show statistical significance. The results of this study 
support the assertion that a difference of doses or serum levels of antiepileptic drugs 
does not predict a difference in efficacy or adverse effects of these drugs. The reason 
can only be guessed at. The paroxysmal character of the seizures makes it difficult to 
titrate the endpoint "freedom from seizures". In those patients who were seizure-free 
the dose may well have been higher than necessary. With respect to the outcome 
measures of drug toxicity the occurrence of tolerance to adverse effects may interfere 
with the expected relation between the PDD/DDD ratio or ASL/ATL ratio and the 
NTX and STX. As this has been an observational study it can only signal the problem. 
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7. USE OF ANTIEPILEPTIC DRUGS IN A COMMUNITY-DWELLING 
DUTCH POPULATION. 
7.1 Introduction 
Several studies on the prevalence of epilepsy have been performed in The 
Netherlands (Bongers et al., 1976; Voorn, 1983; Rutgers, 1984; Lapperre-Regelink et 
al., 1988). However, few studies have focused on the use of antiepileptics and these 
included only a small population of mostly hospitalized patients (Crobach, et al., 1988; 
Wuis et al., 1985). Over the past years several new drugs have been introduced for the 
treatment of epilepsy. Also the role of monotherapy and polytherapy in the treatment 
of epilepsy has been under discussion. In order to get an insight in antiepileptic drug 
use in Dutch outpatients with epilepsy we employed a database in which amongst 
others data of dispensed AEDs were collected. 
This data from 1992 were subsequently compared to prescription data from patients 
from secondary and tertiary epilepsy referral centres as described in previous studies 
(Wijsman et al., 1993; Lammers et al., 1994a; Lammers et al., 1994b). 
7.2 Statistical analysis 
In the analysis of AEDs distribution or number of AEDs used from 1989-1992 and 
in the analysis of prevalence over the age groups the χ2 test was applied. For the 
analysis of prevalence in gender the combination of χ2 tests over the age categories 
was applied. Statistical significance was set at p<0.05. 
7.3 Results 
7.3.1 Antiepileptic drugs used 
According to the Dutch Central Bureau of Statistics the total population of the six 
cities on 1 January 1992 was 302,149; 149,647 (49.5%) men and 152,502 (50.5%) 
women (Centraal Bureau voor de Statistiek, 1993). In this population 2735 people 
(0.91%) used one or more AEDs. The use of AEDs increased statistically significantly 
with age for both men and women. The highest prevalence was observed for men, 75 
years of age and older. No statistically significant difference in prevalence was 
observed for men and women in any age group (Table 7.1). 
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Table 7.1. Use of AEDs in the PHARMO population 1992 (N=300,000) by age and gender. 
Age 
0-4 
5-9 
10-14 
15-24 
25-34 
35-44 
45-54 
55-64 
65-74 
74+ 
Total 
Men 
η ( % ) 
22 0 21 
43 0 41 
61 0 58 
157 0 65 
202 0 81 
201 0 82 
177 100 
161 129 
132 142 
119 2 45 
1275 0 85 
Women 
η ( % ) 
38 0 38 
34 0 34 
42 0 41 
147 0 64 
221 0 90 
247 102 
193 1 14 
158 120 
207 179 
173 198 
1460 0 96 
Total 
η ( % ) 
60 0 29 
77 0 37 
103 0 49 
304 0 65 
423 0 85 
448 0 92 
370 107 
319 124 
339 162 
292 215 
2735 0 91 
n= number of patients using AEDs 
%= percentage of patients using AEDs of the total population of the six cities 
The use of individual AEDs by the PHARMO population by year is presented in table 
7.2a. 
Table 7.2a. Use of AEDs in the PHARMO population 1989-1992. 
AED 
MPB 
PB 
PRM 
PHT 
ESM 
MSM 
CZP 
CBZ 
OCB 
VPA 
GVG 
Total* 
1989 
N=2333 
η % 
49 2 1 
344 14 8 
43 18 
560 24 0 
39 17 
4 0 2 
164 7 1 
1149 49 1 
562 241 
2914 124 9 
1990 
N=2453 
η % 
37 15 
360 14 7 
47 19 
628 25 6 
35 14 
5 0 2 
253 10 4 
1305 53 2 
624 25 5 
4 0 2 
3298 134 6 
1991 
N=2517 
η % 
31 12 
308 12 3 
44 17 
627 25 0 
36 14 
5 0 2 
223 8 9 
1348 54 0 
3 01 
628 25 0 
68 2 7 
3321 132 5 
1992 
N=2735 
η % 
19 07 
329 121 
45 16 
666 24 3 
34 12 
6 0 2 
255 9 3 
1350 49 4 
5 0 2 
673 24 6 
90 3 3 
3472 126 9 
η= number of patients 
' Some patients use more than one AED 
MPB= metylphenobarbital, PB= phénobarbital, PRM= primidone, PHT= phenytoin, ESM= ethosuximide, NSM= metylsuximide, CZP= 
clonazepam, CBZ= carbamazepine, OCB= oxcarbazepme, VPA= valproate, GVG= vigabatnn 
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Carbamazepin was the most frequently prescribed AED, followed by valproate and 
Phenytoin. During 1989-1992 a statistically significant decrease was seen in the 
percentage of patients using methylphenobarbital and phénobarbital (p<0.05). Also a 
slight but not statistically significant decrease was observed in the percentage of 
patient using ethosuximide. The increase of the percentage of patients using 
clonazepam was statistically significant (p<0.05). The percentage of patients using 
Phenytoin, carbamazepine and valproate at first showed some increase, after which the 
percentage decreased again. But over the four year period the percentage of patients 
using these AEDs increased slightly, although not statistically significant. 
The AEDs vigabatrin and oxcarbazepine were registered in 1990 and in 1991, 
respectively. Over a period of three years the percentage of patients using vigabatrin 
increased from 0.2% to 3.3%. In 1992 16 of the 90 patients (17.7%) stopped using 
GVG. No patients stopped using GVG during 1990 and 1991. In 1990, when GVG 
was registered in The Netherlands, no patient used this AED in monotherapy. In 1992 
11% of the patients used GVG in monotherapy, as compared to an overall use of 80% 
monotherapy. When another AED was prescribed together with GVG, the most 
frequently used AED was carbamazepine, followed by valproate. In triple therapy 
GVG was most frequently prescribed in combination with carbamazepine and 
valproate. 
The percentage of patients using oxcarbazepine increased from 0.1 to 0.2%. 
The individual AEDs prescribed in the population from the epilepsy centres are 
shown in Table 7.2b 
Table 7.2b. AEDs used in the epilepsy centres. 
AED 
PB 
PRM 
PHT 
ESM 
CZP 
DZP 
CLB 
CBZ 
OCB 
VPA 
GVG 
Epilepsy Centres 
N=529 
% 
11.3 
3.8 
31.0 
2.5 
2.1 
0.8 
15.3 
72.2 
2.5 
37.4 
14.2 
η 
60 
20 
164 
13 
11 
4 
81 
382 
13 
198 
75 
n= number of patients 
DZP= diazepam; CLB= clobazam. 
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Some difference was observed with respect to the AEDs used in the PHARMO 
population and the population from the secondary and tertiary epilepsy referral centres. 
In the population from the epilepsy centres a larger variety in the prescribed benzo­
diazepines (CZP, DZP, CLB) were seen compared to the PHARMO population. Also 
AEDs like MPB and MSM were not prescribed for the patients of the epilepsy centres. 
The difference in the percentage of patients using CBZ in both population was 
statistically significant (p<0.05). 
7.3.2 Number of antiepileptic drugs 
Approximately 80% of the patients were treated with monotherapy. This percentage 
did not change much over the four year period. In polytherapy the percentage of 
patients using 2 AEDs decreased slightly, from 18.2% to 15.8%, and the percentage of 
patients using 3 AEDs slightly increased, from 2.8% to 4% (table 7.3a). This change in 
number of AEDs from 1989-1992 was not statistically significant. The average number 
of AEDs prescribed per patient was 1.25 and did not change over the years. 
Table 73a. Number of AEDs prescribed per patient in the period 1989-1992. 
1 AED 
2 AEDs 
3 AEDs 
4 AEDs 
5 AEDs 
Total 
η 
1834 
425 
66 
7 
1 
2333 
1989 
% 
78.60 
18.20 
2.80 
0.30 
0.07 
99.9 
η 
1936 
438 
70 
8 
1 
2453 
1990 
% 
78.90 
17.90 
2.80 
0.30 
0.07 
99.9 
η 
1992 
428 
83 
13 
1 
2517 
1991 
% 
79.10 
17.00 
3.30 
0.50 
0.04 
99.9 
η 
2185 
432 
109 
11 
1 
2735 
1992 
% 
79.90 
15.80 
4.00 
0.40 
0.04 
100.1 
η= number of patients 
In all years carbamazepine was the most frequently prescribed AED used in 
monotherapy, followed by valproate and phenytoin. The percentage of carbamazepine 
used in monotherapy increased from 41% in 1989 to 45% in 1992. Phénobarbital use 
decreased in monotherapy from 10% in 1989 to 6% in 1992. 
When two AEDs were used, the combination carbamazepine with valproate 
occurred most often, followed by the combination of carbamazepine with phenytoin. 
The percentage of patients on two AEDs, using the combination carbamazepine with 
valproate increased gradually over the years up to 31% in 1991. In 1992 this 
percentage decreased to 26%, while the percentage of patients using the combination 
carbamazepine and vigabatrin increased to 8%. 
Those patients who used vigabatrin in 1992 were studied separately as the 
vigabatrin group. The percentage of patients in the vigabatrin group using monotherapy 
declined over the four year period from 46% in 1989 to 11% in 1992. 
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The percentage of patients on monotherapy differed considerably between the two 
populations studied. Monotherapy was used by only 37.4% of the patients from the 
epilepsy centres (Table 7.3b), while almost 80% of the PHARMO population were 
treated with monotherapy (p<0.05). Like in the PHARMO population in the centres 
CBZ was the drug most often prescribed in monotherapy. Also when 2 AEDs were 
prescribed the combination most frequently used was CBZ with VP A, followed by the 
combination of CBZ with PHT. 
Table 73b. Number of AEDs used in Epilepsy Centres. 
1 AED 
2 AEDs 
3 AEDs 
4 AEDs 
Epilepsy Centres 
N=529 
% η 
37.2 198 
34.8 164 
22.9 119 
5.1 27 
n= number of patients 
7.3.3 Dosing 
The median PDD/DDD ratio for each AED whether on monotherapy or polytherapy 
remained nearly constant over the four years as shown in Table 7.4a. Patients exposed 
to a PDD/DDD ratio of 0.00 or >6.00 were considered an inaccuracy and were 
excluded from the assessment. Also patients under 15 years were excluded in the 
PDD/DDD analysis because the DDD is defined as the average maintenance dose for 
adults. 
With the exception of methylphenobarbital, phénobarbital, and oxcarbazepine, the 
median PDD/DDD ratio was lower than 1.00. With the exception of MSM no 
statistically significant differences were found in the median PDD/DDD ratio's over 
the four year period. The increase in median PDD/DDD ratio for MSM in 1990 was 
statistically significant (p=0.04) 
The PDD/DDD ratio for CZP was under 0.20 in all four years. 
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Table 7.4a. Median PDD/DDD ratio per AED in the period 1989-1992/ 
AED 
MPB 
PB 
PRM 
PHT 
ESM 
MSM 
CZP 
CBZ 
OCB 
VPA 
GVG 
1989 
PDD/DDD 
1.50 
0.90 
0.40 
0.67 
0.60 
0.67 
0.19 
0.60 
0.60 
η 
49 
342 
43 
557 
39 
4 
164 
1147 
-
559 
-
199C 
PDD/DDD 
1.50 
0.90 
0.40 
0.61 
0.49 
0.84 
0.15 
0.60 
0.60 
0.50 
η 
37 
353 
47 
621 
35 
5 
253 
1300 
-
619 
4 
1991 
PDD/DDD 
1.50 
0.90 
0.40 
0.64 
0.60 
0.67 
0.19 
0.60 
1.20 
0.60 
0.50 
η 
31 
304 
44 
625 
36 
5 
223 
1348 
3 
626 
67 
1992 
PDD/DDD 
1.50 
0.90 
0.40 
0.61 
0.60 
0.56 
0.19 
0.60 
1.20 
0.60 
0.50 
η 
19 
321 
45 
659 
34 
6 
253 
1347 
5 
664 
90 
n= number of patients 
*= Patients with incorrect prescription data and younger than 15 years of age were left out of the analysis 
The median PDD/DDD ratio's in both populations were similar for PRM, CZP, OCB, 
and ESM. CBZ, VPA, GVG, and PHT doses were considerably higher in the 
population from the epilepsy centres than in the PHARMO population. Only the 
median PDD/DDD ratio for PB was lower in the epilepsy centres (Table 7.4b). 
Table 7,4b. Median PDD/DDD ratio for the epilepsy centres. 
AED 
PB 
PRM 
PHT 
ESM 
CZP 
DZP 
CLB 
CBZ 
OCB 
VPA 
GVG 
Epilepsy Centres 
PDD/DDD ratio 
0.65 
0.46 
1.15 
0.55 
0.18 
1.00 
0.87 
0.93 
1.22 
0.92 
0.73 
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7.4 Discussion 
The results of this study show that 0.91% of the population used AEDs longer than 
180 days. Although we did not estimate the prevalence of epilepsy, our data suggests 
that the number of AED users found in this study is slightly higher than the epilepsy 
prevalence found in Rochester by Hauser et al., which was 6.76 per 1,000 (Hauser, et 
al., 1991). The higher "prevalence" in our study may be explained by the fact that for 
our study the only definition used for the diagnosis epilepsy was the use of AEDs for 
more than 180 days. Even though this period was considered sufficient to eliminate 
patients using these drugs for indications other than epilepsy, it is conceivable that 
some of the latter may be included in our study. All patients in the population used in 
this study were outpatients who collected their medication themselves from one of the 
pharmacies included in the PHARMO database. Patients who used AEDs and live in 
institutions or special epilepsy centres were not included. This would influence the 
estimation of the prevalence of AEDs use. 
The percentage of patients on monotherapy was almost 80% in the PHARMO 
population. This is in accordance with the observation of Shorvon et al, who showed 
that in 78% of the patients epilepsy can be well controlled with monotherapy (Shorvon 
et al., 1982). When looking at the percentage of patients on monotherapy in studies 
performed over the years there is a definite tendency towards monotherapy for the 
treatment of epilepsy (Lloyd Jones, 1980; Goodridge and Shorvon, 1983; McCluggage, 
et al., 1984; Cooper, et al., 1986; Hall and Ross, 1986; Crobach, et al., 1988; Remy, et 
al., 1992, Wijsman, et al., 1993). Although in the PHARMO population the percentage 
of patients using 3 AEDs increased slightly, the percentage using 2 AEDs decreased 
slightly, and no overall increase in the average number of AEDs prescribed was 
observed. 
Little change was seen in the AEDs prescribed over the years. Only 
methylphenobarbital (MPB) and phénobarbital (PB) showed a distinct decrease in the 
percentage of patients using these AEDs. MPB was most prescribed among older 
patients. The decrease in use could be explained by an increased mortality in this 
group of elderly patients, and the fact that MPB was not prescribed to newly diagnosed 
patients. 
The increase in prescriptions for clonazepam (CZP) is surprising, because patients 
may develop a tolerance for this drug, which makes it less advantageous for chronic 
treatment and its continuous use could also diminish its effect in the treatment of status 
epilepticus. 
For most AEDs the PDD/DDD ratio was well under 1.00. The reason for this could 
be that the Defined Daily Dose, as recommended by the WHO, is in fact too high. It 
should be also noted that the WHO Collaborating Centre For Drug Statistics in Oslo 
presents the DDD of oxcarbazepine as being equal to the DDD of carbamazepine, 
while all clinical trials show that the DDD of OCB should be 1V4 times the DDD of 
CBZ. 
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The percentage of prescriptions for GVG increased rapidly after its introduction in 
1990. Also the percentage of patients using GVG in monotherapy in the "vigabatrin 
group" increased considerably during the three year period, although GVG was 
primarily registered as add-on therapy for partial seizures. The fact that the overall 
percentage of patients on monotherapy decreased and the average number of AEDs per 
patient increased in this group is not surprising, since GVG would mostly have been 
used for patients with intractable seizures, and would not have been introduced in 
patients whose epilepsy was well controlled. 
Further studies in which record linkage is applied could demonstrate the use of 
AEDs for different seizure types in outpatients. 
The AEDs prescribed in the epilepsy centres differed from the PHARMO 
population mostly with respect to dosage and number of AEDS. Patients from the 
epilepsy centres were mostly prescribed higher dosages of AEDs, and more patients 
were treated with polytherapy. This could be expected since in the PHARMO 
population all patients with epilepsy are included and epilepsy centres are mostly 
involved in the treatment of patients with a severe form of epilepsy. 
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8. PROGNOSTIC FACTORS FOR THE SEVERITY OF EPILEPSY. 
8.1 Introduction 
In previous studies by this group a clinimetric score, the Composite Index of 
Impairments (СП), was employed in the assessment of severity of epilepsy. By using 
the СП, the overall impact of seizure frequency, seizure severity and side effects of 
antiepileptic drugs was assessed. 
In this study the outcome of the СИ is employed in order to assess the presence of 
possible prognostic factors which may predict the severity of epilepsy. Only patients 
for whom the СП did not change in the course of several subsequent assessments were 
selected. 
8.2 Statistical analysis 
Possible prognostic factors for the severity of epilepsy were determined by means of 
multiple regression analysis. Multiple regression was used because in this way an 
estimate can be obtained of the independent effects of each explanatory variable, while 
allowing for the effects of the other variables. 
8.3 Results 
8.3.1 Patient characteristics 
A total of 60 patients entered this study, 27 (44%) men and 33 (56%) women. The 
mean age of this group was 32 years (range 15-70 years). The mean age at onset was 
15.5 years (range 0-61 years). 
The СП score ranged from 0 to 480, with a mean score of 35. 
Of the 60 patients 53 patients had localization-related epilepsies, 6 patients had 
generalized epilepsies, and 1 patient had an epilepsy undetermined whether focal or 
generalized. The seizure types in this population are shown in Table 8.1. 
Tabic 8.1. Distribution of seizure type(s). 
Seizure type(s) 
SPS 
CPS 
SGTCS 
PGTCS 
SPS+CPS 
SPS+SGTCS 
CPS+SGTCS 
SPS+CPS+SGTCS 
Percentage of patients (N) 
5 (3) 
35 (21) 
17 (10) 
8 (5) 
10 (6) 
5 (3) 
17 (10) 
3 (2) 
SPS= simple partial seizures; CPS= complex partial seizures; SGTCS= secondarily generalised tonic clonic seizures; PGTCS= Primarily 
generalised tonic clonic seizures. 
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8.3.1 Prognostic factors 
The severity of epilepsy, as expressed by a high score on the СИ, was best 
predicted by primarily generalised tonic clonic seizures (con*, coeff. 0.48). Because 
only 5 patients had this seizure type, and the impact on the total group was so great, 
these patients were left out of consideration for the remainder of the analysis. 
When PGTCS were left out of consideration 5 variables were found to be most 
predictive for the outcome of the СИ (corr. coeff. 0.73), i.e. months of seizure freedom 
in the last two years, history of febrile convulsions (p=0.0004), frequent treatment 
changes, history of development of tolerance for AEDs, history of reduction of AEDs 
due to side effects (Table 8.2). The other variables mentioned in the Methodology 
section were not statistically significant in the prediction of the severity of epilepsy. 
Table 8.2. 
Covariance 
Tolerance development for AED 
Febrile convulsions 
Month of seizure freedom 
Treatment changes 
Reduction of AEDs 
Regression coefficient 
19.0718 
-21.8857 
-14.3562 
7.7837 
14.2456 
ρ value 
0.0001 
0.0004 
0.0092 
0.0111 
0.0169 
A variable which had a positive impact on the severity of epilepsy was months of 
seizure freedom in the last two years. The longer the patients were seizure free, the 
lower the СП score. An other variable with a positive influence on the СИ score was a 
history of febrile convulsions. Variables which increased the СИ score were frequent 
treatment changes, a history of tolerance for AEDs, and a history of reduction of 
medication due to side effects. 
8.4 Discussion 
In this study we tried to determine prognostic factors for the severity of epilepsy by 
analysing data from patients with a stable epilepsy control. Stable epilepsy control 
could mean seizure remission or a high seizure frequency, as long as this did not 
change during the assessment period. Through this analysis we found five variables 
which were of influence on seizure severity. Only one was truly predictive as it 
concerned an event early in life, i.e. febrile convulsions. The other factors were more 
reflections of a difficult to treat epilepsy. Evidence of brain damage or certain 
characteristics of the EEG did not appear to have any predictive value. 
It was rather surprising that a history of febrile convulsions was correlated with a 
favourable outcome. The fact that the months of seizure freedom had a positive effect 
on the seizure severity is obvious, because the less seizures the lower the СП score, 
and thus the better the epilepsy control. All the variables which had a negative impact 
on seizure severity were treatment related. Frequent changes in treatment, due to either 
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inefficacy or side effects of medication, indicates a difficult to treat epilepsy, which 
would be expressed in a high СИ. The development of tolerance may lead to more 
seizures and therefore a higher СП. 
Reduction of antiepileptic medication due to side effects means that the dosage of a 
effective AED has to be reduced, which could lead to more seizures and thus a high 
СИ score. 
Prognosis of epilepsy has been the subject of several epidemiologic studies over the 
years. Prognostic factors for epilepsy have mostly been determined by studies on 
seizure remission and relapse, and seizure recurrence after a first epileptic seizure. Our 
study included all patients with a stable epilepsy, whether they were seizure free or 
not. This might lead to differences in prognostic factors, as this study focuses on the 
prognostic factors for the severity of epilepsy, and not only on the chance of seizure 
remission. 
Most of the predictive variables found in our study do not coincide with prognostic 
factors found in studies on remission and relapse of seizures or first seizure after an 
initial epileptic seizure. In most studies neurological deficit, partial seizures, age of 
onset of seizures, and a long delay before treatment were considered to have a adverse 
effect on epilepsy control (Annegers et al., 1979; Shorvon and Reynolds, 1982; Arts et 
al., 1988; Bouma, et al., 1987; Beghi et al., 1992). The fact that these variables were 
not of influence on the severity of epilepsy in our study could mean that although 
these variables diminish the chance of becoming seizure free, it does not imply that 
these patients will have a severe form of epilepsy. 
The group analysed in this study consisted of only sixty patients with a wide variety 
in treatment outcome. This factor may have biased the outcome of prognostic factors. 
Stratifying patients according to СП score and including more patients may lead to 
different results. 
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9. GENERAL DISCUSSION AND CONCLUSION 
9.1 Utilization of the Composite Index of Impairments in an outpatient setting 
The main objective of this thesis is to test the application of a clinimetric scoring 
method in the assessment of outcome of treatment in outpatients with epilepsy. 
With the help of the selected Composite Index of Impairments (СП), a comparison 
was made between treatment outcome of secondary and tertiary epilepsy referral 
centres. This study showed a difference in outcome of treatment for both centres, even 
after matching patients for seizure type and duration of epilepsy. Yet for the matched 
patients no difference was observed in treatment policies. This result would indicate 
that referral of patients to a tertiary referral centre is mainly for the availability of non-
pharmacotherapeutic care modalities in these centres. These studies also revealed that 
the СП is in sofar incomplete that it does not provide information on the relative state 
of well-being of the patient. It would be of interest to perform a complementary study 
comparing outcome on a quality of life scale between patients with an equal СП in 
respectively a secondary and tertiary epilepsy referral centre. 
In the comparison study of the СП with the subjective assessment of a clinician 
regarding the treatment outcome and clinical status of the patients, a high correlation 
was found between the СП score and the clinician's opinion of the clinical status of 
the patient. The СП score, however, permits more accurate retrospective analysis of 
such clinical status. 
Prevalence and intensity of side effects of AEDs in patients using monotherapy and 
polytherapy were assessed using the toxicity subscales of the CIL The application of 
the Prescribed Daily Dose/Defined Daily Dose ratio proved to be quite useful. The 
strength of the method would be further improved when pharmacological studies 
would provide evidence of linear dose response curves for the drugs under 
consideration. 
The results of this study showed no differences in both prevalence and intensity of 
side effects for patients on monotherapy and patients on polytherapy with a similar 
strength of AEDs. 
The study comparing respectively the predictive value of the dosage of antiepileptic 
drugs and of the serum level for the Seizure Activity Index and for the Neurotoxicity 
Rating showed that neither the dosage nor the serum levels were correlated with either 
the efficacy or the toxicity of AEDs. This indicates that the response to dosage or 
serum level varies for each individual patient, and is not associated with "therapeutic" 
doses or serum levels. Though it might have been expected that dose would correlate 
better than serum level with NTX score in view of the role of toxic (unmeasured) 
metabolites, this was not the case. In particular, studies are warranted which explore 
the relation of dose or serum level with the neurotoxicity score in individual patients. 
Such studies should also examine the development of tolerance to neurotoxic side 
effects. 
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The prevalence of antiepileptic drug use in an exemplary sample of the Dutch 
population coincides with epilepsy prevalences found in other studies in The 
Netherlands which range from 0.29% to 1.0%. Little change was observed in the 
AEDs used from 1989-1992. For most AEDs the PDD/DDD ratio was well under 1.00. 
The reason for this could be that the Defined Daily Dose, as recommended by the 
WHO, is in fact too high. It should be also noted that the WHO Collaborating Centre 
For Drug Statistics in Oslo presents the DDD of oxcarbazepine as being equal to the 
DDD of carbamazepine, while all clinical trials show that the DDD of OCB should be 
IVi times the DDD of CBZ. The percentage of prescriptions for GVG increased rapidly 
after its introduction in 1990. Also the percentage of patients using vigabatrin (GVG) 
in monotherapy increased from 1989-1992, although GVG was registered as add-on 
therapy in partial seizures. The AEDs prescribed in the epilepsy centres differed from 
the PHARMO population mostly with respect to dosage and number of AEDS. Patients 
from the epilepsy centres were mostly prescribed higher doses of AEDs, and more 
patients were treated with polytherapy. This could be expected since in the PHARMO 
population all patients with epilepsy are included and epilepsy centres are mostly 
involved in the treatment of patients with a severe form of epilepsy. 
Prognostic factors for the outcome of the СП, representing the severity of epilepsy, 
found in our study differ from factors found in studies on remission and relapse of 
seizures or first seizure after an initial epileptic seizure. The presence of factors which 
have a negative influence on the chance of seizure remission do reduce the possibility 
of becoming seizure free, but apparently do not necessarily imply a severe form of 
epilepsy. 
9.2 Comparison of Composite Index of Impairments to other scoring methods in 
epilepsy. 
In the assessment of treatment effect in epilepsy, seizure frequency alone is often 
used as a tool for measurement of treatment outcome. It has been acknowledged that 
seizure counts solely do not suffice in the assessment of treatment outcome or the 
evaluation of the severity of epilepsy. 
Important clinical information associated with seizure severity may be lost when 
using only the seizure frequency as parameter for treatment effect. A generalised tonic 
clonic seizure (GTCS) is mostly perceived by the patients as more severe and 
embarrassing than a simple partial seizure (SPS). Treatment may stop GTCS while 
increasing the SPS, thus simply counting seizure occurrence would not describe 
treatment effect. 
Treatment of epilepsy usually requires antiepileptic medication mostly for a long 
period of time. In order to reduce seizure frequency and severity some patients have to 
be treated with high doses of AEDs. This could lead to undesirable side effects. 
Mattson et al. (1985) have demonstrated that most AEDs are equally efficacious, and 
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therefore the rational for selecting an AED would be based on the expected side 
effects. When side effects of antiepileptic drugs are mentioned this is mostly done in a 
descriptive manner and no attention is payed to the severity of these side effects. 
An assessment method for the evaluation of epilepsy treatment allowing better 
comparison should use quantification of seizure severity and of side effects of 
antiepileptic medication. 
The Composite Index of Impairments used in this study has been adapted from the 
Veterans Affairs rating scale which was developed for studies on the efficacy and 
toxicity of antiepileptic drugs. Therefore in that study seizure scores were modulated if 
the serum level of the antiepileptic drugs were under the "therapeutic range". 
In our study we evaluated the situation of chronic patients with epilepsy regardless 
of the number or the dosage of antiepileptic drugs used. Therefore, serum levels are 
not used as a modifying factor in this study. The seizure severity is build into the 
system through the scores for different types and frequencies of seizures. The scores 
reflect the consensus of a number of U.S. epileptologists. On an individual basis 
modulators can change the seizure index. 
Other rating scales have been developed to evaluated epilepsy treatment. 
A rating scale for the severity of epilepsy was developed by Baker et al. (Baker et 
al., 1991; Smith et al., 1991). This Liverpool rating scale was developed to examine 
the relationship between seizure frequency, seizure severity and psychosocial 
consequences of epilepsy. This rating scale does not use quantitative data, but gives a 
description of the patients perception of seizure control. Seizure frequency is not 
recorded with this scoring method, and it also does not register side effects of 
medication. Therefore it would be less suitable than the Composite Index of 
Impairments for the assessment of quality of care. The Liverpool rating scale is 
currently studied as part of a quality of life scale. 
The Chalfont Seizure Severity Scale has also been developed to measure seizure 
severity and not so much seizure frequency (Duncan and Sander, 1991). The items 
used to modulate seizure severity are analogous to the items used in the Composite 
Index of Impairments. It does not affix weighting factors to different seizure types, but 
measures the elements of seizures that concern patients. Differentiation can be made 
however, of the different seizure types. As in the Liverpool rating scale side effects are 
not incorporated in this seizure severity scale, which makes the overall assessment of 
treatment more difficult. 
9.3 Conclusion 
The papers presented in this thesis show the applicability of the Composite Index of 
Impairments in the assessment of treatment outcome. This clinimetric index is 
constructed of three sub-indexes by which seizure frequency and severity as well as 
the side effects of antiepileptic medication can be assessed. 
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The advantage of using this index in the assessment of treatment outcome is that the 
index uses objective data which are easily available in a routine clinical setting. This 
format enables the detection of changes arising in the course of treatment and 
identification of the underlying components responsible for these changes. This makes 
this scoring methods useful in clinical trials but also in the day to day management of 
patients with epilepsy. Because the CII score gives an indication of the degree of 
epilepsy control, it can be used in treatment planning and adjustments. 
The present СП proved to be a useful but not sufficient tool to assess quality of 
care for patients with epilepsy. The present СП was originally developed to compare 
pharmacotherapeutic treatment of patients with epilepsy and not the overall impact of 
epilepsy on the quality of life of the patients. A quality of life scale would require 
additional psychosocial elements not present in the Composite Index of Impairments. 
Also the subscale for neurotoxicity could be improved by adaptations according to the 
types of drugs used and employment of computerized measures of neurotoxicity. 
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10. SUMMARY 
10J Introduction 
The main objective of the studies presented in this thesis is to test the application of 
a clinimetric scoring method in the assessment of outcome of treatment in outpatients 
with epilepsy. Part-I of this thesis shows the validity of the clinimetric scoring method 
used in the studies. Part-II illustrates the usefulness of the Composite Index of 
Impairments in comparing the outcome of treatment in different health facilities where 
people with epilepsy are cared for. Also the usefulness of applying clinimetric indexes 
in the assessment of side effects of antiepileptic drugs is demonstrated in this section. 
In Part-ΠΙ the results of a pharmacoepidemiological study of the prescriptions of 
antiepileptic drugs is presented as well as an evaluation of possible prognostic factors 
for the severity of epilepsy. 
In the subsequent paragraphs the main results from the studies described in this 
thesis will be briefly reviewed. 
10.2 Comparison of two Epilepsy Centres 
In order to test if it is feasible to compare epilepsy treatment policies, a secondary 
(University Hospital) and a tertiary referral care centre (i.e. an Epilepsy Centre) were 
compared with respect to their characteristics, the treatment approaches, and the 
outcome of treatment using clinimetric indexes. At the Epilepsy Centre a greater 
variety of seizure types was seen than at the University Hospital. At the University 
Hospital more patients were treated with monotherapy (62.5%) than at the Epilepsy 
Centre (28.0%). The Composite Index of Impairments (СП), which reflects all 
treatment related impairments, i.e. seizures and adverse events, was significantly higher 
for the patients at the Epilepsy Centre than at the University Hospital. No difference 
was seen in prevalence of the groups of patients with a very high score of the СП 
(>100). 
Since marked differences were observed in the treatment policies and outcome as 
well as in the distribution of seizure types and duration of epilepsy the patients were 
matched according to seizure type and duration of epilepsy, resulting in two groups 
each of 32 patients per centre. 
After matching distinct differences were no longer found in the treatment policies of 
both centres. However, differences were observed in the outcome of treatment. The 
toxicity ratings in this study were significantly higher for the Epilepsy Centre. Also the 
Composite Index of Impairments (СП) was significantly higher at the Epilepsy Centre. 
Again the number of patients with а СП score of > 100 did not differ significantly for 
both centres. 
The finding that pharmacotherapy is similar in both centres, suggests that 
pharmacotherapy is pushed to its limits in both, and that referral to a tertiary facility is 
mainly for the non-pharmacotherapeutic care modalities available. For the 
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corroboration of this assumption the use of a quality of life index would be more 
appropriate than the СП. 
10J A Clinimetric Analysis of Treatment Objectives and Clinical Status 
The achievement of treatment objectives for patients with epilepsy, as defined by 
the treating clinicians, was compared with the scoring of clinimetric indexes. Patients 
with the treatment objectives "Complete Seizure Remission" or "Treatment 
Impairment/Benefit Balance" were included in this study. The clinimetric indexes were 
also compared with a clinical status rating, as assessed by the clinician. 
No correlation was observed between the clinimetric indexes and achievement of the 
treatment objective. The difference found in outcome of treatment objectives and index 
scores may be due to the fact that the indexes are group intended and the clinician's 
judgement is individual oriented. 
The clinician's assessment of clinical status of the patient however, did correlate 
with the Composite Index of Impairments (СП), a clinimetric scale for the severity of 
the impairments caused by epilepsy. 
The advantage of the СП over the clinical status rating is that the СП is constructed 
with objective data and shows the cause of change found during follow up. 
10.4 Monotherapy or Polytherapy for Epilepsy Revisited 
There is uncertainty about the advantage of monotherapy over polytherapy in the 
treatment of epilepsy. The major argument for monotherapy is the assumed increase of 
side effects in polytherapy. In this prospective study we compared the prevalence and 
severity of side effects in patients on monotherapy and patients on polytherapy, using 
clinimetric indexes. We applied two clinimetric scores, i.e. a neurotoxicity and a 
systemic toxicity score. These clinimetric indexes score the severity of side effects. We 
compared patients on monotherapy and polytherapy with similar exposition to AED 
medication, expressed in Prescribed Daily Dose/Defined Daily Dose ratio's. We also 
assessed the prevalence and severity of side effects of AED in all our patients on 
polytherapy stratified in two groups, one with a PDD/DDD ratio of <2.0, the other 
using more. The data of 292 patients, 161 on monotherapy and 131 on polytherapy 
with similar PDD/DDD ratio's, were reanalysed. In the indexgroup (monotherapy) the 
maximum PDD/DDD ratio was 2.0. No difference was seen in either the prevalence or 
the severity of side effects between both groups, with the exception of sedation and 
cognitive impairment. These two side effects occurred more frequently in the group of 
patients on polytherapy, although the severity did not differ from that of patients on 
monotherapy. When considering the data of these 292 patients in combination with 134 
additional patients who belonged to the original study population and who had a 
PDD/DDD ratio >2.0, there was little increase of either prevalence or severity of side 
effects as a function of dosage. We conclude that data in the literature do not permit 
the conclusion that monotherapy should be preferred to polytherapy. We also conclude 
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that due to uncontrollable factors, i.e. duration of disease and higher dosages when 
resorting to polytherapy, observational studies are unsuited to provide an answer to this 
question. 
10.5 Dosage nor Serum Levels of Antiepileptic Drugs are predictive for Efficacy 
and Adverse Effects. 
Antiepileptic drug monitoring has been used increasingly in the assessment of 
pharmacotherapy in epilepsy. However, it is not clear whether an evident relationship 
exists between serum levels and treatment effect. This study was performed in order to 
assess whether dosage or serum levels of AEDs were better parameters in predicting 
drug effects. For this reason an Actual Serum Level/Average Serum Level ratio 
(ASL/ATL ratio) was developed in analogy to the PDD/DDD ratio. For all patients, 
both on mono- and on polytherapy we assessed whether the PDD/DDD ratio or the 
ASL/ATL ratio was a better predictor of the СП and its individual subscales. 
Furthermore we looked at the range and average of the ASL/ATL ratio's stratified 
according to the PDD/DDD ratio's. The mean PDD/DDD ratio for the individual drugs 
was higher in polypharmacy than in monopharmacy. Clinicians might prescribe higher 
dosage in polytherapy in anticipation of or in reaction to pharmacokinetic interactions 
between AED's. This is corroborated by the finding that most individual serum levels, 
expressed in ASL/ATL ratios, were lower in polypharmacy than in monopharmacy. 
Only a marginal correlation was found between the clinimetric indexes and both the 
PDD/DDD ratio and ASL/ATL ratio, although the correlation was slightly better for 
the PDD/DDD ratio. A slightly better correlation was found in polytherapy than in 
monotherapy. Also an only marginal correlation was found between these two ratio's 
and СП in individual patients who had different СП scores at a second time of 
assessment. Again the correlation did not differ significantly between the PDD/DDD 
ratio and the ASL/ATL ratio. 
The effect of individual patient variables which have an impact on drug kinetics, 
such as age, gender, liver and kidney function, and protein binding of the AED have 
not been taken into consideration in this study, which may have clouded the results. 
Also the effect of metabolites on the outcome of the indexes were not analysed in this 
study. The results of this study show that a change of dosage or serum levels of 
antiepileptic drugs does not necessarily predict a change in efficacy or adverse effects 
of these drugs. 
10.6 Use of Antiepileptic Drugs in the Community-dwelling Dutch Population 
In order to assess the use of AEDs in outpatients with epilepsy in The Netherlands 
the data of a database on drug-dispensing in six Dutch cities were applied (PHARMO 
database), from 1989 unwards. Patients who used one or more of the AEDs during a 
period longer than 180 days were defined as patients having epilepsy. This time span 
was considered sufficient in order to eliminate those patients who used these drugs 
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incidentally for indications other than epilepsy. AEDs prescription did not change 
much in the four year period assessed in this study. An increase was seen in 
prescriptions for clonazepam (CZP), which is surprising, because patients may develop 
a tolerance for this drug, which makes it less advantageous for chronic treatment and 
its continuous use could also diminish its effect in the treatment of status epilepticus. 
The percentage of patients on monotherapy was almost 80% in our population. This 
is in accordance with the observation of Shorvon and Reynolds, who showed that in 
78% of the patients epilepsy can be well controlled with monotherapy (Shorvon and 
Reynolds, 1982). 
For most AEDs the dosage was well under the average maintenance dose 
recommended by the WHO-Oslo. The reason for this could be that the Defined Daily 
Dose, as recommended by the WHO, is in fact too high. 
The percentage of prescriptions for vigabatrin (GVG) increased rapidly after its 
introduction in 1990, as did the percentage of patients using GVG in monotherapy, 
although GVG was primarily registered as add-on therapy in partial seizures. 
The AEDs prescribed in the epilepsy centres differed from the PHARMO population 
mostly with respect to dosage and number of AEDS. Patients from the epilepsy centres 
were mostly prescribed higher dosage of AEDs, and more patients were treated with 
polytherapy. This would suggest that the patients from the epilepsy centres have a 
more difficult to treat epilepsy, requiring different and higher dosed AEDs. This could 
be expected since in the PHARMO population all patients with epilepsy are included 
and epilepsy centres are mostly involved in the treatment of patients with a severe 
form of epilepsy. 
10.7 Prognostic Factors for the Severity of Epilepsy 
In sixty patients with stable epilepsy control possible prognostic factors were 
assessed through multiple regression analysis. Five variables were found to be of most 
influence on the outcome of the СП. Variables with a positive impact on the СП score 
were months of freedom in the last two years, and a history of febrile convulsions. 
Frequent treatment changes, a history of developing tolerance to AEDs, and a history 
of reduction of AEDs due to side effects had a negative influence on the СП score. 
Predictive factors found in studies on seizure remission and relapse and on seizure 
recurrence after a first epileptic seizure were not of influence on the СП score in our 
study. The fact that these variables were not of influence on the severity of epilepsy in 
our study could mean that although these variables diminishes the chance of becoming 
seizure free, this does not imply that patients will have a severe form of epilepsy. 
10.8 Conclusion 
The question which initiated this thesis has been answered in the affirmative. A 
clinimetric approach is a practical and effective instrument for the evaluation of 
epilepsy care. The index uses objective data which are easily available in a routine 
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clinical setting. This format enables the detection of changes arising in the course of 
treatment and identification of the underlying components responsible for these 
changes. However, the instrument is still in its infancy and needs further development. 
For the neurotoxicity index computer assisted tests of motor and cognitive function 
appear promising. Furthermore the Composite Index of Impairments presently focuses 
on observer perceived patient based dysfunctions. It lacks information about patient 
perceived impact on his quality of life and about environmental modifiers. However 
these developments are beyond the scope of this thesis. 
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11. SAMENVATTING 
11.1 Doelstelling van het onderzoek 
De behandeling van chronische aandoeningen zoals epilepsie, vereist regelmatige 
poliklinische controles en aanpassingen in de behandeling. Het resultaat van de 
behandeling kan door middel van vele methoden beschreven worden en de 
verscheidenheid van deze methoden kan het vergelijken van de resultaten bemoeilijken. 
Feinstein introduceerde het begrip klinimetrische indices of schalen voor het registreren 
van klinische verschijnselen. Door middel van klinimetrische indices kunnen 
symptomen van een aandoening en de resultaten van de behandeling op 
gekwantificeerde wijze uitgedrukt worden. Klinimetrische indices kunnen gebruikt 
worden in het omschrijven van de huidige klinische situatie van een patiënt en van 
veranderingen die optreden tijdens de behandeling. Deze indices kunnen zo als richtlijn 
fungeren in behandeling of in het voorspellen van het effect van behandeling. 
In de studies beschreven in dit proefschrift wordt gebruik gemaakt van de 
klinimetrische index, de Composite Index of Impairments (СП), om de resultaten van 
de behandeling van patiënten met epilepsie vast te leggen. De СП is afgeleid van de 
index ontwikkeld door de Department of Veterans Affairs Cooperative Study of 
Antiepileptic Drugs voor een onderzoek naar de verschillen in werkzaamheid en 
bijwerkingen van antiepileptica. Het is een samengestelde index die zowel de 
frequentie en de ernst van de aanvallen als de bijwerkingen van de antiepileptische 
medicatie registreert, en op die manier alle nadelige gevolgen van de behandeling 
weergeeft. De CII bestaat uit drie sub-indices: 
1. De Seizure Activity Index (SA). 
Hierin worden zowel aanvalstype als aanvalsfrequentie betrokken door middel van 
de Index of Seizures (IS). De frequentie per aanval wordt berekend vanaf de 
laatste controle. De IS score wordt daarna omgerekend tot de SA score aan de 
hand van factoren die van invloed zijn op de ernst van de aanval. Deze factoren 
zijn: 
I. Aanwezigheid van een aura, waardoor maatregelen genomen kunnen 
worden om letsel te voorkomen. (IS score vermindering met 20%) 
П. Aanwezigheid van uitlokkende factoren voor een aanval. (IS score 
vermindering met 50%) 
III. Aanvallen alleen tijdens slaap of bij ontwaken. (IS score vermindering met 
40%) 
IV. Functiebeperking na de aanval minder dan 15 minuten. (IS score 
vermindering met 50%) 
V. Aanvallen in clusters. (IS score vermindering met 50%) 
2. De Neurotoxicity Rating Scale (NTX) registreert de ernst van neurologische 
bijwerkingen van antiepileptische medicatie. 
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3. De Systemic Toxicity Rating Scale (STX) registreert de andere systemische 
bijwerkingen van antiepileptische medicatie. 
Een СИ score van 0 betekent dat patiënt aanvalsvrij is en geen bijwerkingen heeft, dus 
dat de epilepsie goed ingesteld is. Een СП score van 50 en hoger betekent een 
onacceptabel ingestelde epilepsie en veranderingen in de behandeling zijn geïndiceerd. 
Om de scoringsmethode te testen werden een tweede en derde lijns epilepsiecentrum 
met elkaar vergeleken met gebruik van de Composite Index of Impairments (hoofdstuk 
3). De klinimetrische methode werd bovendien vergeleken met de subjectieve 
beoordeling van de behandelende arts of het behandeldoel voor de patiënt bereikt was 
(hoofdstuk 4). Tevens bleek de klinimetrische methode bruikbaar bij het vergelijken 
van monotherapie en polytherapie aangaande de ernst en het voorkomen van 
bijwerkingen bij deze twee behandelmethoden (hoofdstuk 5). In deze studies 
correleerden het behandelresultaat met de dosis van de medicatie en niet met de 
bloedspiegels. De correlatie tussen bloedspiegels en het resultaat van de behandeling 
werd apart onderzocht (hoofdstuk 6). Tevens werd een farmacoepidemiologisch 
onderzoek verricht gebruik makend van een databank met gegevens met betrekking tot 
alle recepten die zijn afgeleverd aan de inwoners van zes Nederlandse steden. Hiermee 
konden de antiepileptica die werden voorgeschreven worden vastgesteld en vergeleken 
over de periode van 1989 tot en met 1992 (hoofdstuk 7). Tenslotte werden mogelijke 
prognostische factoren onderzocht voor de ernst van de epilepsie in de 
onderzoekspopulatie (hoofdstuk 8). 
In de onderstaande paragrafen worden de uitkomsten van de boven beschreven 
onderzoeken in het kort weergegeven. 
112 Vergelijking van twee epilepsiecentra 
Een tweede en derde lijns epilepsiecentrum werden met elkaar vergeleken wat 
betreft de eigenschappen van de patiënten, de behandeling en het resultaat van de 
behandeling. Hiervoor werd gebruik gemaakt van klinimetrische indices. 
In het derde lijns epilepsiecentrum werd een grotere verscheidenheid aan aanvallen 
gezien. In het tweede lijns epilepsiecentrum werden meer patiënten behandeld met 
monotherapie (62,5%) dan in het derde lijns centrum (28,0%). De score van de CII 
was statistisch significant hoger voor de patiënten van het derde lijns centrum. Er werd 
geen verschil gevonden in het percentage patiënten met een zeer hoge СП score (>100) 
tussen beide centra. Aangezien er grote verschillen werden gevonden in de gegeven 
behandelingen en behandelresultaat, type aanvallen en duur van de epilepsie werden de 
patiënten van beide centra gematcht op aanvalstype en duur van de epilepsie. Dit 
resulteerde in twee groepen van ieder 32 patiënten per centrum. In de gematchte 
groepen werden geen verschillen in behandeling meer waargenomen. Wel werd een 
statistisch significant hogere toxiciteits score en СП score gevonden in het derde lijns 
epilepsiecentrum. Het feit dat de behandelingen in beide centra hetzelfde waren kan 
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betekenen dat verwijzing naar een derde lijns epilepsiecentrum voor de niet-
farmacotherapeutische zorg mogelijkheden plaatsvindt. 
113 Een Klinimetrische Analyse van Behandeldoel en Klinische Toestand 
Het al of niet behalen van een behandeldoel bij patiënten met epilepsie, omschreven 
door de behandelend arts, werd vergeleken met de score van de klinimetrische indices. 
Patiënten met als behandeldoel "volledige aanvalsvrijheid" of "balans tussen voor- en 
nadelen van de behandeling" werden ingesloten in dit onderzoek. De klinimetrische 
indices werden ook vergeleken met de klinische toestand van de patiënt, beoordeelt 
door de behandelend arts. 
Er werd geen correlatie gevonden tussen de klinimetrische indices en het bereiken 
van het behandeldoel. Het verschil in de score van de indices en het bereiken van het 
behandeldoel kan het gevolg zijn van het feit dat de klinimetrische indices voor 
groepen zijn ontworpen en dat de beoordeling door de arts meer per individuele patiënt 
bepaald wordt. 
Het oordeel van de arts over de klinische toestand van de patiënten correleerde wel 
met de CII score, een klinimetrische index voor de ernst van de epilepsie. Het voordeel 
van de CII ten opzichte van een schaal voor de klinische toestand is dat de СП 
opgebouwd is uit objectieve gegevens en hierdoor kan de oorzaak van eventuele 
veranderingen in de ernst van de epilepsie worden aangeven. 
11.4 Monotherapie of Polytherapie voor Epilepsie 
In de behandeling van epilepsie is monotherapie de eerste keus. De reden hiervoor 
is dat wordt aangenomen dat polytherapie meer en ernstigere bijwerkingen geeft. In 
een prospectief onderzoek zijn de prevalentie en de ernst van bijwerkingen bij 
monotherapie en polytherapie met elkaar vergeleken, gebruik makend van 
klinimetrische indices. Er werd gebruik gemaakt van twee klinimetrische 
scoringsmethoden, de neurotoxiciteits score (NTX) en de systemische toxiciteits score 
(STX). Door middel van deze indices kan de ernst van de bijwerkingen van 
antiepileptica bepaald worden. 
In dit onderzoek werden patiënten met elkaar vergeleken die behandeld werden met 
monotherapie of polytherapie met dezelfde blootstelling aan antiepileptica, uitgedrukt 
in de Prescribed Daily Dose/Defined Daily Dose ratio (PDD/DDD ratio). Tevens werd 
de prevalentie en de ernst van de bijwerkingen bepaald in alle patiënten die 
polytherapie kregen, onderverdeeld in twee groepen: patiënten met een PDD/DDD ratio 
<2,0 en met een PDD/DDD ratio >2,0. De gegevens van 292 patiënten, 161 met 
monotherapie en 131 met polytherapie met een PDD/DDD ratio <2,0 werden 
vergeleken. Er werd geen verschil gevonden in zowel prevalentie als ernst van de 
bijwerkingen tussen de groepen met monotherapie en polytherapie, met uitzondering 
van sedatie en cognitieve functiestoornissen. Deze twee bijwerkingen kwamen vaker 
voor bij de polytherapie groep, hoewel de ernst niet verschilde met de groep die werd 
108 
CHAPTER 11: Samenvatting 
behandeld met monotherapie. Bij het vergelijken van de beide groepen met 
polytherapie werd weinig toename gevonden van zowel prevalentie als ernst van de 
bijwerkingen met de toename van de dosis. Onze conclusie is dat gegevens uit de 
literatuur niet toestaan te concluderen dat monotherapie is te verkiezen boven 
polytherapie. Tevens concluderen wij dat ten gevolge van oncontroleerbare factoren, 
zoals duur van de aandoening en het hoger doseren bij polytherapie observationele 
onderzoeken niet geschikt zijn om een antwoord te geven op de vraag of polytherapie 
meer bijwerkingen geeft dan monotherapie. 
11.5 Noch de Dosering noch de Bloedspiegels van Antiepileptica zijn voorspellend 
voor Werkzaamheid en Bijwerkingen. 
Het gebruik van bepalingen van bloedspiegels van antiepileptica in de 
farmacotherapeutische behandeling van epilepsie is de laatste jaren toegenomen. Het is 
echter niet geheel duidelijk of er een relatie bestaat tussen de bloedspiegels en het 
resultaat van de behandeling. Dit onderzoek werd uitgevoerd om te bepalen of de dosis 
dan wel de bloedspiegel van antiepileptica een betere parameter is voor de voorspelling 
van het effect van de antiepileptica. 
Er is voor dit onderzoek een Actual Serum Level/Average Serum Level ratio 
(ASL/ATL ratio) ontworpen analoog aan de PDD/DDD ratio. Bij alle patiënten met 
zowel monotherapie als polytherapie werd gekeken of de PDD/DDD ratio dan wel de 
ASL/ATL een betere voorspellende waarde had voor de uitkomst van de CII en de 
sub-indices van de CII. 
De gemiddelde PDD/DDD ratio voor de afzonderlijke antiepileptica was hoger bij 
polytherapie dan bij monotherapie. Het kan zijn dat artsen een hogere dosis 
voorschrijven bij polytherapie vanwege verwachte farmacokinetische interacties tussen 
de afzonderlijke antiepileptica. Dit wordt ondersteund door de bevinding dat voor de 
meeste afzonderlijke antiepileptica de bloedspiegels, uitgedrukt in de ASL/ATL ratio, 
lager waren bij polytherapie dan bij monotherapie. Er werd slechts een geringe 
correlatie gevonden tussen de kl inimetrische indices en zowel de PDD/DDD ratio als 
de ASL/ATL ratio. De correlatie was iets beter bij polytherapie dan bij monotherapie. 
Het effect van individuele patiëntvariabelen die van invloed zijn op de 
farmacokinetiek zoals leeftijd, geslacht, lever- en nierfunctie en eiwitbinding van de 
antiepileptica werden niet in beschouwing genomen in dit onderzoek. Tevens zijn de 
effecten van de metabolieten van antiepileptica op de uitkomst van de indices niet 
geanalyseerd. Dit kan van invloed zijn geweest op de uitkomsten van dit onderzoek. 
Dit onderzoek toont aan dat een verandering van doses of bloedspiegels van 
antiepileptica niet een verandering in het effect van de antiepileptica hoeft te 
betekenen. 
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11.6 Antiepileptica Gebruik in Nederland 
Om het antiepileptica gebruik in Nederland te onderzoeken werd gebruik gemaakt 
van gegevens van een databank waarin de gegevens met betrekking tot alle recepten 
die afgeleverd zijn aan 300.000 inwoners van zes Nederlandse steden opgeslagen zijn 
(PHARMO database). De gegevens vanaf 1989 werden geanalyseerd. Wanneer 
patiënten één of meer antiepileptica langer dan 180 dagen gebruikten werden zij 
beschouwd als hebbende epilepsie. Deze termijn werd als afdoende beschouwd om alle 
patiënten uit te sluiten die deze medicijnen incidenteel gebruikten voor andere 
indicaties dan epilepsie. De antiepileptica die werden voorgeschreven veranderden 
weinig gedurende die vier jaar die werden geanalyseerd voor dit onderzoek. Er werd 
een toename gezien in het aantal voorschriften van clonazepam. Dit is verwonderlijk 
omdat patiënten tolerantie kunnen ontwikkelen voor clonazepam, waardoor het minder 
geschikt is voor chronische behandeling en het voortdurende gebruik kan ook het 
effect van clonazepam verminderen bij de behandeling van een status epilepticus. Het 
percentage patiënten dat met monotherapie behandeld werd was 80% in deze populatie. 
Dit is in overeenstemming met de bevindingen van Shorvon dat in 78% van de 
patiënten epilepsie goed is in te stellen met één antiepilepticum. Voor de meeste 
antiepileptica waren de doses ruim onder de gemiddelde onderhoudsdosering die 
aanbevolen wordt door de WHO-Oslo. De oorzaak hiervoor kan zijn dat de voor de 
Defined Daily Doses aanbevolen doseringen van de WHO-Oslo te hoog zijn. Het 
percentage voorschriften vigabatrine nam sterk toe na de introductie van dit middel in 
1990. Ook het percentage patiënten dat vigabatrine als monotherapie gebruikte nam 
toe, hoewel vigabatrine oorspronkelijk was geregistreerd voor add-on therapie bij 
partiële aanvallen. 
De antiepileptica die werden voorgeschreven voor de populatie van de 
epilepsiecentra verschilden van die voor de PHARMO populatie, voornamelijk met 
betrekking tot de dosering en het aantal antiepileptica per patiënt. De patiënten van de 
epilepsiecentra kregen meestal een hogere dosering van de antiepileptica en werden 
vaker behandeld met polytherapie. Dit zou kunnen betekenen dat de patiënten van de 
epilepsiecentra een moeilijker te behandelen epilepsie hebben, waardoor meer 
antiepileptica en hogere doseringen worden voorgeschreven. Dit is te verwachten 
aangezien in de PHARMO populatie alle patiënten met epilepsie zijn opgenomen en 
epilepsiecentra meer moeilijk instelbare patiënten behandelen. 
11J Prognostische Factoren voor de Ernst van Epilepsie 
In dit onderzoek werden van zestig patiënten met een stabiele vorm van epilepsie de 
prognostische factoren voor de ernst van de epilepsie bepaald door middel van multiple 
regressie analyse. Er werden vijf variabelen gevonden die van invloed waren op de 
ernst van de epilepsie. Variabelen die een positieve invloed op de CII score hadden 
waren het aantal maanden dat een patiënt aanvalsvrij was en koortsconvulsies in de 
anamnese. Veelvuldige veranderingen in de behandeling, ontwikkeling van tolerantie 
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voor antiepileptica in de anamnese en vermindering van dosis ten gevolge van 
bijwerkingen van antiepileptica in de anamnese hadden een negatieve invloed op de 
СП score. Prognostische factoren die werden gevonden in onderzoeken waarbij 
gekeken werd naar de kans op volledige aanvalsvrijheid, de kans op het weer optreden 
van aanvallen en de kans op het optreden van een aanval na een eerste epileptische 
aanval waren niet van invloed op de СП score in dit onderzoek. Het feit dat deze 
variabelen niet van invloed waren op de CII score kan betekenen dat hoewel deze 
variabelen de kans op aanvalsvrijheid verminderen het nog niet behoeft te betekenen 
dat patiënten een ernstige vorm van epilepsie hebben. 
11.8 Conclusies 
De resultaten die in dit proefschrift gepresenteerd worden tonen de toepasbaarheid 
van de Composite Index of Impairments voor het beoordelen van de behandelresultaten 
voor epilepsie. De klinimetrische index bestaat uit drie sub-indices waarmee de 
aanvalsfrequentie en ernst van de aanvallen alsmede de bijwerkingen van antiepileptica 
beoordeeld kunnen worden. 
Het voordeel van het gebruik van deze index bij de beoordeling van 
behandelresultaten is dat er voor deze index gebruik gemaakt wordt van objectieve 
gegevens die makkelijk beschikbaar zijn in de dagelijkse praktijk. Door het gebruik 
van deze index zijn veranderingen die op kunnen treden tijdens een behandeling te 
ontdekken en kunnen de factoren die de verandering veroorzaken aangewezen worden. 
Hierdoor is deze scoringsmethode nuttig als toepassing in klinische onderzoeken maar 
ook in de alledaagse behandeling van patiënten met epilepsie. Omdat de CII een 
aanwijzing geeft van de mate van de ernst van de epilepsie kan er gebruik van 
gemaakt worden in de planning en aanpassingen van de behandeling, 
In zijn huidige vorm is de СП niet geschikt voor de beoordeling van kwaliteit van 
het leven van patiënten met epilepsie. De huidige CII was ontworpen om 
farmacotherapeutische behandelingen van patiënten met epilepsie te vergelijken en niet 
de invloed van de epilepsie op de kwaliteit van het leven van de patiënten. Een index 
om de kwaliteit van het leven te beoordelen vereist bijkomende psychosociale factoren 
die niet aanwezig zijn in de CIL Tevens zou de subindex voor de neurotoxiciteit 
verbeterd kunnen worden door aanpassingen aan de hand van het soort antiepilepticum 
dat gebruikt wordt en het gebruik van gecomputeriseerde meetinstrumenten voor 
neurotoxiciteit. 
111 

References 
Aldenkamp AP, Alpherts WCJ, Moerland MC, Ottevanger Ν, Van Parijs JAP. 
Controlled release carbamazepine: cognitive side effects in patients with epilepsy. 
Epilepsia 1987;28:507. 
Aman MG, Werry JS, Paxton JW, Turbott SH. Effect of sodium valproate on 
psychomotor performance in children as a function of dose fluctuations in 
concentration and diagnosis. Epilepsia 1987;28:115. 
Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients 
with epilepsy. Epilepsia 1979;20:729-737. 
Arts WFM, Visser LH, Loonen MCB, Tjiam AT, Stroink H, Stuurman PM, Poortvliet 
DCJ. Follow-up of 146 children with epilepsy after withdrawal of antiepileptic therapy. 
Epilepsia 1988;29:244-250. 
Baker GA, Smith DF, Dewey M, Morrow J, Crawford PM, Chadwick DW. The 
development of a seizure severity scale as an outcome measure in epilepsy. Epilepsy 
Research 1991;8:245-51. 
Beghi E, Sasanelli F, Spagnoli A, Tognoni G. Quality of care of epilepsy in Italy: A 
multi-hospital survey of diagnosis and treatment of 1104 epileptic patients. Epilepsia 
1982;23:133-148. 
Berent S, Sackellares JC, Giordani В, Wagner JG, Donofrio PD, Abou-Khalil B. 
Zonisamide (CT-912) and cognition: results from a preliminary study. Epilepsia 
1987;28:61 
Berg MJ, Fincham RW, Ebert BE, Schottelius D. Decrease of sodium folates in 
healthy male volunteers taking phenytoin. Epilepsia 1988;29:67. 
Bongers E, Coppoolse J, Meinardi H, Posthuma EPS, van Zijl CHW. A survey of 
epilepsy in Zeeland, The Netherlands. Heemstede: Instituut voor Epilepsiebestrijding, 
1976. 
113 
Clinimetrics in epileptology 
Bouma PAD, Peters ACB, Arts RJHM, Stijnen Th, van Rossum J. Discontinuation of 
antiepileptic therapy: a prospective study in children. J Neurol Neurosurg Psychiatry 
1987;50:1579-1583. 
Carenini L, Bottachi E, Camerlingo M, D'Allesandro G, Mamoli A. Carbamazepine 
does not affect short latency somatosensory evoked potentials: a longitudinal study in 
newly diagnosed epilepsy. Epilepsia 1988;29:145. 
Centraal Bureau voor de Statistiek, Leeftijdsopbouw per gemeente, op 1 januari 1992, 
kerncijfers, Voorburg/Heerlen 1993. 
Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic 
drugs: A follow-up study of 355 patients with chronic antiepileptic drug treatment. 
Epilepsia 1988;29:787-793. 
Commission on Classification and Terminology of the ILEA. Proposal for revised 
clinical and electroencephalographic classification of epileptic seizures. Epilepsia 
1981;22:489-501 
Commission on Classification and Terminology of the ILEA. 
Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 
1989;30:389-399. 
Cooper GL, Huitson A. An audit of the management of patients with epilepsy in thirty 
general practices. J Royal Coll Gen Practit 1986;36:204-208. 
Cramer JA, Smith DB, Mattson RH, et al.. A method of quantification for the 
evaluation of antiepileptic drug therapy. Neurology 1983;33(Suppl l):26-37. 
Crobach MJJS, Niezink GM, van der Leden J, Springer MP. Epilepsie en huisarts: 
toeval of hoofdzaak? Ned Tijdschr Geneeskd 1988;132(4):1888-1892. 
Dastur DK, Dave UP. Effect of prolonged anticonvulsant medication in epileptic 
patients: serum lipids, vitamins B6, В12, and folic acid, proteins, and fine structure of 
liver. Epilepsia 1987;28: 147. 
Duncan JS, Sander JWAS. The Chalfont seizure severity scale. J Neurol Neurosurg 
Psychiatry 1991;54:873-876. 
Eadie MJ. Anticonvulsant drugs. An update. Drugs 1984;27:328-363. 
114 
References 
Eadie MJ. The risk-benefit ratio of anticonvulsant drugs. Medical toxicology 
1987;2:324-337. 
Ettinger A, Moshe S, Shinnar S. Edema associated with long-term valproate therapy. 
Epilepsia 1990;31:211. 
Feinstein AR. Clinimetrics. New Haven and London. Yale University Press 1987. 
Feinstein AR. Principles and practice of clinimetrics in epilepsy. In: Meinardi H, 
Cramer JA, Baker GA, Martins da Silva A, eds. Quantitative Assessment in Epilepsy 
Care. Plenum Press, New York 1993: 1-10. 
Fletjer WJ, Astemborski JA, Hassel TM, Cohen MM. Cytogenic effects of phenytoin 
and/or carbamazepine on human peripheral leucocytes. Epilepsia 1989,30:374. 
Fröscher W, Eichelbaum M, Gugler R, Hildenbrand G, and Penin H. A prospective 
randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. 
Journal of Neurology 1981;224:193-201 
Gardner-Thorpe C, Janz D, Meinardi H, Pippenger CE, eds. Antiepileptic drug 
monitoring. Pitman Medical Publishing Co. Ltd., Tunbridge Wells, 1977. 
Gilhus NE, Tor L. Carbamazepine: effect in IgG subclasses in epileptic patients. 
Epilepsia 1988;29:317. 
Goodridge MG, Shorvon SD, Epileptic seizures in a population of 6000. II: Treatment 
and prognosis. Br Med J 1983;287:645-647. 
Gough H, Goggin T, Crowley M, Callaghan N. Serum bilirubin levels with 
antiepileptic drugs. Epilepsia 1989,30:597. 
Goyle S, Maurya AK, Kailash S, Maheshwari MC. Mutagenic risk in epileptic patients. 
Epilepsia 1991 ;32:122. 
Guelen PJM, van der Kleijn E, Woudstra U. Statistical Analysis of pharmacokinetic 
parameters in epileptic patients chronically treated with anti-epileptic drugs. In 
Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin AL eds. Clinical 
pharmacology of anti-epileptic drugs. Springer-Verlag, Berlin Heidelberg New York 
1975:2-10. 
115 
Clinimetrics in epileptology 
Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, 
Minnesota: 1940-1980. Epilepsia 1991;32(4):429-445. 
Hekster YA, Wijsman DJP, Wuis EW, Vree ТВ, Meinardi H. Individualization of 
antiepileptic drug therapy. In: Meinardi H, Cramer JA, Baker GA, Martins da Silva A 
eds. Quantitative Assessment of Epilepsy Care. Plenum Press, New York 1993:109-
116. 
Herings RMC. PHARMO. A record linkage system for postmarketing surveillance of 
prescription drugs in The Netherlands. Thesis Utrecht The Netherlands, 1993. 
Herranz JL, Arinijo JA, Arteaga R. Clinical side effects of phénobarbital, primidone, 
Phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 
1988;29:794. 
Ilium N, Taudorf K, Heilmann С, et al. Intravenous Immunoglobuline in a single-blind 
trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990;21:87. 
Isojärvi JIT. Serum steroid hormones and pituitary function in female epileptic patients 
during carbamazepine therapy. Epilepsia 1990;31:438. 
Isojärvi JIT, Pakarinen AJ, Myllylä VV. Effects of carbamazepine on the 
hypothalamic-pituitary-gonadal axis in male patients with epilepsy: a prospective study. 
Epilepsia 1989;30:446. 
Janz D. How does one assess the severity of epilepsy? In: Trimble MR, ed. Chronic 
Epilepsy: Its Prognosis and Management. John Wyllie, New York 1989:21-36. 
Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, eds. 
Antiepileptic therapy: Advances in drug monitoring. Raven Press, New York, 1980. 
Keränen Τ, Sillanpää M, Riekkinen PJ. Distribution of seizure types in an epileptic 
population. Epilepsia 1988;29:1-7. 
Keyser A, Hekster Y, Schaap M, Termond E. Antiepileptic drug therapy in outpatients. 
Journal of Pharmacoepidemiology 1990a; 1:35-47. 
Keyser A, Hekster YA, Termond E, Schaap M, Rwiza HT, Side-effects of drugs in 
epileptic patients. Pharmaceutisch Weekblad [Sci] 1990b; 12(4): 145-150. 
116 
References 
Koeppen D, Baruzzi A, Capozza M. Clobazam in therapy-resistant patients with partial 
epilepsy: a double-blind placebo-controlled crossover study. Epilepsia 1987;28:495. 
Lammers MW, Hekster YA, Keyser A, Renier WO, Meinardi H, van Lier H, Wijsman 
DJP. Epilepsy treatment in The Netherlands. Comparison of matched groups of two 
medical centres. Acta Neurologica Scandinavica 1994(a): Acta Neurologica 
Scandinavica 1994;89:415-420. 
Lammers MW, Hekster YA, Keyser A, Renier WO, Meinardi H, van Lier H, Wijsman 
DJP. A clinimetric analysis of treatment objectives and clinical status. Individualised 
treatment in epileptic patients. Epilepsia 1994(b): in press. 
Lammers MW, Hekster YA, Keyser A, Meinardi H, Renier WO. Monotherapy or 
polytherapy for epilepsy revisited. A quantitative assessment. Submitted for 
publication. 
Lammers MW, Meinardi H. On the Reporting of Adverse Drug Events. In: Meinardi 
H, Cramer JA, Baker GA, Martins da Silva A eds. Quantitative Assessment of 
Epilepsy Care. Plenum Press, New York 1993:117-122. 
Lapperre-Regelink M, Aben DJM, Höppener RJEA. Analyse van de 
gezondheidssituatie in het verzorgingsgebied van de GGD regio Geldrop-
Valkenswaard. Bouwstenen voor gezondheidsbeleid 1986, 1. Valkenswaard: GGD, 
1988. 
Larkin JG, Herrick AL, McGuire GM, Percy-Robb IW, Brodie MJ. Antiepileptic drug 
monitoring at the epilepsy clinic: A prospective evaluation. Epilepsia 1991;32:89-95. 
Lloyd Jones A, Medical audit of the care of patients with epilepsy in one group 
practice. J Royal Coll Gen Practit 1980;30:396-400. 
Lunde I. Data collection, data registration and drug utilization. In Muller NF, Hekster 
YA, eds. Progress in clinical pharmacy. Amsterdam Medical Press, Noordwijk 
1989:33-44. 
Martins da Silva A, Lourenço E, Nunes JM, Mendonça. Seizure frequency as treatment 
effect parameter. In: Meinardi H, Cramer JA, Baker GA, Martins da Silva A eds. 
Quantitative Assessment of Epilepsy Care. Plenum Press, New York 1993:35-42. 
117 
Clinimetrics in epileptology 
Mattson RH, Cramer JA, Collins JF, et al.. Comparison of carbamazepine, 
phénobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-
clonic seizures. The New England Journal of Medicine 1985;313:145-151. 
McCluggage JR, Ramsey HC, Irwin WG, Dowds MF. Anticonvulsant therapy in a 
general practice population in Northern Ireland. J Royal Coll Gen Practit 1984;34:24-
31. 
Meijer JWA. Knowledge, attitude and practice in antiepileptic drug monitoring. Thesis. 
Nijmegen. Acta Neurologica Scandinavica 1991;134(suppl 1):P1-P128. 
Meijer JWA, Meinardi H, Gardner-Thorpe C, van der Kleijn E, eds. Methods of 
analysis of antiepileptic drugs. Excerpta Medica, Amsterdam, 1973. 
Meinardi H. Clinical trials of anti-epileptic drugs. Psychiat. Neurol. Neurochir. 
1971;74:41. 
Meinardi H. Special centres in The Netherlands. Epilepsia 1972;13:191-197. 
Meinardi H. Side effects of new drugs and new side effects of old drugs. In: Canger 
R, Angeleri F, Penry JK, eds. Advances in epileptology. Raven Press, New York, 
1980:391-398. 
Meinardi H, Cramer JA, Baker GA, Martins da Silva, eds. Quantitative Assessment in 
Epilepsy Care. Plenum Press, New York 1993. 
Meinardi H, Meijer JWA. Modern concepts of antiepileptic therapy. Journal for 
Drugtherapy and Research 1990;15:149-155. 
Meinardi H, Pachlatko C. Special centers for epilepsy. Comprehensive Epileptology 
1990, Raven Press, New York. 
Meinardi H, Stoel LMK. Side-effects of antiepileptic drugs. In: Magnus O, Lorentz de 
Haas AM, eds. Handbook of Neurology vol. 15. North Holland Pubi. Cie, 
1974:705-738. 
Mitchell WG, Chavez JM. Carbamazepine versus phénobarbital for partial onset 
seizures in children. Epilepsia 1987;28:56. 
Overweg J, Ashton D, de Breukelaar F, et al. Add-on therapy in epilepsy with calcium 
entry blockers. Eur. Neurol. 1986;25(suppl.l):93. 
118 
References 
Oxley J, Janz D, Meinardi H, eds. Chronic Toxicity of antiepileptic drags. Raven 
Press, New York 1983. 
Pacifici R, Paris L, DiCarlo S, Immunologic aspects of carbamazepine treatment in 
epileptic patients. Epilepsia 1991 ;32:122. 
Pelekanos J, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs; clinical 
features and management. Epilepsia 1991;32:554. 
Pippenger CE. Rationale and clinical application of therapeutic drug monitoring. 
Paediatric Clinics of North America 1980;27(4):891-925. 
Reinvang I, Bjartveit S, Johannessen SI, Hagen OP, Larsch S, Fagerthun H, Gjerstad 
L. Cognitive function and time-of-day variation in serum carbamazepine concentration 
in epileptic patients treated with monotherapy. Epilepsia 1991 ;32:116. 
Remy C, Dellatolas G, Genton P, Vespignani H. Monothérapie versus polythérapie: 
habitudes thérapeutiques dans Γ épilepsie. (Résultats d'une étude transversale effectuée 
en 1988 dans trois centres français). Epilepsies 1992;4:61-66. 
Reynols EH, Ashton F, de Beukelaar F. Add-on therapy in epilepsy with calcium entry 
blockers. Eur Neurol 1986;25(suppl 1):93. 
Reynolds EH, Elwes RDC, Shorvon SD. Why does epilepsy become intractable. 
Lancet 1983;ii:952. 
Reynolds EH, Ring HA, Farr IN, Heller AJ, Elwes RDC. Open, double-blind and long-
term study of vigabatrin in chronic epilepsy. Epilepsia 1991;32:530. 
Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 
1981;22:1-10. 
Reynolds EH, Shorvon SD, Galbraith AW, et al. Phenytoin monotherapy for epilepsy: 
a longterm prospective study, assisted by serum level monitoring, in previously 
untreated patients. Epilepsia 1981;22:475. 
Robertson MM, Trimble MR, Townsend HRA. Phenomenology of depression in 
epilepsy. Epilepsia 1987;28:364. 
Rodin EA. The prognosis of patients with epilepsy. Springfield: Thomas 1968. 
119 
Clinimetrics in epileptology 
Rutgers MJ. Geneeskundige en maatschappelijke aspecten van de zorg voor 
epilepsiepatiënten in Nederland. Thesis Rotterdam The Netherlands, 1984. 
Rwiza HT, Keyser A, Hekster YA, Pool M, Verwey H. Retrospective analysis of drug 
treatment in epileptic patients. Pharmaceutisch Weekblad [Sci] 1989;11:50-55. 
Schmidt D. Reduction on two-drug therapy in intractable epilepsy. Epilepsia 
1983;24:368-376. 
Schmidt D. Adverse effects of anti-epileptic drugs. Raven Press, New York, 1982. 
Schneider H, Janz D, Gardner-Thorpe C, Meinardi H, Sherwin, eds. Clinical 
pharmacology of antiepileptic drugs. Springer Verlag, Berlin, Heidelberg, New York, 
1975. 
Schobben AFAM. Pharmacokinetics and therapeutics in epilepsy. Thesis Nijmegen, 
The Netherlands 1979. 
Shorvon SD, Reynolds EH. Early prognosis of epilepsy. Br Med J 1982;25:699-1701. 
Smith DF, Baker GA, Dewey M, Jacoby A, Chadwick DW. 
Seizure frequency, patient perceived severity and the psychosocial consequences of 
intractable epilepsy. Epilepsy Res. 1991;9:231-241. 
Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans 
Administration cooperative study comparing the efficacy and toxicity of 
carbamazepine, phénobarbital, phenytoin, and primidone. Epilepsia 
1987;28(Suppl.3):S50-S58. 
Spilker B. Standardisation of quality of life trials. PharmacoEconomics 
1992;l(2):73-75. 
Voorn Th В. Chronische ziekten in de huisartspraktijk. Thesis Nijmegen The 
Netherlands, 1983 . 
WHO Collaborating Centre for Drugs Statistics Methodology and Nordic Council on 
Medicines. Guidelines for DDD. Oslo 1991. 
Woo E, Chan YA, Yu YL, Chan YW, Huang CY. If a well-stabilized epileptic patients 
has a sub-therapeutic antiepileptic drug level, should the dose be increased? Epilepsia 
1988;29:129. 
120 
References 
Wuis EW, Hekster YA, Zuidgeest UB, de Goede WJ, Hommes OR, Keyser A. Drug 
utilization patterns of antiepileptic drugs in a University Hospital. Journal of Social and 
Administrative Pharmacy 1985;3(2):59-63. 
Wijsman DJP, Hekster YA, Keyser A, Renier WO and Meinardi H: Clinimetrics and 
epilepsy care. Pharmaceutisch Weekblad [Sci] 1991; 13(4): 182-188. 
Wijsman DJP, Lammers MW, Hekster YA, Keyser A, Renier WO, Meinardi H, Van 
Lier H. Epilepsy treatment in The Netherlands. Comparison of two medical centres. 
Acta Neurologica Scandinavica 1993;87:438-442. 
121 

APPENDICES 
References in referencelist 
123 
Clinimetrics in epileptology 
124 
Appendix I 
This paper has been published in: Meinardi H., Cramer J.A., Baker G.A. and Martins 
da Silva A. eds. Quantitative Assessment in Epilepsy Care. Plenum Press New York, 
1993:29-34 
Seizure Frequency as Treatment Effect Parameter: 
General Considerations. 
M.W. Lammers, M.D. and H. Meinardi, M.D., Ph. D. 
Clinimetrics in epileptology 
Introduction 
As epilepsy is a paroxysmal disorder it seems self-evident that the frequency of 
occurrence of paroxysms is a sensible index. However, as Feinstein admonishes in his 
teaching on Clinimetrics, the first question to be asked is for what purpose do we 
intend to use the index. 
If we simply wish to know what chance we have in a given period to register a 
seizure, the bare frequency will offer an estimate. If we wish to study the influence of 
different conditions on the outcome of one seizure type in one patient, again frequency 
per se will suffice. If we wish to study the impact of seizures on the quality of life of 
the patient seizure frequency per se will not longer be sufficient. If two seizure types 
occur in the same patient, and if these types are related (e.g., complex partial and 
secondarily generalized seizures), the occurrence of the one excluding the presence of 
the other while the seizure-type-specific seizure frequency differs, then simple counting 
of events per period will not be meaningful. If indexes are needed to evaluate different 
interventions in groups of people with epilepsy, simply referring to the seizure 
frequency may not be relevant. A case in point is the custom to assess the efficacy of 
anti-epileptic drugs by measuring percent change in seizure frequency. Such a choice 
implies that it should not make any difference in the efficacy of a drug whether it 
provides a reduction of 50% in seizure frequency in a patient suffering from 4 
generalized tonic-clonic seizures a day, or in a patient who suffered 4 generalized 
tonic-clonic seizures a week, or for that matter from 4 generalized tonic-clonic seizures 
a year. Whether the differences in inherent frequency and in therapy-resistance 
between different seizure types are harmonized by assessing the changes in frequency 
by percentage is doubtful. When the efficacy of an anti-epileptic drug is assessed by 
summing up the frequencies of all seizure types, several authors have applied 
(presumably intuitively) weighting coefficients (Meinardi, 1971; Cramer et al., 1983). 
The effect of clustering of seizures is more or less provided for by taking a study 
period of sufficient length, however, other diseases or patient related periodicities in 
seizure frequency are rarely ever accounted for. 
A scrutiny of ten randomly selected trials of anti-epileptic drugs reveals that most 
authors identify in the inclusion criteria at least a demarcating lowest seizure 
frequency, but do not try to obtain a fairly homogeneous study group as far as seizure 
frequency is concerned. Many but not all mention seizure type and group participants 
according to the individual pattern of seizure type(s). Even those authors consider 
seizures regardless of type as equivalent events, and present change as percentage of 
seizures with respect to a baseline period. Occasionally a specific seizure type is 
analyzed separately, however, without mentioning whether patients were included with 
only a single seizure type. 
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Change in Seizure Frequency as a Clinimetric Index 
Let us examine change in seizure frequency with the help of the checklist which 
Feinstein has provided to appraise the sensibility of this index (Feinstein, 1987). 
Purpose and Framework 
The index is clearly disorder specific. The function is to measure the transit between 
two states. The clinical justification to select seizure frequency is supported by the fact 
that seizures are the typical manifestations of epilepsy, however, the point of debate is 
whether the type of seizure is irrelevant for the severity of the disease process. 
The applicability of seizure counts is reasonable as seizures are behavioral 
manifestations that can easily be detected. A cautionary remark is, however, that in 
case of certain seizure types the patient may not be aware that a seizure occurred. 
Recording of seizures in that case will depend on the presence of an observer (or in 
theory a registering device). 
Comprehensibility 
As far as comprehensibility is concerned seizure frequency is a simple concept; 
sometimes there are several variables included (e.g., in studying patients with Lennox 
Gastaut syndromes, Ilium et al. distinguished Absence seizures, Tonic seizures, 
Myoclonic seizures, and Atonic seizures. (Ilium et al., 1990)). This index, contrary to 
the Index of Seizures (Cramer et al., 1983; Wijsman et al., 1991), does not use 
weighting factors; the biological connotation is clear. 
Replicability 
Replicability seems guaranteed, however, in practice problems may arise if some of 
the patients under study have seizures that occur in series with very brief intervals. 
Even though such series may comprise twenty or thirty distinct seizures, many authors 
would consider them as a manifestation of a single epileptic event comparable with 
status epilepticus. Replicability may also be jeopardized if the situation of the patient 
changes from having an observer present or not. 
Suitability of Scale 
With respect to the suitability of the scale one may argue that seizure frequency is 
insufficiently comprehensive as no account is give of elements like seizure duration, 
predictability of the seizure occurrence, presence or absence of an aura. Overweg 
mentioned that in a clinical trial of flunarizine patients were unhappy with the drug 
even though their seizure frequency diminished for in those seizures that persisted the 
aura was no longer noticeable (Overweg, 1986). Seizure frequency per se fulfils the 
requirement of easy discrimination; percent change in seizure frequency, however, does 
not as was stated before. 
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Face Validity 
The face validity of seizure frequency may be less strong as patients may differ in 
opinion which behavioral manifestation are part of an ictal event. 
The focus of basic evidence usually is a mark made by the patient on a seizure 
calendar, if a phenomenon has occurred which the patient and the physician have 
agreed to consider a seizure. Biological coherence of components is not an issue 
because the index is only comprised of one component. 
Content Validity and Ease of Usage 
The discussion of content validity repeats the discussion about the suitability of 
seizure frequency as an index. The widespread use of the index in the literature is 
proof of its ease of usage. 
Discussion 
Seizure frequency can also be used in assessing the difference in seizure frequency 
in different types of seizures. Reynolds et al. performed a study for assessing the 
efficacy of phenytoin as monotherapy in newly diagnosed patients with generalized 
tonic-clonic seizures, and patients with partial seizures, both with simple and complex 
symptomatology (Reynolds et al.,1981). There was a marked difference in seizure 
frequency between the two aforementioned seizure types. Before therapy the seizure 
frequency for generalized tonic-clonic seizures was 0.95 attacks/month compared to 
8.15 attacks/month for partial seizures. After optimalisation of the phenytoin levels the 
frequency for generalized tonic-clonic seizures was 0.01 attacks/month compared to 
0.60 attacks/month for partial seizures. 
In spite of the ease of usage of seizure frequency as an index, several authors felt 
the need to improve this index. Meinardi decided to affix weighting factors to the 
counts generalized tonic-clonic, complex partial, and absence seizures (Meinardi, 
1971). The aim was to facilitate comparison of efficacy between patients suffering 
from different seizure types. The coefficients were intuitively assigned to the 
difference in seizure frequency manifested by the aforementioned seizure types. 
Cramer et al. modified seizure counts first according to type of seizure, generalized 
tonic-clonic seizures collected twice as many points as complex partial seizures, and 
the latter again collected about three times as many points as simple partial seizures 
(Cramer et al., 1983). Neither Meinardi nor Cramer et al. appear to have based their 
scoring differences on epidemiological studies of seizure counts. Cramer et al. also 
modified their counts by terms that would refer to seizure severity. Seizure severity is 
a separate topic of discussion and will be dealt with further on. Furthermore Cramer et 
al. constructed a composite score, designed to reflect the total effect of seizures and 
toxicity of medication on the quality of life of the patient. The score is the summation 
of seizure frequency rating, systemic toxicity rating, and a combination of 
neurotoxicity and behavioral toxicity ratings. So the composite score is an example of 
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differentiation by seizure type and differential attribution of point scores. Wijsman et 
al. validated a similar Composite Index of Impairments by testing the correlation of the 
independently assessed score by the investigator with the interval between clinic visits 
ordained by the physician in charge of the patient (Wijsman et al., 1991). Wijsman et 
aL, however, did not compare this correlation with the correlation of either the 
frequency of seizures per se, or the frequency of seizures weighted according to 
seizure type. Smith et al. constructed a patient-based severity scale to analyze the 
relationship seizure severity, seizure frequency and psychosocial factors such as 
anxiety, self-esteem and locus of control (Smith et al., 1991). Based on the study 
Smith expected that seizure frequency alone may not be sensitive enough to assess the 
efficacy of anti-epileptic drugs. Several others have indicated that seizure frequency 
alone will not be sufficient in assessing the severity of epilepsy. Martins da Silva et al. 
on the other hand has shown that seizure frequency is a relevant parameter if the 
seizure characteristics remain constant (Martins da Silva et al., 1993). On pursuing the 
introduction of Clinimetrics in epilepsy care further analysis of the advantage of the 
possible scores is undoubtedly needed. 
129 

Appendix II 
This paper has been published in: Meinardi H, Cramer JA, Baker GA and Martins da 
Silva A eds. Quantitative Assessment in Epilepsy Care. Plenum Press New York, 
1993:117-122. 
On the Reporting of Adverse Drug Events· 
M.W. Lammers, M.D. and H. Meinardi, M.D., Ph. D. 
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Introduction 
In this paper only dose dependent adverse drug events will be discussed. 
Adverse drug events are by definition a problem in efficacy studies. In studies of 
antiepileptic drugs an additional problem arises. As the desired effect of an 
antiepileptic drug is the suppression of a paroxysmal and unpredictable event, titration 
to reach an optimal dose is not readily practicable using the desired effect parameter. 
It is commonly accepted to substitute the occurrence of adverse events as endpoint 
minus one for the titration phase. Of course this poses a problem with respect to the 
reporting of the occurrence of side effects. Proper policy would be to disregard side 
effects elicited during a titration phase. The possibility to monitor serum levels did 
offer a way out of this problem by choosing a serum level below the "toxic range" as 
first endpoint of titration. However, recent antiepileptic drugs show little or no 
correlation between serum levels and pharmacodynamic properties of these drugs. 
Examples are vigabatrin and milacemide. If adverse effects are only to be reported 
during steady state and in relation to seizure suppression the whimsical nature of 
adverse events may become a confounding factor. As was shown by the epileptologists 
from Milan adverse effects may or may not disappear spontaneously (Collaborative 
Group for Epidemiology of Epilepsy, 1988). There are no systematic studies about the 
pathophysiology of this tolerance phenomenon. However, there are anecdotal reports of 
people withdrawn from antiepileptic drug treatment who felt much improved even 
though they did not have any formal complaints about adverse effects prior to 
withdrawal. 
In drug-trial reports the methods section often contains little information about the 
procedures with respect to the evaluation of adverse drug events. For example in a 
recent paper by Reynolds et al. on a study of vigabatrin it is stated that "Efficacy was 
assessed by seizure frequency, calculated from patient's diaries. Possible adverse 
events were recorded from patient's spontaneous reports, responses to questions, 
physical examination and haematologic/metabolic investigations (blood count, urea, 
electrolytes, sugar, calcium, liver function) performed on each clinic visit." 
Subsequently the account of the statistical analysis in this paper only refers to the 
analysis of change in seizure frequency. From the discussion on withdrawal and on 
adverse events in this paper it is clear that some criterion was used called 
"unacceptable adverse events" (Reynolds EH, et al., 1991). However, no description of 
that criterion was presented in the paper. The specific adverse events leading to 
withdrawal were tabulated as follows (table 1). 
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Table 1. Adverse events leading to study withdrawal. 
Patient 
1 
2 
3 
4 
5 
6 
7 
Days with GVG 
14 
23 
56 
56 
56 
56 
56 
Adverse Event 
Headache, abdominal pain 
Depression 
Increased lability of mood, unsteady gait, disturbed 
sleep 
Headache, nocturia 
Dizziness 
Depression, swollen breasts 
Depression, confusion 
GVG, vigabatrin 
Reproduced with permission from Reynolds, E.H. et al. Open, double-blind and long-term study of vigabatrin in chronic epilepsy. 
Epilepsia 32:530, 1991. 
However, headache and depression were also seen in other patients without subsequent 
withdrawal from the trial as witnessed from the summary of adverse events presented 
in that paper (table 2). 
Table 2. Summary of adverse events. 
Adverse Events 
Drowsiness 
Depression/irritability 
Headache 
Behaviour disturbance 
Confusion 
Increased micturition 
Dizziness 
Increased appetite and 
weight 
Baseline 
Phase 
(n = 33) 
9 
2 
1 
0 
0 
0 
0 
0 
Open 
Phase 
(n = 33) 
17 
8 
6 
3 
3 
3 
2 
2 
Double Blind 
Phase 
Active Placebo 
(n = 10) (n = 10) 
2 0 
0 0 
0 1 
0 1 
0 0 
0 0 
1 0 
0 0 
Long-term 
Phase 
6-12 mo 12-18 mo 
(n = 17) (n = 17) 
2 0 
0 2 
0 1 
0 1 
1 0 
0 0 
1 1 
3 2 
In order to obtain an assessment of the present reporting of adverse events it was 
decided to make a limited but systematical overview. 
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Methods 
The screening of the literature was restricted to the official journal of the 
International League Against Epilepsy Epilepsia for the years 1987 trough 1991. All 
papers reporting on aspects of the treatment of epilepsy with antiepileptic drugs were 
included. In total 118 papers were screened. Twenty-two papers presented quantitative 
data. These papers will be further analysed in the result section. 
Results 
Twenty papers were specially concerned with adverse effects. Five papers dealt with 
the effects of antiepileptic drugs on cognition (Berent, et al , 1987; Aman, et al., 1987; 
Reinvang, et al., 1991; Mitchell and Chavez, 1987; Aldenkamp, et al, 1987). The 
paper by Reinvang et al. also measured subjective symptoms of discomfort i.e. fatigue, 
headache, nausea, incoordination, diplopia, and blurred vision using a visual analog 
scale. However, the reported level of discomfort was generally very low (Reinvang, et 
al., 1991). Four papers also used the quantitative data of serum levels (Berent, et al., 
1987; Aman, et al., 1987; Reinvang, et al., 1991; Aldenkamp, et al., 1987). One paper 
by Robertson et al. used depression rating scales in the assessment of depression in 
epilepsy (Robertson, et al., 1987). Twelve papers were concerned with other specific 
adverse effects, which usually are reported in a global manner like the problem of 
rashes (Pelakanos, et al., 1991), edema (Ettinger, et al., 1990), or are intrinsically 
quantitative, because they concerned laboratory measurements like levels of lipids, 
vitamins, and proteins (Dastur and Dave, 1987). These authors also discussed 
morphology of liver biopsy specimens which were, however, not judged in a 
quantitative manner. M. Berg et al. looked at changes in the folate level after taking 
Phenytoin (Berg, et al., 1988). Jouko LT. Isojärvi et al. looked in two studies at 
sexhormone levels in male and female patients (Isojärvi, et al,, 1989; Isojärvi, 1990). 
Gough et al. studied bilirubin levels (Gough, et al., 1989) and two papers were 
concerned with the changes in immunoglobulin levels (Gilhus and Tor, 1988; Pacifici, 
et al., 1991), Goyle et al. looked at mutagenicity of antiepileptic drugs measuring the 
miotic index and sister chromatid exchanges (Goyle, et al., 1987) and W. Fletjer 
studied the cytogenic effects of AED using the same parameters (Fletjer, et al., 1989). 
L. Caranini et al. studied SSEP (somatosensory evoked potentials) changes (Caranini, 
et al., 1988). One paper was a comprehensive study of side effects, both adverse and 
favourable comparing five major antiepileptic drugs (Herranz, et al., 1988). Two 
papers concerned efficacy studies of antiepileptic drugs. Koeppen et al. compared 
clobazam with placebo and used mood scales and a global assessment of adverse 
events as "not significantly interfering with patient's functioning,'1 "significantly 
interfering" and "outweighing therapeutic effect" (Koeppen, et al., 1987). Woo et al. 
studied the changes of recurrence of seizures in groups of patients in remission though 
on a dosage of antiepileptic drugs producing serum levels in the subtherapeutic range 
(Woo, et al., 1988). Part of the patients received additional doses in order to increase 
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the serum level to the therapeutic range, while the other part was maintained on a 
subtherapeutic level as before. They assessed their patients using systemic toxicity and 
neurologic toxicity scales modified from Cramer et al. (Cramer, et al., 1983). 
The other papers screened used no quantitative measures in assessing adverse 
effects. In most drug efficacy studies authors described the number or percentage of 
patients, who suffered from adverse effects of the medication. In some papers case 
reports were used when describing rare adverse events. 
Discussion 
Studies about the adverse effects of antiepileptic drugs rarely used quantitative data 
in order to describe the adverse effects. In studies of the efficacy or toxicity of 
antiepileptic drugs the adverse effects are rarely described according to severity but in 
most cases according to frequency or number of patients with adverse effects of 
medication. When quantitative data has been used to describe adverse effects, the 
adverse effects studied were intrinsically quantified, because they were based on 
laboratory findings. Also when assessing cognitive functions standardised tests are 
available. Semi-quantification is variably used, but then categories are generally poorly 
characterised, like mild, moderate or severe With no explanation of what exactly is 
meant by these terms. 
When quantification scales for adverse effects are applied, most authors develop 
new rating scales and rarely are rating scales of other authors used. For this reason 
comparing results of different studies concerned with adverse events is difficult. 
Especially as the complaints suggesting adverse drug effects sometimes are already 
present before the drug under evaluation has been administered, a more quantitative 
comparison of the two phases would be in place. The lack of detail in the reports on 
adverse effects is also reflected in the reviews of the subject (Meinardi and Stoel, 
1974; Meinardi, 1980; Schmidt, 1982). 
While dose dependent toxicity may prevent full use of the seizure suppressing 
capacity of the compound, idiosyncratic adverse effects can necessitate complete 
abandon of the drug. Here again in the past little or no use has been made of 
quantitative presentation of the associated problem. Yet it is well recognised that the 
severity of idiosyncratic reactions is not always the same. At least from the literature, 
it is not clear whether for example granulocytopenia should be considered a mild form 
of agranulocytosis or whether allergic exanthemas are abortive cases of exfoliative 
dermatitis. 
Consensus on quantification of adverse events for clinical symptoms as well as for 
laboratory findings and other standardised tests, will be useful in order to be able to 
compare studies on this topic. 
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Conclusions 
Apart from symptoms characterised by changes in clinical chemistry or 
haematological data, very little quantification is used to report about the adverse effects 
of antiepileptic drugs as witnessed by a review of papers which appeared over the past 
five years in the official journal of the International League Against Epilepsy 
"Epilepsia". 
136 
Appendix Ш 
Liverpool Seizure Severity Scale. 
PERCEPTION ITEMS 
1. Time of day of seizure occurrence (day or night) 
2. Ability to predict seizure occurrence 
3. Ability to abort ("fight off') seizure 
4. Presence of a warning or simple partial seizure (aura) preceding some or 
all attacks 
5. Perception of control over attacks 
6. Clustering of seizures 
7. Frequency of nocturnal seizures 
8. Degree of seizure interference with daily function (lifestyle) 
9. Severity of seizure 
ICTAL/POST-ICTAL ITEM 
10. Duration of altered consciousness 
11. Degree of post-ictal confusion 
12. Duration of post-ictal confusion 
13. Falling during a seizure 
14. Frequency of post-ictal headache 
15. Frequency of post-ictal sedation 
16. Frequency of urinary incontinence 
17. Frequency of tongue biting 
18. Frequency of self-injury related to seizure 
19. Duration of altered function after seizure 
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Chalfont Seizure Severity Scale. 
Classification of Seizure Types 
Loss of awareness 
no = 0, yes = 1 
Warning (if loss of awareness) 
no = 0, yes = 1 
Drop, spill a held object 
no = 0, yes = 4 
Fall to ground 
no = 0, yes = 4 
Injury 
no = 0, yes = 20 
Incontinent 
no = 0, yes = 12 
Automatisms no = 0 
mild (chew, swallow, fiddle) = 4 
severe (shout, undress, run, hit) =12 
Convulsion 
no= 0, yes = 12 
Duration of seizure 
<10 sec = 0, 10 sec-1 min = 1 
1-10 min = 4, >10 min = 16 
Time to return to normal from onset 
<1 min = 0, 1-10 min = 5, 
10-30min = 20, 30-64) min = 30, 
l-3hr=50, >3hr= 100 
If epileptic event (e.g. brief aura) with total score = 0, 
then add 1 
Divide score by 2 if seizures are only in sleep 
TOTAL SCORE 
Typel Type 2 ТуреЗ 
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Appendix Notes on Completion of Chalfont Seizure Severity Scale 
1) Classification of seizure type, according to International League against Epilepsy 
Classification. 
2) In each section, score what usually occurs in that seizure type with fractionation as 
follows; No score if that factor does not occur; Quarter score if occurs up to 25% of 
occurrences; Half score if occurs in 25%-50% of occurrences; Three quarters score if 
occurs in 50%-75% of occurrences; Full score if occurs in >75% of occurrences; For 
example, if injury in 50%-75% of occurrences, injury score = 15. If dropping a held 
object in up to 25% of occurrences, dropping a held object score = 1. Scores for loss 
of awareness and warning to a seizure are not amenable for fractionation. 
3) Drop, spill a held object includes spilling a held drink, even if the vessel is not 
dropped. 
4) Injury includes tongue-biting, bruising and lacerations. 
5) Incontinence includes urine and faeces. 
6) Automatisms. Mild implies features that are not socially disabling, for example, 
chewing, repeated swallowing, fiddling with objects. Severe implies features that are 
socially disabling, such as swearing, running, undressing, hitting out. This score may 
also be fractionated (see note 2, above). 
7) Convulsion is taken to mean clonic jerking of limbs. 
8) Duration of seizure. Time from onset, until judged to have terminated, by patient 
and/or reliable witness. 
9) Time to return to normal from onset is taken as the duration of time until the 
patient is able to resume the activity that they were pursuing when the seizure 
occurred. 
10) A score of 1 is added, if the total score otherwise = 0. For example a simple 
partial seizure consisting of an epigastric rising sensation that lasts less than 10 
seconds. 
11) If a given seizure type occurs only in sleep, the total score, for that seizure type is 
divided by 2. 
12) The total of the scores obtained for a given seizure type is its severity score. 
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Occupational Hazard scale. 
TYPE OF SEIZURES 
TREATMENT STATUS 
Seizure free (allowed to drive motor vehicle) 
OCCUPATIONAL HAZARD 
Seizures only during sleep not more than 1/month 
Unilateral jerks without loss of consciousness not more than 1/week 
# 
1 
2 
Seizures only during sleep not more than 1/week 
Very brief seizures impairing or interrupting ongoing activity not more 
than 1/six month 3 
Brief seizures impairing or interrupting ongoing activity not more than 
1/six month 
Unilateral jerks without loss of consciousness 
Seizures with falling lasting less than 5 minutes including reorientation 
not more than 1/six month 4 
Seizures during which person does not behave according to demands of 
situation not more than 1/month 
Seizures with falling lasting less than 
15 minutes including reorientation not more than 1/month 5 
Seizures impairing or interrupting ongoing activity 
Seizures during which a person does not behave according to demands of 
situation not more than 1/week 
Seizures with falling lasting less than 15 minutes not more than 1/week 6 
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Veterans Affairs Seizure Type and Frequency Rating 
Patient's name 
Form completed by , 
type , Drug type 
(Ho) (Day) (YD 
Protocol 
Rating period: 1 wk 2 мк 1 mo 2 mo 3 no 4 mo 6 mo 9 mo 12 n» 1S no 18 
21 mo 24 mo 30 mo 36 mo 42 mo 48 mo 54 mo 60 no Unscheduled 
Instructions: Record all seizures reported by patient since last visit. Use section A, 
necessary for each type of seizure reported. 
B, and С as 
Section A. 
GENERALISED TONIC CLONIC SEIZURES 
Complete this section if patient has either primary 
or secundary generalised tonic clonic seizures. 
1. Total пшЪег of seizures since last visit 
2. Total number of seizures since start drug___. 
Select the seizure frequency category that applies to 
the patient from the following list and enter on 
score line. 
a. Three or more se i zure/12 months « 20 each seizure 
(After one year review past 12 months only for 
multiple seizures) 
b. Two seizures/first 3 month « 50 
c. Two seizures/6 month - 45 
d. One seizure/first 3 months = 
e. One seizure/6 month » 
40 
40 
Two seizures/6-12 month « 
One seizure/6-12 month « 
30 
20 
20 
10 
h. Two seizures/12-24 months * 
i. One seizure/12-24 month » 
Score__________ 
3. Was seizure(s) modified by an aura (allowing 
avoidance of harm)? 
1. Yes 2. No 
If yes, change score to 80% of score in item 2; if 
no, keep score the same. Score 
4. Was seizure(s) precipitated by unusual, remedial 
factors (e.g., lack of sleep, alcohol, illness)? 
1. Yes 2. No 
If yes, change score to 50% of score in item 3; if 
no, keep score the same. Score 
5. a. If subtherapeutic drug levels, change 
score to 30% of score in item 4; if not, 
keep score the same. 
Scores 
b. If low therapeutic drug levels, change 
score to 80% of score in item 4; if not, 
keep score the 
Score-
6. Are seizures modified by known cyclic or diurnal 
pattern (e.g., nocturnal or early a.m.) 
1. Yes 2.No 
If yes, change score to 60% of score in item 5; if 
no, keep score the same. 
Generalised Tonic Clonic: 
Section A Final Score 
Section B.C0MPLEX PARTIAL SEIZURES 
Complete this section if patient had complex 
partial seizures (with altered consciousness) 
that did not generalise. 
1. Total number of seizures since last visit 
2. Did seizures occur as a cluster (greater than 
2 seizures within 24 hours)? 
1. Yes 2. No 
a. If yes, how many seizures occurred? 
b. If three or more seizures/cluster, 
count only one-half the number of 
seizures in that cluster. 
3. Select the seizure frequency category that 
applies to the patient from the following list 
and enter on score line. 
a. Equal or greater than 4/month 
(•10 for each additional seizure/mo over 
= 50 (*10 each) 
Equal to 3/month s 40 
Equal to 2/month » 30 
Equal to 1/month * 20 
Less than 1/mo I greater 
than 1/3 mos * 15 
Less than or equal 
to 1/3 mos s 10 
Score 
4. Was seizure(s) modified by an aura (allowing 
avoidance of harm)? 
1. Yes 2. No 
If yes, change score to 80% of score in 
if no, keep score the 
item 3; 
Score 
5. Was seizure(s) precipitated by unusual, 
remedial factors (e.g., lack of sleep, alcohol, 
illness)? 
1. Yes 2. No 
If yes, change score to 50% of score in item 4; 
if no, keep score the same. 
Score 
6. a. If subtherapeutic drug levels, change 
score to 30% of score in item 5; if not 
keep score the same. 
Score 
b. If low therapeutic drug levels, 
change score to 80% of score in item 5; 
if not, keep score the same. 
Score 
7. Are seizures modified by known cyclic and 
diurnal pattern (e.g., nocturnal or early a.m.)? 
1. Yes 2. No 
If Yes, change score to 60% of score in item 6; 
if no, keep score the same. 
Score 
8. Did seizure(s) cause loss of consciousness 
(include psychic, cognitive, and autonomic 
disturbances) or significant interference with 
functioning? 
1. Yes 2. No 
If no, change score to 50% of score in i ten 7; if 
yes, keep score the same 
Complex Partial: Section В Final Score 
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Section С. SIMPLE PARTIAL SEIZURE 
Complete this section if patient had simple partial 
seizures (without loss of consciousness). 
1. Total number of seizures since last visit 
2. Did seizures occur as a cluster (greater than 2 
seizures within 24 hours)? 
1. Yes 2. No 
a. If yes, how «any seizures occurred? 
b. If three or «юге seizures/cluster, count 
only one-half the number of seizures in that 
cluster (e.g., 6 seizures/cluster • 3 
seizures/week). 
sei zures/week 
3. Select the seizure frequency category that applies 
to the patient from the following list and enter on 
score line. 
a. Equal or greater than 7/month 
(•3 for each additional seizure/mo over 7) 
« 33 (*3 each) 
b. Equal to 6/month s 30 
c. Equal to 5/month * 28 
d. Equal to 4/month * 25 
e. Equal to 3/month « 23 
f. Equal to 2/month « 20 
g. Equal to 1/month = 15 
h. Less than 1/mo I greater 
than 1/3 mos « 13 
f. Less than or equal 
to 1/3 mos * 10 
Score 
4. Was seizure(s) precipitated by unusual, remedial 
factors (e.g., lack of sleep, alcohol, illness)? 
1. Yes 2. No 
If yes, change score to 50% of score in item 3; if 
no, keep score the same. 
Score 
5. a. If subtherapeutic drug levels, change 
score to 30X of score in item 4; if not keep 
score the same. 
Score 
b. If low therapeutic drug levels, change 
score to 80% of score in item 4; if not, 
keep score the same. 
Score 
6. Are seizures modified by known cyclic and diurnal 
pattern (e.g., nocturnal or early a.m.)? 
1. Yes 2. No 
If Yes, change score to 60% of score in item 5; if 
no, keep score the same. 
Score 
7. Did seizure(s) cause loss of consciousness 
(include psychic, cognitive, and autonomic 
disturbances) or significant interference with 
functioning? 
1. Yes 2. No 
If no, change score to 50% of score in i ten 6; if 
yes, keep score the same 
Simple Partial: Section С Final Score: 
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Veterans Affairs Neurotoxicity Rating 
Patient's name Study no. / / 
Form completed by _ _ _ _ ^ _ _ _ D e t e / / 
(Ho) (Day) (YD 
Rating period: 1 wk 2 нк 1 mo 2 mo 3 mo 4 mo 6 mo 9 mo 12 mo 15 mo 18 ю 
21 no 24 mo other 
Instructions: all toxicity is scored relative to normal for this patient before starting this 
médication. Do not change drug if toxicity occurs with high serum level; reduce drug dose. Circle all 
scores that apply and record on score line. Record O's on score line if no toxicity is present 
Section A; Score 
1. Diplopia 
a. Intermittent 15 
b. Constant 30 
2. Nystagmus (not end point): 
a. Horizontal 5 
b. Vertical 10 
3. Dysarthria 
a. Mild (intermittent slurring) 5 
b. Moderate (constant slurring, no difficulty communi cat ing) 10 
c. Severe (understanding of speech difficult if topic unknown to listener) 30 
4. Gait, normal valking 
a. Slight ataxia (slowness or unsteady turning) 5 
b. Mild ataxia (veer from side to side, difficulty with tandem gait) 15 
c. Moderate ataxia (quite unsteady, walks with wide base gait; tendency to fall toward 
one side or other) 25 
d. Severe gait disturbance (can walk only with assistance; some unsteady sitting) 50 
5. Rapid alternating movements (hand on knee, flip side to side, grossly clumsy) 15 
6. Tremor (finger to nose, long reach; eyes open/eyes closed-resting and with arms extended 
forward): 
[Circle type: Intention-Resting-Postural-None] 
a. Mild (intermittent tremor, not functionally important, noticeable by patient o:· doctor) 10 
b. Moderate (usually or often evident to patient/doctor on exam: may be embarrassing, but 
not significant compromise: skilled motor acts) 25 
с Moderately Severe (frequent or constant tremor, compromises to some degree: writing, 
fine motor movements, etc.) 35 
d. Severe (disturbs everyday functioning: eating, writing, working) 50 
7. Enter total for items 1-6(if more than one score, sum and multiply by 50%; 
if only one score, enter score) 
Sect ι on an S c o r e _ 
Section B; 
8. Sedation (level of consciousness): 
a. Lethargic in early AM or evening 5 
b. Occasionally sleepy during day 10 
с Often difficulty staying awake 25 
d. Stuporous 50 
Score 
9. Affect and Hood (depression; tension/agitation; anger/hostility; vigor/excitability; 
fatigue/apathy; confusion/thought disorder) 
a. Mild (a disturbance is recognized by the patient, but it results in no interference 
with usual life) 5 
b. Moderate (the mood disturbance results in reduced abilities, but only periodically) 15 
c. Severe (continuous or nearly continuous mood disturbance interfering with usual life) 50 
Score 
10. Cognitive Function (attention/concentration) 
a. Mild (symptoms recognized, but no interference with usual life) 5 
b. Moderate (interference with some daily activities) 10 
с Severe (interference with all daily activities) 50 
Score 
145 
Clinimetrìcs in epileptology 
146 
Appendix HI 
11. Drug-related Dîzzîness/Lightheediness 
(record only highest single score) 
a. Mild (symptoms recognizable but no interference with 
life) 
b. Moderate (interference with some daily activities) 
c. Severe (interference with all daily activities) 
Transient/ 
Occasionally 
After Meds 
3 
5 
10 
Often Often 
After During 
Meds Day Score 
5 
10 
25 
10 
25 
50 
12. Drue-related Headaches 
(enter zero if categories do not apply) 
a. Mild (symptoms recognizable but no interference with usual 
life) 
b. Moderate (interference with some daily activities) 
c. Severe (interference with all daily activities) 
13. Other Neurotoxicity (describe):_ 
14. Neurotoxicity Rating Score (sum question 7 trough 13) 
Transient/ Often Often 
Occasionally After During 
After Meds Meds Day Score 
3 
5 
10 
5 
10 
25 
10 
25 
30 
Score 
Total 
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Veterans Affairs Systemic Toxicity Rating 
Patient's name Study no. / / 
Form completed by _ _ _ _ _ 0*te / / 
(Mo) (Day) (YD 
Rating period: 1 wk 2 ык 1 mo 2 mo 3 mo 4 roo 6 mo 9 mo 12 ею 15 вю 18 во 
21 roo 24 mo other 
Instructions; all toxicity is scored relative to normal for this patient before starting this 
medication. 
1. Does patient have any drug-related 
gastrointestinal problems? 
Yes No 
If yes, circle the highest applicable score and enter 
on the appropriate score line. Enter zero on the other 
two score lines. 
Distress Nausea Vomiting Other Score 
a. Transient or 
occasionally 
after 
medication 3 5 10 
b. Often after 
medication 5 10 25 
c. Often during 
the day 10 25 50 
a. Reduced platelet count <75,000 (seen on more 
than 1 test) 
(Score 25 points if under observation, score 
50 if drug discontinued) 
b. Reduced WBC <2,000 (1000 granulocytes) 
(seen on more than 1 test) or discontinue 
drug) 
(Score 25 points if under observation, score 
50 if drug discontinued) 
c. Other hematopoietic problem (describe): 
d. Score 
3. Does patient have a hypersensitivity reaction 
to the study drug (general maculopapular 
rash)? 
Yes No 
If yes, score the following: 
Transient (stopped with treatment) 15 
Severe (did not stop with treatment) 50 
a. Score 
4. Does patient have problems with impotence 
(libido or potency) related to drug use? 
Yes No 
If yes, score one of the following: 
Transient, occasional or tolerable 20 
Continuous or intolerable 50 
a. Score 
5. Does patient have hyponatremia with serum 
sodium <120 mmol/l Yes No 
If yes, score 50 
Scoi* 
6. Does patient have liver disease (related to 
drug) with abnormal liver function tests (SGOT, 
SGPT repeatedly more than twice normal)? (Verify 
with liver consultant). 
Yes No 
If yes, score 25 if under observation, score 50 
if drug discontinued. 
a. Scocfi 
7. Has patient gained weight because of 
increased appetite related to drug? 
If yes, score the following: 
Weight Gain: Small (4-6lbs.) « 3 
Moderate (7-12 lbs.) * Ю 
Large (13-18 lbs.) * 20 
a. Scot* 
8 Does patient have any changes in hair quantity 
or texture since starting drug? 
Yes No 
If yes, score all of the following that apply: 
a. Hair loss: 
Mild: Notice excess hair in comb 5 
Moderate: Visible thinning of hair 
or hair loss in clumps 20 
Severe: Visible alopecia or 
exceedingly bothersome to patient 50 
b. Hair texture or change other than loss, 
e.g., becoming coarse, fine, curly 5 
с Hirsutism (excess hair growth): 
Moderate: Noticible on face trunk 
or limbs) 20 
Severe (excessive and bothersome 
to patient 50 
d. Scocm 
9. Other (describe): 
Scoce 
10. Systemic Toxicity SCOT» 
(sum of querist i on 1-9) 
Total Scoce. 
2. Does patient have hematopoietic system 
problems? 
Yes No 
If yes, enter a score for each of the following (enter 
zeros if not present): 
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Clinimetrics in epilepîology 
Questionnaire for physician 
1. Patient*s name: 
2. Diagnosis 
-seizure type(s): 
-epilepsy 
3. Treatment Objective for this patient: 
A. Complete seizure remission 
B. Impairment/benefit balance 
C. Other: 
4. Has the treatment objective been achieved? 
Yes 
No 
AED Serum Level AED (Mg/ml) Dosage (mg/dag) 
-Carbamazepine 
-Valproate 
-Phenytoine 
-Phénobarbital 
-Primidone 
5. Global clinical state of the patient. 
1 2 3 4 5 6 7 
1 = very well/considering discharge 
7 = very poorly/considering hospital admittance 
or referral for epilepsy surgery 
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Appendix IV 
Questionnaire for investigator 
consultation date:../../., 
consultation interval: ...months 
medication and dosage: 
AED 1 
2 
3 
4 
PDD/DDD ratio: 
Seizure Type 
Frequency 
1. Aura 
2. Prov.fact 
3. Sleep/ 
awakening 
4. Impairment 
(>15min) 
5. Clustering 
P/S GTCS 
.../year 
yes/no 
yes/no 
yes/no 
yes/no 
CPS 
.../month 
yes/no 
yes/no 
yes/no 
yes/no 
yes/no 
SPS 
.../month 
yes/no 
yes/no 
yes/no 
yes/no 
Side effects caused by AED medication spontaneously reported by patient: 
Clinimetrics in epileptology 
IS score: 
SA score: 
NTX score: 
STX score: 
CII score: 
Serum levels determined today: yes/no 
Therapy unchanged/changed, namely : 
Next appointment in ... months 
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